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SUMMARY 
Name: Justin Christopher Yang 
Dissertation Title: Social disparities in the epidemiology and treatment of substance-
related use disorders in the United States, 2002-16 
Although substance use disorders have long been considered a public health problem, 
new developments in the supply, trade, and misuse or abuse of substances have prompted 
researchers, practitioners, and policymakers to cast a more critical eye towards their root 
causes in order to develop more effective drug policy. While historical approaches to 
substance use disorders have primarily focused on abstinence and law enforcement 
approaches to stem the illicit production and supply of controlled substances, more recent 
research and practice has led to policy based on the harm reduction paradigm which seeks 
to mitigate the harm from substance abuse and misuse rather than eliminating use 
altogether as a goal. Yet, there has been a growing recognition that harm reduction alone 
is insufficient to address the rapidly evolving problem of substance use disorders in 
society, particularly considering new literature from medical sociology which has 
underscored the importance of identifying and addressing disparities in health outcomes 
based upon social determinants. As such, this dissertation seeks to contribute to our 
understanding of the scale of substance use disorders among adults in the United States 
by analysing social disparities in the epidemiology and, using the opioid epidemic as a 
case study, treatment of substance use disorders with the intention of highlighting 
potential areas for intervention and policy development. Drawing upon administrative 
datasets funded and maintained by the Substance Abuse and Mental Health Services 
Administration, specifically the National Survey for Drug Use and Health, the National 
Survey of Substance Treatment Services, and the Treatment Episode Data Set, I examine 
disparities in the prevalence of substance use disorders in the United States and expressed 
unmet need for mental health treatment. Using the opioid epidemic as a case study for the 
treatment of substance use disorders, I examine disparities in service provision among 
substance abuse treatment facilities as well as disparities in receipt of medication-assisted 
therapy among admitted patients. I also present an analysis of substance use disorders in 
England and Wales drawn from the Crime Survey for England and Wales for context. 
The findings of these analyses are presented with an overarching aim of informing sound 
policy and practice with respect to substance-related use disorders.  
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1 INTRODUCTION 
1.1 Background 
Substance use disorders (SUDs), including misuse and abuse, have long been a part of 
the human condition; excessive consumption of alcohol is referenced, for instance, in the 
Bible on several occasions (1) while art historians have documented depictions of 
substance use and abuse through time as varied as engravings by William Hogarth to 
Dutch still life paintings, from works by the French post-Impressionist, Henri de 
Toulouse-Lautrec to posters by the American pop artist, Keith Haring (2). Increasingly, 
the global burden of substance use disorders and, more broadly, mental disorders, have 
been a topic of interest for scholars, practitioners, and policymakers (3). This increased 
interest in substance use disorders has yielded major advancements in our understanding 
of the neurobiological pathways underlying addiction (4) as well as a transition towards 
a harm-reduction approach for the treatment of substance use disorders (5). Developments 
in health and health care, including health care reform through the Affordable Care Act 
and the ongoing and escalating opioid epidemic in North America, have presented new 
opportunities and challenges, respectively, to practitioners and policymakers with respect 
to substance use disorders while medical sociology has prompted a new focus on the 
social causes and consequences of health and illness (6). Considering these developments, 
my dissertation aims to synthesize and provide an analysis of recent trends in the 
epidemiology and treatment of substance-related disorders in the United States in the 
context of recent developments and with a focus on identifying social disparities with the 
intention of informing policy and practice to address the growing burden of substance use 
disorders. 
1.2 Aims and Objectives 
In this dissertation, I set out to create new knowledge regarding the social disparities of 
substance use disorders in the United States, with a focus on the opioid epidemic, by 
addressing the following questions: 
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i. To describe and characterise patterns of substance-related use disorder in the 
United States with a focus on identifying demographic, socioeconomic, and health 
correlates and disparities; 
ii. To describe and characterise patterns of unmet need for mental health treatment 
(including for substance use disorder) in the United States with a focus on 
identifying demographic, socioeconomic, and health correlates and disparities; 
iii. Drawing upon the opioid epidemic as a case study, to describe and characterise 
patterns in substance abuse treatment provider characteristics with respect to 
offering pharmacotherapy for opioid use disorder and to identify any disparities 
based on provider characteristics; 
iv. Drawing upon the opioid epidemic as a case study, to describe and characterise 
variations in receipt of pharmacotherapy for opioid use disorder and delays to 
enter treatment among specialty addiction programs based upon patient 
characteristics; and 
v. To provide a comparative analysis and international context by describing and 
characterising patterns of substance-related use disorders in England and Wales. 
1.3 Structure 
As shown in Figure 1, the substantive analyses within this dissertation can be divided into 
three main sections following the introduction (Chapter 1: Introduction), literature review 
(Chapter 2: Narrative Synthesis), and general discussion of the methodological 
approaches undertaken in this dissertation (Chapter 3: Methodology):  
i. Epidemiology; 
ii. Treatment; and 
iii. Context. 
In the section on epidemiology, I provide an updated account of the prevalence of 
substance use in the United States drawing upon the National Surveys for Drug Use and 
Health (NSDUH) (Chapter 4: Binge alcohol and substance use across birth cohorts and 
the global financial crisis in the United States) followed by  an analysis of unmet need 
for mental health treatment and the reasons for unmet need using the NSDUH (Chapter 
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5: Demographic, socioeconomic, and health correlates of unmet need for mental health 
treatment in the United States, 2002-16). 
Further analysis of the social disparities follows in the treatment of substance-
related use disorders, focusing on treatment of opioid use disorder in the context of the 
opioid epidemic as a case study. I first consider the types of providers which offer 
pharmacotherapy for opioid use disorder (Chapter 6: Variations in substance abuse 
treatment facility services by geography, ownership, and payment characteristics, 2007-
14) before analysing the characteristics of individual patient populations at heightened 
risk of not receiving opioid agonist treatment and/or delays to enter treatment (Chapter 
7: Regional Disparities in Opioid Agonist Treatment and Delays to Enter Treatment for 
Opioid Misuse in the United States, 2003-14). 
I offer an international comparison using England and Wales as a case study 
(Chapter 8: Patterns of substance use among adults aged 16-59 in England and Wales, 
2006-16) to contextualize the situation in the United States. Finally, this dissertation 
will conclude with a brief synthesis of my findings, reflection on the strengths and 
limitations on the approach I have taken including analytic approaches taken in 
substantive analyses, future directions for research, implications for society and policy 
and final (Chapter 9: Discussion). 
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2 NARRATIVE SYNTHESIS 
2.1 Introduction 
Though there have been several reviews of the epidemiology of substance use disorders 
(SUDs) specifically among older adults (7-20) or women (21-25), reviews of 
epidemiologic studies of SUDs among the American adult population more generally 
have been limited (3, 26-28). Reviews based on estimates of the global prevalence of 
substance-related use disorders underscore their sizable contribution towards the overall 
global burden of disease and highlight the relatively high prevalence of illicit substance 
use in developed countries (3, 27). Reviews focused on synthesizing epidemiologic 
studies based on American datasets exclusively have also found evidence of the high 
prevalence of lifetime illicit substance use among American adults and document 
increasing patterns of misuse of prescription drugs in recent years (26, 28). The most 
recent of these reviews were conducted more than five years ago and the epidemiology 
of substance-related disorders is likely to have changed substantially over recent years, 
with an escalating opioid crisis (29, 30) amid changes to health policy, including 
implementation of the Patient Protection and Affordable Care Act (ACA) (31). 
Attention has been renewed for a holistic understanding of emerging evidence regarding 
the epidemiology of substance-related disorders among American adults. Consequently, 
this narrative synthesis seeks to extend and update our understanding of the 
epidemiology of substance-related disorders among American adults using a broad 
search strategy and focusing on findings from the past 10 years. 
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2.2 Methods 
Though consensus has emerged over the methods, structure, and format of systematic 
reviews (32, 33), other methods of synthesising evidence related to SUDs have been 
less clearly and consistently defined (34). In the absence of a clearly defined research 
protocol for this narrative synthesis, guidance established by the Economic and Social 
Research Council (ESRC) Methods Programme for the conduct of narrative synthesis in 
systematic reviews has been adopted (35). A narrative synthesis format was selected for 
this review for several reasons. Given the heterogeneity of substance-related use 
disorders, not only involving the misuse of licit substances such as alcohol and 
prescription drugs but also the use of illicit substances, and the consequently wide range 
of research questions, a narrative synthesis format provides for the opportunity to 
combine and explicate findings in a textual manner from disparate sources of evidence 
(35). The narrative synthesis format provides the opportunity to summarize the current 
state of knowledge in relation to a specific review question or review questions and, 
although these questions typically pertain to interventions, narrative syntheses can be 
useful for other types of evidence synthesis, such as epidemiology as presented here 
(35). More quantitative methods, such as meta-analysis, were considered unsuitable for 
this review as outcomes were disparate and not directly comparable to one another.  
2.2.1 Search Strategy 
A broad search of English-language literature was conducted using PubMed/MEDLINE 
for articles within the last 10 years (i.e. since 2008). Searches were filtered to only 
include articles pertaining to the United States and adults as this is the focus of my 
thesis. Searching was conducted during from August 13-14, 2018, so all literature 
published before August 13, 2018 were eligible for inclusion. 
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Search terms were selected from the Medical Subject Headings (MeSH) 
database and included several MeSH focused on substance-related disorders (C25.775 
under the Diseases category and F03.900 under the Psychiatry and Psychology 
category) and related terms, including epidemiology, ethnology, history, mortality, 
prevention and control, statistics and numerical data, and trends. Though MeSH for 
more specific substance-related disorders exist, such as for alcohol-related disorders, 
amphetamine-related disorders, and cocaine-related disorders, the term substance-
related disorders is a higher-order MeSH which includes all other lower MeSH, 
including those which pertain to a specific substance or substances. Moreover, the 
MeSH substance-related disorders include lower-order MeSH for both abuse and 
dependence. 
Exclusions were non-English language literature, literature focusing on children 
(i.e. under 19), and ex-United States geographies. In addition, literature focusing on 
tobacco use were excluded. Moreover, theoretical papers discussing topics such as 
methodological considerations for measuring the prevalence of substance use disorders, 
comparisons among measurement instruments, and the validity of diagnostic criteria for 
substance use disorders were excluded from this paper as they did not present empirical 
results. 
2.2.2 Screening 
Original, peer-reviewed, non-review articles with empirical findings were included. 
Articles were first screened by title, then abstract, then full-texts by the first author 
using Endnote X8. 
2.2.3 Extraction 
Articles were reviewed to extract information regarding study population, dataset(s) 
used, number of study participants, main outcome variables, and key findings. 
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Extraction was conducted by me using Endnote X8 and Microsoft Excel. 
2.2.4 Synthesis 
In accordance with ESRC guidance, articles were grouped thematically based on study 
population, dataset(s) used, main outcome variables, and key findings (35). This 
narrative synthesis adopted several proposed tools and techniques for developing a 
preliminary synthesis, including: tabulation and translating data based on both thematic 
and content analyses (35). These will be presented in the following results section. 
2.3 Results 
2.3.1 Included Studies 
The initial search strategy yielded 3,935 non-duplicate articles for screening. Of these, 
1,998 articles were excluded based on a title screen and 1,285 articles were excluded 
based on an abstract screen. Full-text screening further excluded 533 articles, yielded 
119 studies to be included. This study attrition is documented in Figure 2 while key 
study characteristics are shown in Table 1. 
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Figure 2 PRISMA Study Attrition Diagram 
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Table 1 Studies included in review. (Acronyms are detailed in the List of Abbreviations.) 
Author(s) Year 
Study 
Population 
Dataset n Outcome Measure(s) Result(s) 
Liebling, EJ, Green, TC, 
Hadland, SE and Marshall, BDL 
2018 
Rhode Island 
young adults 
aged 18-29 
RAPiDS 199 NMUPO 29.6% of the sample had ever injected drugs 
Short, VL, Hand, DJ, MacAfee, 
L, Abatemarco, DJ and Terplan, 
M 
2018 
Admissions of 
pregnant women 
with OUD 
TEDS 395,811 Opioid SUD 
The proportion of pregnant admissions where opioids 
were the primary substance of use increased from 
16.9% to 41.6% 
Vivolo-Kantor, AM, Seth, P, 
Gladden, RM, Mattson, CL, 
Baldwin, GT, Kite-Powell, A and 
Coletta, MA 
2018 
ED visits for 
suspected opioid 
overdoses 
ESSENCE 142,557 Opioid-involved overdoses 
The rate of opioid-involved overdose ED visits 
increased by 5.6% per quarter from July 2016-
September 2017 
Austin, AE and Shanahan, ME 2017 
Adults aged 24-
32 
NLSAAH 14,800 Prescription opioid use 
Significantly higher percentage of young parents 
inappropriately using opioid prescriptions 
Bahorik, AL, Satre, DD, Kline-
Simon, AH, Weisner, CM and 
Campbell, CI 
2017 
Patients with 
SUDs 
EHR 45,461 
Prevalence and types of 
SUD 
Most commonly diagnosed SUDs were alcohol, 
cannabis, and opioid; patients with these SUDs had 
higher disease burden than non-SUD patients 
Brooks, B, McBee, M, Pack, R 
and Alamian, A 
2017 
Respondents 
aged 12 and over 
NSDUH 12,140 
Latent class structures 
based on urban/rural 
Rural sample fits a 3-class structure for SUD while 
urban sample fits a 6-class structure 
Cantor, J, Stoller, KB and 
Saloner, B 
2017 SAT facilities N-SSATS 
Not 
reported 
Changes to treatment 
setting, accepted payment 
forms, charity care, offered 
services, special programs, 
and use of 
pharmacotherapies 
A one percentage point increase in the state 
unemployment rate is associated with a 2.5% 
reduction in outpatient clients by non-profit providers 
and a 1.8% increase in the acceptance of private 
insurance as a form of payment overall 
Carpenter, CS, McClellan, CB 
and Rees, DI 
2017 
Respondents 
aged 12 and over 
NSDUH 945,200 Illicit drug use and SUD 
Economic downturns lead to increases in the 
intensity of prescription pain reliever use as well as 
SUDs, concentrated among working-age white males 
with low educational attainment 
Fairman, BJ, Hwang, S, 
Alexandre, PK, Gallo, JJ and 
Eaton, WW 
2017 
Medicare claims 
from Baltimore 
Medicare 
claims data 
566 
Medicare costs associated 
with SUD status 
Those with a history of SUD had higher costs than 
those without 
Gonzalez, CA, Gallego, JD and 
Bockting, WO 
2017 
Transgender 
adults aged 18 
and over 
Original 
study 
1,229 Substance use 
Sexual orientation and gender incongruence 
contributed to predicting excessive alcohol and illicit 
drug use among transgender women and cannabis 
use among both transgender women and men 
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Author(s) Year 
Study 
Population 
Dataset n Outcome Measure(s) Result(s) 
Han, B, Compton, WM, Blanco, 
C, Crane, E, Lee, J and Jones, 
CM 
2017 
All adults aged 18 
and over 
NSDUH 51,200 
Prescription opioid use, 
misuse, and use disorders 
In 2015, weighted estimates suggest that 91.8 million 
US civilian, noninstitutionalized adults used 
prescription opioids, 11.5 million misused them and 
1.9 million had a use disorder 
Han, BH, Moore, AA, Sherman, 
S, Keyes, KM and Palamar, JJ 
2017 
Adults aged 50 
and over 
NSDUH 
Not 
reported 
Past-month binge alcohol 
use and AUD 
Both past-month binge alcohol and AUD increased 
significantly 
Hand, DJ, Short, VL and 
Abatemarco, DJ 
2017 
Women who 
reported being 
pregnant at time 
of admission with 
reported opioid 
use 
TEDS 8,656 Differences by US regions 
Compared to the South, pregnant women admitted 
for OUD treatment in other regions were twice as 
likely to be admitted to MAT; fewer women in the 
South reported having medical insurance, education 
beyond high school and being married 
Hartzler, B, Dombrowski, JC, 
Crane, HM, Eron, JJ, Geng, EH, 
Christopher Mathews, W, Mayer, 
KH, Moore, RD, Mugavero, MJ, 
Napravnik, S, Rodriguez, B and 
Donovan, DM 
2017 
HIV-positive 
adults 
n/a 10,652 Prevalence of SUDs 
48% SUD prevalence rate with 20% of the sample 
showing polysubstance use disorder 
Hingson, RW, Zha, W and 
White, AM 
2017 
Respondents 
aged 18 and over 
NESARC 78,831 
Prevalence of binge 
drinking 
23% of adults reported past-year binge drinking 
Hu, MC, Griesler, P, Wall, M and 
Kandel, DB 
2017 
Respondents 
aged 12-34 
NSDUH 542,556 NMUPO 
Past-year NMUPO increases during adolescence, 
peaks at ages 18-21 then decreases through ages 
30-31 
Jarlenski, M, Barry, CL, Gollust, 
S, Graves, AJ, Kennedy-
Hendricks, A and Kozhimannil, K 
2017 
Female 
respondents 
aged 18-44 
NSDUH 4,498 Polysubstance use 
Of all women with NMUPO, 11% reported only opioid 
use; polysubstance use was highest in non-Hispanic 
White women and women with lower educational 
attainment 
John, WS and Wu, LT 2017 
Respondents 
aged 12 and over 
NSDUH 281,242 
Cocaine use and cocaine 
SUD 
Prevalence of past-year cocaine use from 2011-2015 
increased among females, ages 18-25, age over 50, 
non-Hispanic Blacks, and persons reporting low 
income 
Jones, CM 2017 
Respondents 
aged 12 and over 
NSDUH 
Not 
reported 
Past-year NMUPO 
Rates of NMUPO have decreased from 2003-5 to 
2012-14 however abuse and dependence on opioids 
has increased 
Jones, CM, Christensen, A and 
Gladden, RM 
2017 
Prescription 
opioid abuse 
treatment 
admissions 
TEDS 19,009,159 
Prescription opioid 
treatment admissions 
reporting oral, injection, or 
smoking/inhalation 
Oral abuse decreased from 73.1% to 58.9%, 
injection abuse increased from 11.7% to 18.1%, and 
smoking/inhalation abuse increased from 15.3% to 
23.0% 
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Author(s) Year 
Study 
Population 
Dataset n Outcome Measure(s) Result(s) 
Kozhimannil, KB, Graves, AJ, 
Levy, R and Patrick, SW 
2017 Pregnant women NSDUH 23,855,041 NMUPO 
5.1% reported NMUPO in the past year; depression 
or anxiety were strongly associated with past-year 
NMUPO 
Mack, KA, Jones, CM and 
Ballesteros, MF 
2017 
Respondents 
aged 12 and over 
NSDUH and 
NVSS 
Not 
reported 
Illicit drug use, illicit drug 
disorders and drug 
overdose deaths 
Both metropolitan and nonmetropolitan areas 
experienced significant increases from 2003-2005 to 
2012-2014 
Martins, SS, Sarvet, A, 
Santaella-Tenorio, J, Saha, T, 
Grant, BF and Hasin, DS 
2017 Adults NESARC 79,402 Heroin use and disorder 
Heroin use and heroin use disorder increased 
significantly with greater increases among white 
individuals 
Martins, SS, Segura, LE, 
Santaella-Tenorio, J, Perlmutter, 
A, Fenton, MC, Cerda, M, 
Keyes, KM, Ghandour, LA, 
Storr, CL and Hasin, DS 
2017 12-34 year olds NSDUH 46,180 
Prescription opioid use 
disorder and heroin use 
Opioid disorder increased in NMUPO users aged 18-
34, trends in heroin use increased significantly 
McCabe, SE and West, BT 2017 
Adults aged 18 
and over 
NESARC 34,653 Multiple SUDs 
Multiple SUDs are associated with a more persistent 
three-year course of disease over time relative to 
individual SUDs 
McCabe, SE, West, BT, 
Jutkiewicz, EM and Boyd, CJ 
2017 
Adults aged 18 
and over 
NESARC 
Not 
reported 
Lifetime and past-year 
prevalence of multiple 
SUDs 
Most past-year nonalcohol SUDs had at least 1 other 
co-occurring past-year SUD; by contrast, only 15% of 
past-year AUDs had a co-occurring past year SUD 
Mosher, H, Zhou, Y, Thurman, 
AL, Sarrazin, MV and Ohl, ME 
2017 
Hospitalizations 
for heroin or 
prescription 
opioid overdose 
NIS and ACS 
Not 
reported 
Hospitalization for opioid 
overdose 
Hospitalization rates for heroin overdose increased in 
all years and were higher in urban residents 
compared with rural residents; however, 
hospitalization rates for prescription opioid overdose 
were 20% to 30% higher in rural populations 
compared with large urban populations 
Patrick, ME, Terry-McElrath, 
YM, Miech, RA, Schulenberg, 
JE, O'Malley, PM and Johnston, 
LD 
2017 
Young adults 
from ages 18-
29/30 
MTF 6,711 Binge drinking 
Between 2005-2015, binge and high intensity 
drinking generally decreased for individuals in their 
early 20s, remained somewhat stable for individuals 
in their mid-20s, and increased for individuals at the 
end of young adulthood 
Perlmutter, AS, Conner, SC, 
Savone, M, Kim, JH, Segura, LE 
and Martins, SS 
2017 
Adults aged 26 
and over 
NSDUH 58,486 NMUPO 
Prevalence of NMUPO was higher than stimulant 
use; unemployed participants had the highest odds 
of NMUPO 
Ruggles, KV, Fang, Y, Tate, J, 
Mentor, SM, Bryant, KJ, Fiellin, 
DA, Justice, AC and Braithwaite, 
RS 
2017 Veterans VACS 5,479 
Unhealthy alcohol use and 
other substance use 
Current depression was associated with current use 
of every substance except for unhealthy alcohol use 
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Author(s) Year 
Study 
Population 
Dataset n Outcome Measure(s) Result(s) 
Sahker, E, Yeung, CW, 
Garrison, YL, Park, S and Arndt, 
S 
2017 
Asian American 
and Pacific 
Islanders 
TEDS 8,938,982 
Substance use admission 
trends 
AAPI demonstrated a greater increase in admissions 
than non-AAPI, especially for prescription opioids 
Spinelli, MA, Ponath, C, Tieu, L, 
Hurstak, EE, Guzman, D and 
Kushel, M 
2017 
Older homeless 
adults aged 50 
and above 
n/a 350 Substance use 
64.6% had moderate or greater severity symptoms 
for at least one illicit drug; 25.8% had moderate or 
greater severity alcohol symptoms 
Surratt, HL, Kurtz, SP, Buttram, 
M, Levi-Minzi, MA, Pagano, ME 
and Cicero, TJ 
2017 
Miami-based club 
and prescription 
drug users 
n/a 750 NMUPO 
67.5% met DSM-IV criteria for substance 
dependence 
Unick, GJ and Ciccarone, D 2017 Hospitalizations NIS 
Not 
reported 
Prescription opioid and 
heroin-related overdose 
hospitalizations 
POD hospitalization rates were highest in the South 
and lowest in the Northeast, HOD hospitalization 
rates were highest in the Northeast region and grew 
the fastest in the Midwest 
Vasilenko, SA, Evans-Polce, RJ 
and Lanza, ST 
2017 Adults age 18-90 NESARC 36,309 SUD prevalence 
Estimated prevalence was higher for men compared 
to women at most ages until the 70s 
Veldhuis, CB, Talley, AE, 
Hancock, DW, Wilsnack, SC and 
Hughes, TL 
2017 
Sexual minority 
women 
CHLEW 726 Alcohol use 
Drinking does not decline as sharply with age as it 
does for heterosexual women 
Victor, GA, Walker, R, Cole, J 
and Logan, TK 
2017 
Kentucky drug 
treatment clients 
n/a 53,360 Self-reported drug use 
The prevalence of illicit opioid use declined from 
2010-2013 
Votaw, VR, Wittenauer, J, 
Connery, HS, Weiss, RD and 
McHugh, RK 
2017 
NMUPO users 
aged 12 and over 
NSDUH 49,045 Heroin use 
A significant association exists between lifetime 
heroin use and lower likelihood of reporting great risk 
of trying heroin 
Walker, ER and Druss, BG 2017 
Respondents 
aged 12 and over 
NSDUH 115,921 
Comorbid mental disorders 
and SUDs 
Most adults (52.2%) had at least one type of 
condition (mental illness, substance 
abuse/dependence, or chronic medical conditions), 
with substantial overlap across the conditions. 1.2%, 
or 2.2 million people, reported all three conditions 
Woo, B, Wang, K and Tran, T 2017 
Adults from 
California 
CHIS 130,556 Binge drinking 
Psychological distress was significantly associated 
with binge drinking across all racial and ethnic 
groups 
Zapolski, TCB, Baldwin, P, 
Banks, DE and Stump, TE 
2017 
Respondents 
aged 12 and over 
NSDUH 205-198 
Crossover age effect for 
binge drinkers 
A crossover effect was found for African American 
males and females among the lowest income level 
Burns, RM, Pacula, RL, Bauhoff, 
S, Gordon, AJ, Hendrikson, H, 
Leslie, DL and Stein, BD 
2016 
Medicaid officials 
and other 
designated state 
SAT specialists 
Survey 45 states 
Change in state policies for 
opioid use disorders 
Trend towards adoption of coverage for OAT 
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Author(s) Year 
Study 
Population 
Dataset n Outcome Measure(s) Result(s) 
Calhoun, PS, Schry, AR, 
Wagner, HR, Kimbrel, NA, 
Dennis, P, McDonald, SD, 
Beckham, JC, Dedert, EA, 
Kudler, H and Straits-Troster, K 
2016 
OEF/OIF 
veterans in the 
Mid-Atlantic 
region 
VA 1,087 
Prevalence of binge 
drinking and incidence of 
provider drinking advice 
51% of the sample reported at least one episode of 
binge drinking in the past year and 19% were 
identified as frequent binge drinkers 
Carliner, H, Delker, E, Fink, DS, 
Keyes, KM and Hasin, DS 
2016 Black participants NESARC 6,587 Past-year illicit drug use 
Racial discrimination was associated with past-year 
drug use and with frequent drug use 
Castaldelli-Maia, JM, Andrade, 
LH, Keyes, KM, Cerda, M, 
Pilowsky, DJ and Martins, SS 
2016 
Adult (18 and 
over) nonmedical 
users of 
prescription 
opioids 
NSDUH 806 
Latent trait of opioid use 
disorder 
Three-class model was the best-fitting solution 
Cummings, JR, Wen, H and Ko, 
M 
2016 SAT facilities N-SSATS 
3,139 
counties 
Trends in SAT facility 
ownership and geography 
Between 2002-2010, the number of publicly owned 
facilities declined 17.2% while the number of private, 
for-profit facilities grew 19.1 percent 
Fearn, NE, Vaughn, MG, 
Nelson, EJ, Salas-Wright, CP, 
DeLisi, M and Qian, Z 
2016 
Probationers and 
parolees 
NSDUH 491,457 
Prevalence rates for 
substance abuse and 
dependence 
Probationers/parolees have high prevalence rates 
across all SUDs categories and these trends have 
been constant 
Gilder, DA, Stouffer, GM, Lau, P 
and Ehlers, CL 
2016 American Indians SSAGA 876 
Clinical characteristics of 
alcohol and other SUD 
57% with a SUD had multi-substance use disorder 
and 94% of those were with AUD 
Krill, PR, Johnson, R and Albert, 
L 
2016 
American 
attorneys 
Survey 12,825 Alcohol and drug use 
20.6% screened positive for hazardous, harmful, and 
potentially alcohol-dependent drinking 
Lee, JH, Gamarel, KE, Bryant, 
KJ, Zaller, ND and Operario, D 
2016 LGB adults NESARC 577 SUDs 
Sexual minority men who ever experienced 
discrimination reported higher odds of any lifetime 
drug use disorder 
Liebling, EJ, Yedinak, JL, Green, 
TC, Hadland, SE, Clark, MA and 
Marshall, BD 
2016 
Rhode Island 
young adults 
aged 18-29 
RAPiDS 200 
Access to substance use 
treatment 
45.5% had never attempted to enrol in substance 
use treatment while 35% had successfully enrolled 
without ever facing barriers and 19.5% were 
unsuccessful in at least one attempt to enrol 
Mauro, PM, Furr-Holden, CD, 
Strain, EC, Crum, RM and 
Mojtabai, R 
2016 SAT facilities N-SSATS 14,037 Latent classes A four class solution fit the model best 
Mennis, J and Stahler, GJ 2016 
Outpatient 
treatment 
discharges 
TEDS 416,224 
Completion of treatment 
episode for SUD 
African Americans and Hispanics are less likely to 
complete a treatment episode than Whites and these 
disparities vary among users of different substances 
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Author(s) Year 
Study 
Population 
Dataset n Outcome Measure(s) Result(s) 
Terry-McElrath, YM and Patrick, 
ME 
2016 
Young adults 
aged 25-26 
MTF 3,542 
Binge and high-intensity 
drinking 
39.9% of young adults aged 25/26 reported being 
intoxicated at least once in the past 30 days; past 
two-week binge drinking was reported by 36.3% of 
respondents 
West, NA and Dart, RC 2016 
Misuse cases 
reported to 
participating US 
poison centres 
n/a 57,681 NMUPO 
Population rates of misuse of prescription opioids 
were higher for older adults than for younger adults, 
and this disparity increased over time 
Wu, LT, Zhu, H and Swartz, MS 2016 
Respondents 
aged 12 and over 
NSDUH 503,101 
Past-year alcohol/drug use 
treatment 
Most people with OUD report no use of OUD 
treatment 
Ali, MM, Teich, JL and Mutter, R 2015 
Adults with SUD 
but no 
diagnosable MH 
condition 
NSDUH 18,600 Receipt of treatment 
>80% receives no treatment and 97% do not 
perceive a need for treatment 
Andrews, CM, Guerrero, EG, 
Wooten, NR and Lengnick-Hall, 
R 
2015 
Adults residing in 
states that did not 
expand Medicaid 
in 2014 
NSDUH 16,616 
Number of individuals 
meeting new Federal 
eligibility guidelines for 
Medicaid 
African Americans and Native Americans with SUD 
who met new eligibility requirements were less likely 
than those of other groups to live in states that 
expanded Medicaid 
Blanco, C, Iza, M, Rodriguez-
Fernandez, JM, Baca-Garcia, E, 
Wang, S and Olfson, M 
2015 
Respondents 
who reported a 
lifetime diagnosis 
NESARC 
Not 
reported 
Treatment-seeking for 
drug/alcohol dependence 
and abuse 
In the first year after disorder onset, rates of 
treatment-seeking were 13% for drug dependence, 
5% for alcohol dependence, 2% for drug abuse, and 
1% for alcohol abuse. 
Choi, NG, DiNitto, DM and Marti, 
CN 
2015 
Adults aged 50 
and over 
NSDUH 29,634 
MH problems, treatment 
use, and perceived unmet 
need 
Heavy alcohol, illicit drug, and tobacco use increased 
the odds of having a mental health problem 
D'Aunno, T, Friedmann, PD, 
Chen, Q and Wilson, DM 
2015 SAT facilities N-SSATS 
635 SAT 
facilities 
Contracting with ACOs 
Only 15% of SAT facilities had signed contracts with 
ACOs 
Fink, DS, Hu, R, Cerda, M, 
Keyes, KM, Marshall, BD, 
Galea, S and Martins, SS 
2015 
Respondents 
aged 12 and over 
NSDUH 113,665 
Past year NMUPO and/or 
MDE 
Females were more likely to report either MDE alone 
and comorbid NM 
Flentje, A, Heck, NC and 
Sorensen, JL 
2015 LGB persons 
Admissions 
records 
1441 
Substance of abuse, route 
of administration, age of first 
use, and frequency of use 
prior to treatment 
Gay and bisexual men showed greater rates of 
methamphetamine use and lower heroin use 
Han, B, Compton, WM, Jones, 
CM and Cai, R 
2015 
Adults aged 18-
64 
NSDUH and 
NVSS 
472,200 NMUPO 
Among adults aged 18-64, the percentage of 
NMUPO declined from 2003-2013 but the prevalence 
of prescription opioid use disorders, frequency of 
use, and related mortality increased 
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Author(s) Year 
Study 
Population 
Dataset n Outcome Measure(s) Result(s) 
Hawkins, EJ, Malte, CA, 
Grossbard, JR and Saxon, AJ 
2015 
Patients receiving 
care through VA 
Pharmacy 
records 
66,210 
Concurrent use of opioid 
and benzodiazepines 
Long-term concurrent use of opioid and 
benzodiazepines increased 52.7% in men and 79.5% 
in women from 2003-2011 
Hess, KL, Chavez, PR, Kanny, 
D, DiNenno, E, Lansky, A, Paz-
Bailey, G and Group, NS 
2015 
MSM aged 18 
and older 
NHBS 
Not 
reported 
Prevalence of binge 
drinking 
59% of MSM who drank reported 1 episode of binge 
drinking in the preceding 30 days; binge drinking was 
associated with condomless anal intercourse at last 
sex with an HIV-positive or unknown status partner, 
having exchanged sex for money or drugs at last sex 
and having concurrent partners in the past year 
Jones, CM and McAninch, JK 2015 
Any drug-related 
ED visit 
DAWN and 
NVSS 
Not 
reported 
Opioid analgesic and 
benzodiazepine-related ED 
visits and drug overdose 
deaths 
NMUPO and benzodiazepine-related ED visits 
increased more than three times while the rate of 
drug overdose deaths also tripled 
Jones, CM, Logan, J, Gladden, 
RM and Bohm, MK 
2015 
Respondents 
aged 12 and over 
NSDUH and 
NVSS 
Not 
reported 
Heroin use 
Annual average rates of past-year heroin increased; 
rates of heroin abuse or dependence were strongly 
positively correlated with rates of heroin-related 
overdose deaths over time 
Keuroghlian, AS, Reisner, SL, 
White, JM and Weiss, RD 
2015 
Transgender 
adults 
Survey 452 
SUD treatment history and 
recent substance use 
10% of the sample reported lifetime SUD treatment 
Martins, SS, Santaella-Tenorio, 
J, Marshall, BD, Maldonado, A 
and Cerda, M 
2015 NMUPO users NSDUH 448,597 
Heroin use and heroin-
related risk behaviours 
Individuals with NMUPO are at high risk of heroin 
use and heroin-related risk behaviours 
Morley, KI, Lynskey, MT, Moran, 
P, Borschmann, R and 
Winstock, AR 
2015 
Adults aged 18 
and over 
GDS 14,869 Polysubstance use 
Six latent classes were identified among 
polysubstance users 
Oreskovich, MR, Shanafelt, T, 
Dyrbye, LN, Tan, L, Sotile, W, 
Satele, D, West, CP, Sloan, J 
and Boone, S 
2015 
American 
physicians 
AMA 
Physician 
Masterfile 
7,288 Prevalence of SUDs 
12.9% of male physicians and 21.4% of female 
physicians met diagnostic criteria for alcohol abuse 
or dependence but abuse of prescription and use of 
illicit drugs was rare 
Palamar, JJ, Davies, S, Ompad, 
DC, Cleland, CM and Weitzman, 
M 
2015 Adults aged 18 NSDUH 154,328 
Lifetime and annual use of 
cocaine and crack 
Crack users were at higher risk than cocaine users 
for reporting a lifetime arrest or multiple recent 
arrests; racial minorities were at low risk for cocaine 
use and Hispanics were at low risk for crack use 
Rade, CB, Desmarais, SL, Van 
Dorn, RA, Lutnick, A, Kral, AH 
and Lorvick, J 
2015 
Women on 
probation and 
parole 
n/a 406 NMUPO 
41.6% reported lifetime NMUPO and 20% reported 
use in the past year 
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Author(s) Year 
Study 
Population 
Dataset n Outcome Measure(s) Result(s) 
Schulenberg, JE, Patrick, ME, 
Kloska, DD, Maslowsky, J, 
Maggs, JL and O'Malley, PM 
2015 
Participants 
followed from 
high school to the 
age of 35 
MTF 25,536 SUDs 
At 35, the estimated prevalence of past five-year 
AUD was 28% 
Setnik, B, Roland, CL, Goli, V, 
Pixton, GC, Levy-Cooperman, 
N, Smith, I and Webster, L 
2015 
Adults aged 18 
and over 
NSDUH 72,600 
Prescription opioid use, 
misuse, and use disorders 
In 2015, about 38% of adults used prescription 
opioids in the prior year 
Warner, DO, Berge, K, Sun, H, 
Harman, A, Hanson, A and 
Schroeder, DR 
2015 
Anaesthesiology 
residents 
n/a 384 SUDs 
Receiving medical education within the United 
States, but not performance on the first in-training 
examination, was associated with an increased risk 
of developing SUD as a resident 
Becerra, BJ, Becerra, MB, 
Gerdine, MC and Banta, JE 
2014 
Hispanic adults 
(18 and over) 
NSDUH 6,119 Substance use 
Importance of religious influence in life and Spanish 
language interview were associated with lower odds 
of substance use while history of incarceration was 
associated with increased odds 
Chen, LY, Strain, EC, 
Alexandre, PK, Alexander, GC, 
Mojtabai, R and Martins, SS 
2014 
Adolescent and 
adult stimulant 
users 
NSDUH 170,042 
Substance and psychiatric 
comorbidities 
Adult methamphetamine users were less likely to 
report prescription drug use than stimulants users 
Chermack, ST, Murray, R, 
Kraus, S, Walton, MA, 
Cunningham, RM, Barry, KL, 
Booth, BM and Blow, FC 
2014 
Individuals 
presenting with 
SUD to ED with 
past six-month 
history of 
violence or 
victimization 
ED 1,441 Treatment interests 
Demographic variables, alcohol and cocaine 
disorders and rating treatment for psychological 
problems vary based on violence towards others 
Choi, NG, DiNitto, DM and Marti, 
CN 
2014 
Adults aged 16 
and over 
NSDUH 96,966 
Treatment use, perceived 
need, and barriers to 
treatment-seeking for SUD 
and MH problems 
65+ group least likely to use treatment and perceive 
treatment need 
Clark, TT 2014 
African American 
and African 
Caribbean young 
adults (aged 18-
35) 
NSAL 1,910 
Lifetime and recent 
substance use 
Perceived racial discrimination and lifetime 
substance use is positively related and fully mediates 
the relationship for recent substance use 
Cummings, JR, Wen, H, Ko, M 
and Druss, BG 
2014 SAT facilities N-SSATS 
13,317 
facilities 
Counties with at least 1 
outpatient SAT facility 
accepting Medicaid 
About 60% of US counties have at least 1 outpatient 
SAT facility accepting Medicaid, but this rate is lower 
in Southern and Midwestern states 
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Author(s) Year 
Study 
Population 
Dataset n Outcome Measure(s) Result(s) 
Golder, S, Hall, MT, Logan, TK, 
Higgins, GE, Dishon, A, Renn, T 
and Winham, KM 
2014 
Women on 
probation and/or 
parole in 
Jefferson County, 
Kentucky 
n/a 406 Substance use 
93% reported lifetime use of an illicit substance while 
45% reported use of at least one illicit substance in 
the past 12 months 
Guerrero, EG, Marsh, JC, Cao, 
D, Shin, HC and Andrews, C 
2014 
SAT facility 
clients 
NTIES 3,142 
Utilization of comprehensive 
services 
Women in all racial and ethnic groups needed and 
received more services targeted to their needs 
Hasegawa, K, Espinola, JA, 
Brown, DF and Camargo, CA, 
Jr. 
2014 
Adult ED visits for 
opioid overdose 
NHAMCS 731,000 Visits for opioid overdose 
ED visit rate for opioid overdose quadrupled from 
1993 to 2010 
Jeffery, DD, May, L, Luckey, B, 
Balison, BM and Klette, KL 
2014 
All active duty 
personnel serving 
for 12 months 
PDTS, SIDR, 
TED-NI, 
TED-I, 
DEERS 
1,446,519 Drug use 
Nearly one-third of active duty service members 
received at least one prescription for opioids, CNS 
depressants or stimulants 
Keen, L, 2nd, Dyer, TP, 
Whitehead, NE and Latimer, W 
2014 
Heterosexual 
Black men 
n/a 127 
Binge drinking and stimulant 
use 
17% reported binge drinking in the past month, binge 
drinking was associated with HIV 
Otiniano Verissimo, AD, Gee, 
GC, Ford, CL and Iguchi, MY 
2014 Latinos/Latinas NLAAS 2,312 
Alcohol abuse and drug 
abuse 
Discrimination was significantly associated with 
increased risk of alcohol abuse for women and 
increased risk of drug abuse for men 
Otiniano Verissimo, AD, Grella, 
CE, Amaro, H and Gee, GC 
2014 Latinos NESARC 6,294 
Alcohol and drug use 
disorders 
Discrimination was significantly associated with 
increased odds of alcohol and drug use disorders 
among Latinos, but this varies by gender, nativity, 
and ethnicity 
Parsons, JT, Starks, TJ, Millar, 
BM, Boonrai, K and Marcotte, D 
2014 
HIV-positive 
adults over 50 
n/a 557 
Use of alcohol, 
cocaine/crack, opiates, and 
other drugs 
Latent class analysis identified four patterns of use: 
alcohol use only, alcohol and marijuana, alcohol and 
cocaine/crack, and polysubstance 
Paul, JP, Boylan, R, Gregorich, 
S, Ayala, G and Choi, KH 
2014 
MSM aged 18 
and over 
EMMHS 1,196 Substance use 
Alcohol use was common among the sample though 
lowest among African Americans; ecstasy was most 
common among Asian/Pacific Islander 
Rosario, M, Reisner, SL, Corliss, 
HL, Wypij, D, Calzo, J and 
Austin, SB 
2014 Young adults GUTS 5,647 Substance use 
Sexual minorities were more likely to report lifetime 
and past-year substance use 
Salas-Wright, CP, Vaughn, MG, 
Clark, TT, Terzis, LD and 
Cordova, D 
2014 
First and second 
generation 
immigrants 
NESARC 19,073 SUDs 
Prevalence of SUDs was highest among native-born 
Americans, slightly lower among second-generation 
immigrants, and markedly lower among first-
generation immigrants 
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Author(s) Year 
Study 
Population 
Dataset n Outcome Measure(s) Result(s) 
Arndt, S, Acion, L and White, K 2013 
All discharges 
from 2006-2008 
classified as 
White, Latino, or 
Black/African 
American 
TEDS 940,058 
Successful completion of 
treatment 
Minorities typically showed a disadvantage for 
completion rates which varied by state 
Calcaterra, S, Glanz, J and 
Binswanger, IA 
2013 
Deaths among 
15-64 year olds 
WONDER 
Not 
reported 
Trends in pharmaceutical 
opioid related overdose 
deaths 
Age-adjusted death rate related to pharmaceutical 
opioids increased almost four times from 1999-2009 
Centers for Disease, C and 
Prevention 
2013 Women 
NVSS and 
DAWN 
15,323 
Overdoses of prescription 
opioid pain relievers and 
other drugs 
A drug overdose death rate of 9.8 per 100,000 was 
observed in 2010 
Chen, LY, Strain, EC, Crum, RM 
and Mojtabai, R 
2013 
Adults aged 18 
and over 
NSDUH 336,003 
Use of SUD services and 
unmet need for treatment 
Both men and women with comorbid SUD and MDE 
were more likely to use SUD services or to report 
unmet need 
Golub, A, Vazan, P, Bennett, AS 
and Liberty, HJ 
2013 
Veterans aged 
21-34 
NSDUH 3,826 
Unmet need for treatment of 
SUD 
Prevalence of unmet need for SUD treatment was 
16% among veterans 
Jones, CM 2013 
Respondents 
aged 12 and over 
NSDUH 334,295 
Past-year heroin use and 
past-year NMUPO 
Past year heroin use increased among people 
reporting past-year NMUPO 
Kissinger, P, Althoff, M, Burton, 
N, Schmidt, N, Hembling, J, 
Salinas, O and Shedlin, M 
2013 
Latino migrant 
men 
Survey 125 Substance use 
Drug use was 15% and binge drinking was 58.3% 
which decreased over follow-up 
Lee, HK, Han, B and Gfroerer, 
JC 
2013 
adult Asian 
Americans aged 
18 and above 
NSDUH 8900 Rates of binge drinking 
Korean Americans and Japanese Americans 
reported higher rates of past-month alcohol use than 
Chinese Americans, Filipino Americans and Asian 
Indian Americans; Korean Americans reported the 
highest rate of past-month binge alcohol use; 
foreign-born Asian Americans were less likely to 
have past-month alcohol use than their 
corresponding US-born counterparts 
Reback, CJ, Fletcher, JB, 
Shoptaw, S and Grella, CE 
2013 
Substance-using 
MSM 
n/a 5,599 Recent substance use 
Reported use of alcohol and/or methamphetamine 
was common 
Wu, LT, Blazer, DG, Swartz, 
MS, Burchett, B, Brady, KT and 
Workgroup, NA 
2013 
Respondents 
aged 12 and over 
NSDUH 
Not 
reported 
Illicit and nonmedical drug 
use 
No significant yearly changes in drug use prevalence 
among Asian-Americans, NHs/PIs, and mixed-race 
people 
Iwamoto, D, Takamatsu, S and 
Castellanos, J 
2012 
Asian American 
undergraduate 
students 
n/a 1,575 Binge drinking 
Japanese Americans reported the highest number of 
binge drinking episodes and alcohol-related 
problems 
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Author(s) Year 
Study 
Population 
Dataset n Outcome Measure(s) Result(s) 
Lanier, WA, Johnson, EM, Rolfs, 
RT, Friedrichs, MD and Grey, 
TC 
2012 
Decedents with at 
least 1 
prescription 
opioid causing 
death with 
nonintentional 
manner of death 
BRFSS 254 Exposure prevalence ratios 
Decedents were more likely than the comparison 
group to have used prescription pain medication 
more than prescribed 
Mulvaney-Day, N, DeAngelo, D, 
Chen, CN, Cook, BL and 
Alegria, M 
2012 
Respondents 
aged 12 and over 
NSDUH and 
NESARC 
Not 
reported 
Unmet need for SUD 
treatment 
Asians with past year SUD had a higher likelihood of 
unmet need for specialty treatment than whites 
Choi, NG and Dinitto, DM 2011 
Adults aged 57-
85 
NSHAP 2,924 Heavy or binge drinking 
12.3% of males and 8.5% of females were 
heavy/binge drinkers. 
Green, TC, Grau, LE, Carver, 
HW, Kinzly, M and Heimer, R 
2011 
All adult 
accidental/undete
rmined drug 
intoxication 
deaths 
Office of the 
Chief 
Medical 
Examiner 
1,900 Fatal opioid intoxications 77% of deaths involved opioids 
Kuo, I, Greenberg, AE, Magnus, 
M, Phillips, G, 2nd, Rawls, A, 
Peterson, J, Hamilton, F, West-
Ojo, T and Hader, S 
2011 
Heterosexuals 
aged 18-50 
n/a 
Not 
reported 
Substance use 
59% of sampled individuals exhibited past-year binge 
drinking, 28% non-injection crack, 28% injection 
heroin or cocaine, 13% non-injection cocaine, and 
13% ecstasy 
Paul, LA, Grubaugh, AL, Frueh, 
BC, Ellis, C and Egede, LE 
2011 Adults BRFSS 344,793 Binge and heavy drinking 
Rates of binge and heavy drinking in the sample 
were 15% and 5% respectively; both were more 
common among men, younger adults, and 
individuals with higher incomes and at least some 
college education 
Duncan, DF, Nicholson, T, 
White, JB, Bradley, DB and 
Bonaguro, J 
2010 
Adults aged 55 
and over 
TEDS 918,955 
Admissions with a drug 
problem 
Admissions for problems with a primary drug other 
than alcohol have shown a steady and substantial 
increase 
Han, B, Gfroerer, JC and 
Colliver, JD 
2010 
Adults aged 35-
49 
NSDUH 29,195 
Prevalence rates of lifetime 
health conditions 
Positive association between duration of cocaine use 
and anxiety and pancreatitis; heroin use and anxiety, 
hepatitis and tuberculosis 
Naimi, TS, Nelson, DE and 
Brewer, RD 
2010 
Adults aged 18 
and over 
BRFSS 14,143 Binge drinking intensity 
Binge drinkers consumed an average of 8.0 drinks 
during the most recent binge episode; 70% binge 
drinkers consumed six or more drinks and 38.4% 
consumed eight or more drinks 
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Author(s) Year 
Study 
Population 
Dataset n Outcome Measure(s) Result(s) 
Tsai, J, Ford, ES, Li, C, 
Pearson, WS and Zhao, G 
2010 Adults BRFSS 200,587 
Prevalence of binge and 
heavy drinking 
34.7 million adult drinkers in the United States 
engaged in binge drinking in 2008 with 42.2% who 
reported either heavy drinking or at least 4 binge-
drinking episodes in a 30-day period 
Blazer, DG and Wu, LT 2009 
Adults aged 50 
and over 
NSDUH 10,953 
At-risk alcohol use and 
binge drinking 
>14% men aged 6 and over reported binge drinking 
Becker, WC, Fiellin, DA, Merrill, 
JO, Schulman, B, Finkelstein, R, 
Olsen, Y and Busch, SH 
2008 
Respondents 
aged 12 and 
above 
NSDUH 164,911 Opioid SUD 
Young respondents, respondents of Hispanic 
ethnicity, unemployed respondents, and respondents 
with Medicaid or lack of insurance were more likely 
to have opioid SUD 
Nyamathi, A, Dixon, EL, 
Shoptaw, S, Marfisee, M, 
Gelberg, L, Williams, S, 
Dominick, S and Leake, B 
2008 Homeless adults n/a 664 
Self-reported 
methamphetamine use 
Over one-quarter of the overall sample and 60% of 
Whites disclosed lifetime methamphetamine use 
Wong, CF, Kipke, MD and 
Weiss, G 
2008 MSM aged 18-24 n/a 526 Binge drinking 
Race/ ethnicity, gay bar attendance, depression, 
sensation seeking, peer risk behaviours, and age of 
alcohol initiation significantly differentiated between 
non-/light users from frequent and binge drinker 
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2.3.2 Study Characteristics 
Most articles included in this narrative synthesis were published after 2012 with a 
steady increase thereafter, apart from 2016 itself, see Figure 3 below. 
 
Figure 3 Number of Publications by Year, 2008-18 
As shown in Figure 4, over half of the studies focused on the general adult 
population while around 10% of the studies focused on adults from ethnic minorities, 
young adults, adults of sexual minorities, or adult women respectively. The remaining 
12% of studies were evenly divided among studies focused on substance abuse 
treatment (SAT) facilities, military personnel, or other groups of adults (e.g. adults with 
comorbid HIV and substance-related disorders; adults of specific professions). 
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Figure 4 Percentage of Studies by Primary Study Population 
As seen in Figure 5, there were articles published on the general adult 
population every year from 2008-18. Those on adults of ethnic minorities were from 
2012-12. Those on young adults, women, and military personnel started being published 
in 2013 while studies focused on SAT facilities and other groups of adults were 
observed starting in 2014. Except for one study in 2008, those on sexual minorities were 
observed starting from 2013. 
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Figure 5 Percentage of Annual Publications by Primary Study Population 
Of the studies which drew upon large datasets, 39 studies used data from the 
National Survey on Drug Use and Health (NSDUH), 10 from National Epidemiologic 
Survey on Alcohol and Related Conditions (NESARC), 7 from the Treatment Episode 
Data Set (TEDS), 7 from the Behavioral Risk Factor Surveillance System (BRFSS), and 
6 from the National Survey of Substance Abuse Treatment Services (N-SSATS).  
Sample sizes for studies ranged from 125 to 23,855,041 with a median study 
size of 14,800 and a mean study size of 643,806. 
2.3.3 Patterns in Substance-Related Disorders Among Adults 
2.3.3.1 Alcohol-Related Use Disorders 
Evidence regarding the epidemiology of alcohol-related use disorders (AUDs), 
including binge alcohol consumption which is commonly defined as either five or more 
drinks in a single session for men and women or four or more drinks in a single session 
for women (36), suggests that the prevalence of AUDs is not uncommon among 
American adults, ranging between 15% to 25% (37, 38), and that prevalence of binge 
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alcohol use has increased over time by about 10% between 2001 and 2013 (37). Among 
young adults, aged 18 to 30, the prevalence in binge alcohol use ranges from 18-35%, 
highest among those aged 21-26. (39). In contrast, for older adults aged 50 and older, 
prevalence of binge drinking ranges from 3-8% among older women and 12-14% 
among older men (40, 41) with evidence to suggest that the prevalence of binge alcohol 
use has increased by 19% among older adults from 2005 to 2014 (42). Among Latino 
Americans, a nationally representative sample reported the prevalence of binge alcohol 
use at about 16% in 2014 (43). In Asian Americans, the prevalence of binge alcohol use 
from 2002-8 was estimated to be about 25% among Korean-Americans, 15% among 
Filipino-Americans, 14% among Japanese-Americans, 10% among Indian-Americans, 
and 8% among Chinese-Americans (44). Finally, evidence suggests that the prevalence 
of binge alcohol use among young men who have sex with men (MSM) is about 21%, 
40% of whom report frequent binge alcohol use (45). 
2.3.3.2 Illicit Substance-Related Use Disorders 
Studies which examined trends in illicit substance use generally among the American 
adult population primarily focused on identifying the correlates of illicit substance use. 
Use of illicit substances showed growth in both metropolitan and non-metropolitan 
areas from 2003-14 with the highest prevalence of illicit substance use seen in 
metropolitan areas; nevertheless, the prevalence of past-year illicit drug use disorders 
declined during this same period (46). An analysis of a nationally representative sample 
of middle-aged American adults highlights several correlates of illicit substance use, 
including anxiety, hepatitis, tuberculosis, and sexually transmitted infections (STIs) 
(47). Finally, some evidence has been presented to support the link between racial 
discrimination, socioeconomic status (SES), and illicit substance use (48). 
The use of cocaine and heroin has increased in these reports in recent years (49, 
50). Moreover, from 2011 to 2015, the prevalence of cocaine-related use disorders has 
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increased significantly among Americans aged 50 and over (49). Powder cocaine use 
was seen much less among ethnic minorities (51). 
2.3.3.3 Misuse of Prescription Drugs, including Opioids 
Of the studies included in this narrative synthesis which consider substance-related use 
disorders relating to prescription drugs, only one did not focus on the non-medical use 
of prescription opioids (NMUPO), underscoring the keen interest with which 
researchers have taken in NMUPO and prescription opioid use disorders. Researchers 
tracking the increase in the prevalence of NMUPO and associated overdose deaths from 
the 1990s to 2010 find that the age-adjusted death rate due to NMUPO increased 
fourfold (1.54/100,000 person-years to 6.05/100,000 person-years) (52) and that the rate 
of emergency department visits for prescription opioid overdose increased from 
7/100,00 population to 27/100,000 population (53). A more recent analysis of trends in 
NMUPO and prescription opioid use disorders from 2003-2013 reported the prevalence 
of NMUPO to be decreasing from 5.4% in 2003 to 4.9% at the same time as 
prescription opioid use disorders increased from 0.6% to 0.9% (54). Part of this change 
may be attributable to findings by Jones et al. who found that abuse of oral opioids 
decreased from 73.1% of total routes of opioid abuse in 2004 to 58.9% in 2013 while 
injection abuse increased from 11.7% to 18.1% in the same period, suggesting an 
evolving profile of individuals exhibiting NMUPO (55). The most recent estimates of 
NMUPO in the general population, taken from the 2015 wave of the NSDUH, suggest 
that there are 91.8 million Americans who used prescription opioids in 2015, 11.5 of 
which show NMUPO and 1.9 of which exhibited a prescription opioid use disorder (56). 
Some research has also focused on disparities in NMUPO and consequences among 
subpopulations. An analysis conducted by the CDC found that deaths from opioid pain 
relievers among women increased five times between 1999-2010 (57) while another 
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study of a nationally representative sample of pregnant women from 2005-14 showed a 
prevalence of past-year NMUPO of 5.1% and a prevalence of past-month NUMPO of 
0.9% (58). 
2.3.3.4 Polysubstance-Related Use Disorders 
Epidemiologic studies which have focused on investigating polysubstance-related use 
disorders have provided a range of evidence characterising individuals with 
polysubstance-related use disorders. Analysis of the 2015 Global Drug Survey, an 
international survey covering the UK, Australia, and the US, using latent class analysis 
(LCA) suggests that over half of the respondents exhibited polysubstance use (59). An 
American study of a nationally representative survey supports the relatively high 
prevalence of polysubstance-related use disorders, with over half of all respondents with 
an opioid-related use disorder reporting a co-occurring SUD and almost 100% of 
respondents with a hallucinogen-related use disorder reporting a co-occurring SUD 
(60). This high rate of polysubstance-related use disorders is also reflected in a number 
of subpopulations, including women (61), Native Americans (62) and HIV care enrolees 
(63). 
Given the intense interest in opioids noted earlier, a growing body of evidence 
has recently emerged investigating the relationship between opioid-related use disorders 
and heroin related-use disorders specifically, given growing concerns over the 
unintended consequences of novel, abuse-deterrent formulations of oxycodone (64). 
Multiple studies have found evidence to suggest that the prevalence of heroin use and 
heroin use disorders has increased significantly among individuals who engage in 
NMUPO with especially pronounced effects among non-Hispanic White individuals 
and young adults (50, 65-67). In addition, a geospatial analysis of prescription opioid- 
and heroin-related overdose hospitalizations conducted by Unick and Ciccarone from 
2000-2014 has revealed significant disparities in geographic and demographic 
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distributions, suggesting that the relationship between NMUPO and heroin use is not 
simply a case of substance switching among users (68). 
2.3.3.5 Treatment of SUDs 
Studies which have examined trends and patterns in the treatment of SUDs can be 
broadly categorised into two types: those examining perceived need for treatment or 
treatment-seeking among individuals with SUDs and those examining SAT facilities or 
SUD treatment itself.  
Studies looking at perceived need for treatment suggest nearly all adults with 
SUD but no diagnosable health condition, especially those aged 65 and over, do not 
perceive a need for treatment and, consequently, do not receive treatment (69, 70). 
Rates of treatment-seeking in the first year after disorder onset vary by condition, 
ranging from 1-2% for drug or alcohol abuse, 5% for alcohol dependence, and 13% for 
drug dependence (71). One study examining differences in expressed unmet need 
among ethnic minorities provides evidence that Asians and Hispanics with past-year 
SUD exhibit higher likelihood of unmet need for specialty treatment than non-Hispanic 
White Americans (72). 
Several studies have examined characteristics of SAT facilities or SUD 
treatment. Firstly, there is evidence to suggest that SAT facilities have responded during 
periods of economic downturn with a 2.5% reduction in outpatient clinics by non-profit 
providers and a 1.8% increase in the acceptance of private insurance as a form of 
payment (73). Moreover, over the first decade of the 2000s, a period characterised by 
economic recession in the United States, the number of publicly owned SAT facilities 
has declined about 20% while the number of private, for-profit facilities grew about 
20% (74). With respect to SUD treatment, multiple studies have highlighted ethnic 
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disparities in treatment completion with worse rates of treatment completion among 
Black or African Americans and Hispanic Americans (75, 76). 
2.3.3.6 Comorbid Psychiatric Disorders 
Given the complex nature of SUDs, several studies have considered the effects of 
comorbid psychiatric disorders on SUDs and their treatment, specifically depression and 
post-traumatic stress disorder (PTSD).  
Depression as a comorbid condition to SUDs is a documented predictor of 
substance use or SUD for a variety of substances across the general population (42, 47, 
70, 77, 78) and a variety of subpopulations (41, 45, 58, 79-87). In the general 
population, researchers have noted that comorbid depression is, for example, 
significantly associated with cocaine use or cocaine use disorder (49), marijuana and 
inhalant use (47), and alcohol use disorder (42). For women, researchers have observed 
the increased likelihood of NMUPO among women with comorbid depression (80), for 
instance, including among pregnant women (58). Research into the ways in which 
comorbid depression and SUDs are associated among ethnic minority subpopulations 
suggest that comorbid depression mediates the relationship between perceived 
discrimination and substance use (79) and can also predict SUDs among recent migrants 
(83). Comorbid depression is also a major predictor of SUDs among sexual minority 
subpopulations, including MSM (45) and transgender individuals (82). Finally, among 
attorneys and physicians, major depressive symptoms and SUDs were highly associated 
(84, 85).  
Three studies in this narrative synthesis focused on the effects of comorbid 
PTSD on SUDs among US veterans (81, 88, 89). These studies highlight the heightened 
risk of SUDs disorders among veterans suffering from comorbid PTSD; Calhoun et al. 
find, for instance, that frequent binge alcohol use was associated with comorbid PTSD 
among veterans with military service in Iraq or Afghanistan (88). Hawkins et al. 
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provide evidence of increased prescription of opioids and benzodiazepine among high-
risk veterans with comorbid PTSD (89). Golub et al. highlight relatively high rates of 
unmet need for untreated SUDs among veterans in a nationally representative sample 
(16%), including those with other comorbid serious psychological disorders including 
PTSD (81). 
2.4 Discussion 
2.4.1 Summary of Findings 
This narrative synthesis highlights the many ways in which the epidemiology of SUDs 
has recently evolved. Binge alcohol and AUDs have increased over time not only 
among young adults but also older adults. Illicit substances, including cocaine and 
heroin, have increased as well with disparately high increases in metropolitan areas. 
Further evidence has highlighted the ways in which illicit substance use is mediated 
through racial discrimination and SES. The increase in NMUPO and opioid-related use 
disorders, both among the general population and among various subpopulations, has 
been an emergent and primary concern of researchers recently, with growing evidence 
to support concerns over increasing heroin use among individuals exhibiting NMUPO. 
Concomitant with these documented increases in the prevalence of AUDs, illicit SUDs, 
and prescription SUDs, the marketplace of SAT facilities has been dynamic, showing 
increased rates of ownership by private, for-profit organisations and small reductions in 
outpatient clinics by non-profit providers. Treatment for SUDs has shown emerging and 
increasing disparities in completion rate based on ethnicity. Finally, a growing body of 
evidence has emerged regarding comorbid psychiatric disorders and SUDs, highlighting 
the link between depression and SUDs in the general population and PTSD and SUDs 
in the veteran population. 
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2.4.2 Strengths and Weaknesses 
This review extends from a broad search strategy which captures a wide range of 
articles regarding SUDs, including the epidemiology of alcohol-related use disorders, 
the epidemiology of illicit substance-related use disorders, the epidemiology of misuse 
of prescription drugs such as opioids, the epidemiology of polysubstance-related use 
disorders, the treatment of SUDs, and the epidemiology of SUDs with relation to 
comorbid psychiatric disorders. This comprehensive and varied set of articles reflects 
the complex nature of SUDs and their treatment, providing both information about the 
general American adult population as well as specific subpopulations such as women, 
ethnic minorities, sexual minorities, and veterans. Indeed, some included articles 
provide information regarding the epidemiology of SUDs among especially small, 
specific groups such as transgendered individuals or Asian Americans – groups which 
are not normally the subject of wide scholarly attention. In this way, this narrative 
synthesis provides a robust, comprehensive, and wide-ranging review of recent 
literature on the epidemiology of SUDs among American adults. 
However, this wide focus of the narrative synthesis necessarily means that 
included articles are not always drawn from studies of nationally representative 
samples, limiting the ability to remark upon national trends in all cases. Where possible, 
I have attempted to focus on nationally applicable findings while also highlighting 
specific subpopulations. Moreover, this review draws exclusively from the biomedical 
literature regarding SUDs with an emphasis on characterising epidemiological 
considerations; consequently, given the sociocultural milieu in which SUD exists, 
inclusion of more literature from ethnographic, sociological, and/or anthropological 
disciplines could greatly strengthen this synthesis by providing a qualitative lens with 
which to examine the issues of SUDs and disparities in epidemiology and treatment. 
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2.4.3 Unanswered Questions and Further Research 
While this narrative synthesis has yielded a substantial amount of evidence regarding 
the epidemiology of SUDs, further analyses of nationally representative samples are 
needed to ensure that these findings are taken in context of new data regarding the 
dynamic and evolving drug situation in America. Given the major and ongoing changes 
alongside health reforms and other health policies, updated analyses may yield further 
insights on the contemporary epidemiology of AUDs, illicit SUDs, and prescription 
SUDs, as well as treatment. Furthermore, more systematic approaches to understanding 
the epidemiology of SUDs and their demographic, socioeconomic, and health correlates 
will provide more nuanced evidence to inform future SUD policy. Identification of 
regional or state-based trends and patterns can be instructive. Finally, few studies have 
focused on comparative approaches to the epidemiology of SUDs among adults, 
highlighting a major gap in our knowledge. 
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3 METHODOLOGY 
3.1 Introduction 
In order to address the research questions outlined above, this thesis will present the 
quantitative analyses of administrative and routinely collected datasets. In this chapter, I 
will briefly describe the sources of data and analytic approach undertaken in this thesis. 
Following chapters will provide much greater detail on statistical analyses, including 
specificities regarding coding and variable selection. I will conclude with a discussion 
of the strengths and weaknesses of the general approach undertaken in this thesis with a 
specific emphasis on the use of administrative datasets. 
3.2 Data Sources 
Reliable, longitudinal, and large datasets on the epidemiology and treatment of substance 
use disorders in the United States, both misuse and abuse, are scant given abundant 
methodological problems with tracking and following up study participants with 
diagnosed SUDs (90). Though there are several exceptions (91), extant data sources 
primarily rely upon self-reported data, usually collected through face-to-face interviews, 
and often for well-defined and small subpopulations, given the expenses associated with 
this modality of data collection (90). Other countries, such as the Nordic countries which 
routinely use registry-based methods for substance abuse research (92), have proven more 
successful at developing methodologies for the analysis of substance use disorders in 
nationally representative populations over time yet these methods are not generally 
applicable to the American setting given the limitations outlined above. 
Consequently, administrative datasets, that is to say, routinely collected data for non-
research purposes, have been increasingly used in the substance abuse literature (90). 
Though obtaining access to and linking administrative datasets for research purposes can 
be difficult and problematic, statistical software has increasingly reduced the technical 
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barriers to using them for research purposes and, consequently, the academic use of 
administrative datasets is more widespread than ever (93). 
In the United States, the Substance Abuse and Mental Health Services Administration 
(SAMHSA) maintains several datasets related to substance use disorders, including the 
National Survey on Drug Use and Health (NSDUH), the National Survey of Substance 
Abuse Treatment Services (N-SSATS), and the Treatment Episode Dataset (TEDS) (94). 
3.2.1 National Surveys of Drug Use and Health (NSDUH) 
The NSDUH, known from 1971 to 2002 as the National Household Survey on Drug 
Abuse (NHSDA), is an annual, nationally representative, face-to-face survey of non-
institutionalised, civilian individuals aged 12 and over (95). The NSDUH is the primary 
source of data for the use of licit and illicit substances for several government agencies 
and collects data on mental health issues, including depression and suicide, as well (95). 
Data collection and processing is conducted by RTI International who contracts with 
SAMHSA to coordinate the NSDUH (95). 
3.2.2 National Survey of Substance Abuse Treatment Services (N-SSATS) 
Started in 2000, the N-SSATS is an annual census of all known drug and alcohol abuse 
treatment facilities in the United States (96). Data is collected via online and paper forms 
as well as telephone interviews for facilities that do not respond either online or by mail 
(96). The N-SSATS collects data on the characteristics of treatment facilities as well as 
the number of clients in treatment at the time of survey collection (96). 
3.2.3 Treatment Episode Dataset (TEDS) 
The TEDS is an administrative dataset which compiles data on patient characteristics and 
substance abuse problems for patients aged 12 and over admitted for substance abuse 
treatment (97). This data is collected by state substance abuse agencies (SSAs) and, in 
turn, TEDS aggregates this data nationally (97). SSAs coordinate to provide data to TEDS 
on a Minimum Data Set which includes 19 items and, optionally, a Supplemental Data 
Set which includes another 17 items (97). Notably, TEDS does not account for all 
admissions for substance abuse treatment given variations in state regulations on 
reporting requirements, differential licensure and credential practices, and requirements 
on facilities receiving public funds (97).  
Chapter 3: Methodology 
Justin Christopher Yang- March 2019   49 
3.3 Data Processing 
Public use data were obtained from SAMHSA from the Substance Abuse and Mental 
Health Data Archive (SAMHDA) portal or the Inter-university Consortium for Political 
and Social Research (ICPSR) according to each organisation’s respective data access and 
use agreements. All analyses in this dissertation were conducted using publicly available, 
anonymised datasets and, consequently, no analyses presented here are considered human 
subjects research under the Federal Common Rule, 45 CFR Part 46 (98). As such, no 
ethical approval was required for the use and analysis of these datasets. 
Data were obtained in Stata format, where possible, or as comma-separated files and 
converted into Stata format. Data were further processed using syntax files provided by 
SAMHSA to account for complex survey design in the case of the NSDUH. 
Data were reviewed for completeness in Stata and variables were recoded where 
necessary. While many variables, both dependent and independent, were extant in raw 
data files provided by SAMHSA, some composite variables were created as well to reflect 
the research questions presented. These are detailed in the methodology section under 
each respective analysis.  
3.4 Statistical Analysis 
Statistical analyses were conducted in Stata 14. 
Bivariate descriptive analyses, grouped by year, were conducted in each analysis to 
provide a baseline understanding of the situation underlying each analysis and presented 
in this dissertation in tabular format. Where applicable, as in the case of the NSDUH, 
these analyses are presented as estimates based on analytical weights drawn from the 
complex survey design. 
As most outcome variables of interest in this dissertation were dichotomous, 
multivariable logistic regression was most often used to model the effects of independent 
variables on dependent variables. In most cases, both simple and fully adjusted models 
are presented to highlight the decomposition of effects of independent variables in fully 
adjusted models. All estimates are presented with their accompanying 95% confidence 
intervals. In one case, in Chapter 7: Regional Disparities in Opioid Agonist Treatment 
and Delays to Enter Treatment for Opioid Misuse in the United States, 2003-14) censored 
linear regression was used to analyse delay to enter treatment which was a continuous 
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variable with a capped value. Further details are provided under the methodology section 
for that specific analysis. 
3.5 Discussion 
As noted by Evans et al. (90), there are issues when using administrative data for 
substance abuse research, particularly research focused on repeated cross-sectional data 
as in the case of the NSDUH, N-SSATS, and TEDS. Firstly, although these data are 
routinely collected, questions emerge over the “history” effects which are important to 
consider with recourse to claims involving causal inferences from analyses of these types 
of data; variations in behaviours and outcomes over time may be attributable to external 
factors for which analytic models may not account (90). Moreover, administrative data 
are intrinsically biased as only events which come to the attention of a system providing 
the data is collected in any detail – related yet relevant events may be excluded completely 
(90). Consistency, or lack thereof, in defining qualitative variables can also be 
problematic when using administrative data as categories, such as ethnicity, change over 
time as well as methods of data collection and aggregation (90). Finally, questions 
regarding data collection methods in the first instance are central to assessing the 
applicability of an administrative dataset for specific research questions as well as the 
generalizability of findings from their analyses (90). For instance, although most modules 
of the NSDUH are conducted through a face-to-face interview and rigorous data 
validation and imputation processes, answers to questions regarding illicit substance use 
are completed through a self-completion module without an interviewer in order to 
increase the likelihood of honest answers.  
Despite these limitations, the use of administrative data for substance abuse research is 
expanding as the opportunities afforded by such datasets greatly outweigh potential risks, 
many of which can be mitigated or minimised through judicious study design (90). Firstly, 
the secondary analysis of administrative datasets is highly cost-effective, requiring little 
to no resources for data collection (90). In the case of public use datasets, as in this 
dissertation, no effort is required to obtain permissions to access these administrative 
datasets, other than compliance to user access and use agreements. Administrative data 
are also useful when answering questions regarding systems holistically and how such 
systems change over time, given their comprehensive nature (90). Administrative data 
also offer the opportunity to analyse understudied populations as they often offer sample 
sizes large enough for such populations to power robust statistical analyses (90). In 
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addition, as long as there is consistency in data collection and variable definition, using 
administrative data for research benefits from the opportunity to conduct analyses over 
relatively long periods of time (90).  
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4 BINGE ALCOHOL AND 
SUBSTANCE USE ACROSS 
BIRTH COHORTS AND THE 
GLOBAL FINANCIAL CRISIS 
IN THE UNITED STATES 
4.1 Background 
For Millennials, usually defined as those born after 1982 (99), the global financial crisis 
(GFC) of 2007-9 represents the most significant economic crisis of their lifetimes and 
the most serious economic crisis since 1929 with severe social and economic 
consequences that yielded a contraction of world output by 0.6% with potentially 
serious effects upon population health, economic prospects and overall wellbeing (100). 
In the United States, the origins of the crisis were facilitated by low, introductory 
interest rates on sub-prime loans prior to 2007 (101). As the Federal Reserve began to 
increase interest rates, the delinquency rate on home loans steadily increased which led 
to failures among American mortgage lenders and, eventually, major financial 
institutions, most notably Lehman Brothers (101). What began in the United States as a 
subprime mortgage crisis escalated worldwide when ailing banks, severely exposed by 
the American crisis and at serious risk of defaulting, were bailed out and or nationalised 
by different governments in the EU which, in turn, led to rapid increases to sovereign 
debt obligations and consequent interventions on the part of the European Central Bank, 
the International Monetary Fund, and the European Commission (102). Government 
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responses to the GFC have been varied. In European countries such as the UK, Greece, 
Spain, Ireland, Portugal, governments engaged in austerity and fiscal consolidation 
programmes to cap the growth of public spending and to restore the trust of financial 
markets in European government bonds (103). Consequently, many European countries 
saw major declines in public social spending, such as health and education (104). In 
Greece, for instance, government financing of total inpatient expenditure in the health 
sector declined from 82.5% in 2009 to 75.2% in 2011 (105). These changes in social 
spending have had profound collateral effects on poverty; for instance, material 
deprivation increased in the European Union from 9.1% in 2007 to 9.9% in 2012 (103). 
In Greece, Spain, Italy, and Portugal, Matsaganis and Leventi note that some groups, 
especially the young and the poor, suffered cuts to both social programme funding as 
well as wages, while other groups, such as the elderly, only suffered minor losses to 
material wealth signalling a trend that became common in the retreat of social welfare 
across European countries (106).  
In the United States, the American government, in contrast to their European 
counterparts with the exception of the UK, used austerity as the policy of choice to deal 
with the subprime crisis, but also engaged in a policy of fiscal stimulus through the 
American Recovery and Reinvestment Act of 2009 (ARRA). Despite ARRA’s intended 
effects, the median family income in America dropped by about 8% (107), the 90/10 
ratio, a measure of income inequality, increased by 11% (108), and jobs declined by 
4.2% from 2007-9 (109). In addition, quantitative easing, a policy meant to mitigate 
some of the effects of the GFC by increasing the size of the Federal Reserve’s balance 
sheet from less than $1 Trillion in 2007 to over $4 Trillion in 2015, was linked to 
increased income inequality as wealth among the middle and lower classes stagnated 
and declined with disproportionate effects on the young with control of 40 percent of 
the American GDP by the top 1% (110). Economic inequality and hardship engendered 
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by the GFC and its consequent effects on unfavourable labour markets have particularly 
affected Millennials (111). In the United States, major labour trends such as the increase 
in temporary contingent jobs and the increase in overseas outsourcing have affected the 
entry of Millennials into the professional job ladder (112). For those entering the job 
market in the United States, rising underemployment is as high as one in two among 
recent graduates (113) with wage inequality (112) becoming the status quo. In response, 
Millennials have sought ever higher educational attainment  (114) with over 21 million 
students enrolled in higher education in 2010 (115), accompanied by increasing levels 
of indebtedness (116), partly due to increased reliance on student loans as a financing 
mechanism for higher education in the United States, now $1.4 Trillion or 7.5% of the 
USA GDP (117).  
There is a growing focus on how intergenerational inequality and global 
economic crises have affected population health, particularly with respect to mental 
health in disadvantaged population groups (118), including research into excessive 
drinking (119, 120) and substance use (121). Bor’s study of Americans has found, for 
example, that the prevalence of binge drinking has increased from 4.8% in 2006-7 to 
5.1% in 2008-9, corresponding to a national increase of 770,000 binge drinkers in a 12 
month period (122). The ways in which intergenerational inequality and the GFC have 
impacted the mental health of Americans have been relatively understudied and pose a 
crucial question about how economic crises could differentially affect mental health and 
substance use patterns of different generations. In the analysis presented here, we 
present results from National Survey on Drug Use and Health (NSDUH) from 2007-16 
to describe patterns of binge alcohol and substance use among different generational 
cohorts in the United States during and after the subprime mortgage crisis of 2007-8 
with a focus on the socially and economically vulnerable. Our aim is to see how the 
behaviours of Millennials, Gen X and Baby Boomers have or have not been affected by 
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the GFC. I examine rates of binge alcohol and substance use, as well as characterising 
the ways in which ethnicity and social and economic vulnerability are related to patterns 
of binge drinking and substance use. 
4.2 Methods 
4.2.1 Data Source 
Data for adults aged 18 and over were included from the 2007-16 cohorts of the 
National Survey on Drug Use and Health (NSDUH), an annual, nationally 
representative survey of civilian, non-institutionalised individuals aged 12 and above in 
the United States which measures the prevalence and correlates of substance use and 
self rated health (N=307,935) (123). Household selection for each year’s survey is 
conducted independently in all 50 states and the District of Columbia and excluded 
individuals with no fixed household address, active duty military personnel, and 
individuals living in institutionalised group quarters (123). The survey is administered 
via face-to-face interviews using computer-assisted interviewing (CAI) to increase 
respondents’ cooperation and willingness to report honestly about topics such as illicit 
drug use behaviour and mental health issues (123). Questions pertaining to the use of 
regulated substances are self-administered (123). Sampling and analytical weights are 
calculated based on population estimates from the 2000 or 2010 decennial census and 
provided with the NSDUH dataset to address unit- and individual-level non-response 
(123). Respondents are given a $30 cash incentive following completion of the 
interview (123).  
As the NSDUH is a publicly available dataset, this study was not considered 
human subjects research under the federal Common Rule, 45 CFR Part 46. 
Social disparities in the epidemiology and treatment of substance-related use disorders in the United States, 
2002-16 
56  Justin Christopher Yang – March 2019 
4.2.2 Study Variables 
Drawing upon Eyerman and Turner’s definition of generation, we categorised 
individuals from the NSDUH according to socially and culturally defined three groups, 
namely, Millennials, Generation X (“Gen X”) and Baby Boomers (124). Cohort 
assignment was based on age at the time of each survey where (a) respondents aged 18 
to 34 were classified as Millennials, (b) respondents aged 35 to 49 were classified as 
Gen X, and (c) respondents 50 or older were classified as Baby Boomers. 
Sex was coded as either female or male. Respondent ethnicity was coded as 
White, black, native American, Asian or Pacific Islander, Hispanic or Other. Education 
was coded such an education level of seventh grade or less were categorised as 
elementary, an education level between eighth grade and twelfth grade was categorised 
as secondary, and an education level higher than twelfth grade was categorised as 
tertiary. Marital status was coded as single, married, widowed, and divorced or 
separated. Metropolitan size was coded as large, small, or non-metropolitan based on 
2010 census data and 2009 Core Based Statistical Area classifications provided by the 
Office of Management and Budget (OMB) (123). 
Annual income was categorised as less than $20,000, between $20,000 and 
$49,999, between $50,000 and $74,999, and greater than $75,000. Poverty level, based 
on income as a percentage of the Federal Poverty Level (FPL), was categorised as either 
living in poverty (<100% FPL), income up to 200% FPL, and income above 200% FPL. 
A dichotomous variable was created to indicate whether a respondent received any form 
of government assistance (i.e. Supplemental Security Income, food stamps, cash 
assistance, and/or non-cash assistance). 
Self reported health was categorised as excellent, very good, good, or poor. The 
respondent’s primary health insurer was coded as private, Medicare, Medicaid, Tricare 
& Veterans Administration (VA), other, or uninsured. 
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Measures of past-month substance use were obtained for binge alcohol, cocaine, 
crack, heroin, recreational use of oxycontin (i.e. non-prescription), and 
methamphetamine. We recoded these variables as dichotomous variables indicating 
past-month substance use. In addition, we created two new variables to indicate cases of 
poly-substance use other than binge drinking when individuals responded positively to 
having used (a) more than one substance and (b) any use of a substance within the past-
month. From 2015-16, the NSDUH surveys did capture data regarding past-month 
oxycontin use; consequently, for these years, we do not report past-month oxycontin 
use. 
A new composite variable was created to measure social and economic 
vulnerability on a five-point scale. The index is a composite of multiple quantitative 
indicators of social and health vulnerability that by aggregating data in a continuous 
form delivers a single numerical result for each participant of the NSDUH. Through 
such an index, diverse issues can be combined into a standardised framework making 
comparisons possible One point was given for each of (a) uninsured or insured on 
Medicaid, (b) government assistance recipient, (c) annual household income less than 
$20,000, (d) poor self rated health, and (e) unemployment. Consequently, I adjudicated 
a score of 0 to indicate the least vulnerable while a score of 5 to indicate the most 
vulnerable, based on the criteria described above. This is the first attempt to develop an 
index with respect to social and economic vulnerability when analysing substance use in 
the USA though vulnerability as a construct is accepted as a construct in other 
population analyses (125-128). 
The NSDUH addresses item nonresponse using an imputation method known as 
predictive mean neighbourhood (PMN) which has been applied to NSDUH datasets 
since 1999 (123). PMN is applied in a stepwise fashion: (a) response propensity 
adjustment; (b) prediction modelling; and (c) hot-deck imputation (123). In the NSDUH 
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data imputation was used extensively for variables pertaining to ethnicity and 
government assistance and slightly less for education, marital status, income, and health 
insurer (123). 
4.2.3 Statistical Analysis 
All statistical analyses were performed in Stata 14. The NSDUH has a cross-sectional 
survey design with data collection each year conducted independently. Consequently, 
datasets from individual years were combined into a single file for analysis to allow for 
comparison between years. As our outcome variables of interest were dichotomous, we 
utilised bivariate descriptive analysis and multiple maximum-likelihood logit 
regressions with weighted least squares on (a) individual substances and binge drinking, 
(b) poly substance use and (c) any use to simultaneously model how socioeconomic, 
demographic, and health characteristics were related to past-month substance use for 
binge either alcohol, cocaine, crack, heroin, oxycontin, and methamphetamine a 
combination of any of these or any use of them. In our logistic regressions, Generation 
X served as the reference group against which Millennials and Baby Boomers were 
compared. Unadjusted and adjusted odds ratios (OR) with 95% CI’s were calculated for 
the odds of past month substance use and binge drinking. Multiple logistic regression 
analyses were done for past-month use of each of binge alcohol, cocaine, crack, heroin, 
oxycontin, and methamphetamine, separately adjusting for generational cohort, year, 
sex, ethnicity, level of education, marital status, self-reported health, metropolitan size, 
type of health insurance, government assistance status, income, and income as a 
percentage of FPL. All analyses were weighted to account for the complex survey 
design of the NSDUH using analytical weights provided with each dataset. 
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4.3 Results 
The descriptive characteristics of our sample are shown in Table 2. 
Binge alcohol use was highest among Millennials (37.83%; 95% CI= 37.50%-38.15%) 
and lowest among Baby Boomers (14.66%; 95% CI= 14.33%-15.01%) with Gen X 
falling somewhere in between (27.04%; 95% CI= 26.64-27.45%). Use of binge alcohol 
varied significantly between generational cohorts from 2007-16 (F (2,109) = 3792.99, 
p<0.005). These patterns are shown in Figure 6 below. 
 
Figure 6 Prevalence of Binge Alcohol, Cocaine, Crack, Oxycontin, Heroin, and 
Methamphetamine Use by Generational Cohort, 2007-16. Error bars denote 95% 
confidence intervals. 
Use of cocaine varied significantly between generational cohorts from 2007-16 
(F (2,109) = 161.92, p<0.005) as shown in Figure 6. As with binge alcohol, use was 
highest among Millennials (1.31%; 95% CI= 1.24%-1.40%) and lowest among Baby 
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Boomers (0.27%; 95% CI= 0.23%-0.32%), with Gen X (0.70%; 95% CI= 0.64%-
0.77%) in the middle. 
Use of crack is notably higher among Gen X (0.28%; 95% CI= 0.23%-0.33%) as 
compared with Millennials (0.15%; 95% CI= 0.13%-0.17%) and Baby Boomers 
(0.12%; 95% CI= 0.10%-0.16%), particularly in 2007 as shown in Figure 6. Heroin (F 
(2,109) = 59.11, p<0.005), oxycontin (F (2,109) = 44.34, p<0.005), and 
methamphetamine (F (2,109) = 26.72, p<0.005) all varied significantly among 
generational cohorts. 
The variations in past-month substance use among generational cohorts is shown 
in Table 3where, generally, we observe levels of binge alcohol use among all 
generational cohorts ranging between 25-40% as previously mentioned and markedly 
low levels (<4%) of other substance use (i.e. cocaine, crack, heroin, oxycontin, and 
methamphetamine) among all generational cohorts, especially Baby Boomers. Crack 
use is almost twice as much among Gen X as in Millennials. Poly-use, or the use of at 
least two substances excluding binge alcohol, was highest among Gen X (0.34%; 95% 
CI=0.29%-0.39%), followed by Millennials (0.31%; 95% CI=0.27%-0.34%) and lowest 
among Baby Boomers (0.15%; 95% CI=0.12%-0.19%). 
The results of unadjusted and adjusted multivariable logistic regression of 
substance use and generational cohort are also shown in Table 3. Controlling for year, 
socioeconomic, demographic, and health covariates, Millennials showed significantly 
higher odds of use of binge alcohol (AOR=1.51; 95% CI=1.46-1.56) and oxycontin 
(AOR=2.33; 95% CI=1.74-3.12) than Gen X while Baby Boomers showed significantly 
lower odds of use of all substances: binge alcohol (AOR=0.56; 95% CI=0.54-0.58), 
cocaine (AOR=0.44; 95% CI=0.35-0.56), crack (AOR=0.54; 95% CI=0.37-0.79), 
heroin (AOR=0.37; 95% CI=0.21-0.64), oxycontin (AOR=0.42; 95% CI=0.24-0.72), 
methamphetamine (AOR=0.36; 95% CI=0.26-0.52), and poly-use (AOR=0.37; 95% 
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CI=0.30-0.47). Millennials demonstrated significantly lower odds of crack use 
(AOR=0.33; 95% CI=0.25-0.43) and poly-use (AOR=0.56; 95% CI=0.45-0.70) as 
compared to Gen X. 
The range of vulnerability in the study population is shown in Figure 7. Average 
vulnerability was highest among Millennials (0.97; 95% CI=0.96-0.98) and lowest 
among Baby Boomers (0.65; 95% CI=0.64-0.66) with Gen X in the middle (0.72; 95% 
CI=0.71-0.73). As shown in Table 4, increased vulnerability is associated with 
increased odds of use of cocaine, crack, heroin, oxycontin, and methamphetamine with 
particularly pronounced effects on crack, heroin, and methamphetamine use. For 
instance, for crack use, those with a vulnerability score of 1 exhibit an adjusted odds 
ratio of 3.96 (95% CI=2.49-6.30) while those with a vulnerability score of 5 exhibit an 
adjusted odds ratio of 55.32 (24.63-124.28).  
 
Figure 7 Patterns in Social and Economic Vulnerability by Generational Cohort, 2007-
16. Error bars denote 95% confidence intervals. 
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As shown in Error! Reference source not found., we observe some patterns of 
substance use associated with generational cohort and vulnerability by year. The highest 
prevalence of cocaine, crack, heroin, and poly-use was observed among individuals of 
highest vulnerability from the Generation X cohort during 2009. Among Millennials, 
use of methamphetamine and poly-use was highest in 2013. 
 
Figure 8 Patterns in Prevalence of Substance Use by Generational Cohort and 
Vulnerability, 2007-16. Grey cells denote missing data. 
Table 5 shows the results of multivariable logistic regression for past-month use 
of any substance against other socioeconomic, demographic, and health variables in this 
study. Women demonstrated significantly lower odds of substance use in general 
(AOR=0.48; 95% CI=0.43-0.52) as were those of Asian & Pacific Islander descent 
(AOR=0.34; 95% CI=0.25-0.46). Those with either secondary (AOR=1.89; 95% 
CI=1.30-2.74) or tertiary education (AOR=1.92; 95% CI=1.32-2.81) showed higher 
odds of substance use than those with only an elementary education. Those making over 
$20,000 a year were showed lower odds of substance use. Individuals who were married 
Chapter 4: Binge alcohol and substance use across birth cohorts and the global financial crisis in the United 
States 
Justin Christopher Yang- March 2019   63 
(AOR=0.30; 95% CI=0.25-0.35) or widowed (AOR=0.36; 95% CI=0.22-0.57) showed 
lower odds of substance use than single individuals.  
Figure 9 depicts patterns of substance use by generational cohort and ethnicity 
from 2007-16. Native Americans among the Millennial cohort exhibited the greatest 
prevalence of poly-use in 2014. Substance use appears higher among Millennials, 
primarily White and Native American Millennials, than other generational cohorts. 
Among Generation X, substance use appears highest among those identifying as Native 
American or Other, particularly in 2012 for cocaine, crack, and poly-use, and in 2014 
for poly-use. 
 
Figure 9 Patterns in Prevalence of Substance Use by Generational Cohort and Ethnicity, 
2007-16. Grey cells denote missing data. 
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Table 2 Sample characteristics for adults age 18 and over by percentage (%), 2007-16 
Characteristic 
2007 
(n=37,708) 
2008 
(n=37,504) 
2009 
(n=37,707) 
2010 
(n=38,919) 
2011 
(n=39,133) 
2012 
(n=37,869) 
2013 
(n=37,424) 
2014 
(n=41,671) 
2015 
(n=43,561) 
2016 
(n=42,625) 
Age Cohort           
Millennial 
30.6 
(29.7-31.3) 
30.5 
(30.0-31.4) 
30.7 
(30.0-31.6) 
30.8 
(29.6-31.2) 
30.4 
(29.7-31.2) 
30.4 
(29.5-31.3) 
30.4 
(29.7-30.9) 
30.3 
(29.4-31.0) 
30.2 
(29.4-30.7) 
30.0 
(30.1-30.7) 
Gen X 
29.3 
(28.0-29.4) 
28.7 
(27.3-29.1) 
28.2 
(26.6-28.1) 
27.3 
(25.6-27.1) 
26.4 
(25.1-26.7) 
25.9 
(24.8-26.4) 
25.6 
(24.4-25.8) 
25.1 
(24.3-25.5) 
24.9 
(24.2-25.5) 
24.8 
(26.3-26.8) 
Baby Boomer 
40.1 
(39.9-41.8) 
40.8 
(40.0-42.2) 
41.1 
(40.9-42.9) 
41.9 
(42.2-44.3) 
43.2 
(42.6-44.8) 
43.7 
(42.9-45.2) 
44.0 
(43.7-45.5) 
44.6 
(44.0-45.9) 
45.0 
(44.3-46.1) 
45.2 
(42.6-43.4) 
           
Sex           
Male 
48.2 
(47.4-49.1) 
48.3 
(47.3-49.2) 
48.3 
(47.4-49.2) 
48.4 
(47.5-49.3) 
48.1 
(47.3-48.9) 
48.1 
(47.3-49.0) 
48.2 
(47.3-49.0) 
48.2 
(47.6-48.8) 
48.2 
(47.5-49.0) 
48.2 
(47.6-48.9) 
Female 
51.8 
(50.9-52.6) 
51.7 
(50.8-52.7) 
51.7 
(50.8-52.7) 
51.6 
(50.7-52.5) 
51.9 
(51.1-52.8) 
51.9 
(51.0-52.7) 
51.8 
(51.0-52.7) 
51.8 
(51.2-52.4) 
51.8 
(51.1-52.5) 
51.8 
(51.1-52.5) 
           
Ethnicity           
White 
69.2 
(68.1-70.2) 
68.8 
(67.9-69.7) 
68.4 
(67.4-69.4) 
68.0 
(67.2-68.9) 
66.7 
(65.9-67.6) 
66.3 
(65.2-67.3) 
65.8 
(64.7-66.9) 
65.3 
(64.2-66.3) 
64.7 
(63.7-65.7) 
64.4 
(63.5-65.3) 
Black 
11.4 
(10.7-12.2) 
11.5 
(10.9-12.1) 
11.6 
(11.0-12.3) 
11.6 
(11.0-12.3) 
11.5 
(10.9-12.1) 
11.6 
(10.9-12.3) 
11.7 
(10.9-12.6) 
11.7 
(11.1-12.4) 
11.8 
(11.2-12.4) 
11.8 
(11.2-12.4) 
Native American 
13.3 
(12.5-14.1) 
13.5 
(12.9-14.1) 
13.7 
(13.0-14.5) 
13.9 
(13.3-14.5) 
14.6 
(13.9-15.4) 
14.8 
(14.1-15.5) 
15.0 
(14.4-15.7) 
15.3 
(14.5-16.2) 
15.6 
(14.9-16.3) 
15.7 
(15.2-16.4) 
Asian & Pacific Islander 
4.6 
(4.2-5.0) 
4.7 
(4.2-5.2) 
4.8 
(4.2-5.4) 
4.8 
(4.4-5.3) 
5.2 
(4.7-5.8) 
5.3 
(4.9-5.9) 
5.4 
(4.8-6.1) 
5.6 
(5.2-6.2) 
5.8 
(5.3-6.3) 
5.8 
(5.4-6.3) 
Hispanic 
0.5 
(0.4-0.6) 
0.4 
(0.4-0.5) 
0.5 
(0.4-0.6) 
0.5 
(0.4-0.6) 
0.5 
(0.5-0.7) 
0.6 
(0.4-0.7) 
0.5 
(0.4-0.6) 
0.5 
(0.4-0.6) 
0.5 
(0.4-0.6) 
0.6 
(0.5-0.7) 
Other 
1.1 
(0.9-1.2) 
1.1 
(1.0-1.3) 
1.1 
(0.9-1.2) 
1.1 
(1.0-1.4) 
1.4 
(1.2-1.5) 
1.5 
(1.2-1.7) 
1.5 
(1.3-1.7) 
1.5 
(1.4-1.7) 
1.6 
(1.5-1.8) 
1.7 
(1.5-1.8) 
           
Employment           
Full-Time 
54.5 
(53.7-55.4) 
54.2 
(53.1-55.2) 
50.6 
(49.7-51.5) 
49.9 
(48.9-50.9) 
49.8 
(48.8-50.7) 
50.0 
(49.2-50.9) 
50.1 
(49.1-51.0) 
51.2 
(50.4-51.9) 
48.8 
(48.1-49.5) 
49.2 
(48.5-50.0) 
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Characteristic 
2007 
(n=37,708) 
2008 
(n=37,504) 
2009 
(n=37,707) 
2010 
(n=38,919) 
2011 
(n=39,133) 
2012 
(n=37,869) 
2013 
(n=37,424) 
2014 
(n=41,671) 
2015 
(n=43,561) 
2016 
(n=42,625) 
Part-Time 
13.3 
(12.7-13.9) 
13.6 
(13.0-14.1) 
13.9 
(13.3-14.5) 
14.4 
(13.9-15.0) 
14.0 
(13.4-14.5) 
14.0 
(13.5-14.5) 
14.2 
(13.6-14.9) 
13.8 
(13.3-14.2) 
13.4 
(13.0-13.8) 
13.1 
(12.6-13.7) 
Unemployed 
3.2 
(3.0-3.5) 
4.0 
(3.6-4.3) 
6.6 
(6.2-6.9) 
6.5 
(6.1-6.8) 
5.8 
(5.5-6.2) 
5.7 
(5.4-6.1) 
5.0 
(4.7-5.3) 
4.5 
(4.3-4.8) 
4.7 
(4.5-5.0) 
4.6 
(4.3-4.8) 
Other (including not in labour force) 
29.0 
(28.2-29.8) 
28.3 
(27.4-29.3) 
29.0 
(28.0-30.0) 
29.2 
(28.3-30.2) 
30.5 
(29.4-31.5) 
30.3 
(29.4-31.2) 
30.7 
(29.8-31.6) 
30.6 
(29.8-31.3) 
33.1 
(32.3-34.0) 
33.1 
(32.5-33.8) 
           
Education           
Elementary 
3.9 
(3.5-4.5) 
3.5 
(3.2-3.9) 
3.0 
(2.8-3.3) 
3.4 
(3.0-3.8) 
3.0 
(2.7-3.3) 
3.1 
(2.7-3.4) 
3.2 
(2.8-3.6) 
3.2 
(3.0-3.5) 
3.0 
(2.7-3.4) 
3.0 
(2.8-3.2) 
Secondary 
43.0 
(42.1-43.9) 
43.1 
(42.2-44.1) 
43.0 
(41.9-44.2) 
42.2 
(41.2-43.1) 
41.1 
(40.3-42.0) 
41.2 
(40.4-42.0) 
40.0 
(38.8-40.9) 
38.9 
(38.0-39.8) 
36.5 
(35.7-37.4) 
35.2 
(34.5-35.9) 
Tertiary 
53.1 
(52.2-53.9) 
53.4 
(52.4-54.4) 
54.0 
(52.9-55.1) 
54.5 
(53.5-55.5) 
55.8 
(55.0-56.7) 
55.8 
(55.0-56.6) 
57.0 
(55.9-58.1) 
57.9 
(57.0-58.8) 
60.5 
(59.6-61.4) 
61.8 
(61.1-62.5) 
           
Income           
Less than 20,000 
18.3 
(17.5-19.1) 
17.0 
(16.3-17.7) 
17.6 
(16.9-18.4) 
18.7 
(17.9-19.6) 
19.3 
(18.6-20.1) 
18.9 
(18.2-19.6) 
18.4 
(17.5-19.3) 
18.2 
(17.6-18.9) 
17.9 
(17.3-18.4) 
17.0 
(16.3-17.7) 
20,000 to 49,999 
33.1 
(32.1-34.1) 
32.5 
(31.7-33.4) 
32.8 
(32.0-33.6) 
33.5 
(32.5-34.4) 
32.5 
(31.7-33.3) 
33.0 
(32.0-33.9) 
31.5 
(30.7-32.3) 
31.0 
(30.1-31.9) 
30.0 
(29.3-30.8) 
30.0 
(29.3-30.7) 
50,000 to 74,999 
18.3 
(17.4-19.2) 
18.5 
(17.8-19.3) 
17.2 
(16.6-17.9) 
16.9 
(16.2-17.5) 
17.1 
(16.5-17.7) 
16.6 
(15.9-17.3) 
17.2 
(16.4-18.0) 
16.7 
(16.1-17.3) 
16.7 
(16.1-17.2) 
15.9 
(15.3-16.6) 
More than 75,000 
30.4 
(29.4-31.3) 
32.0 
(31.0-33.0) 
32.4 
(31.2-33.6) 
31.0 
(29.8-32.1) 
31.1 
(30.2-32.0) 
31.6 
(30.5-32.7) 
33.0 
(31.7-34.2) 
34.1 
(33.2-35.1) 
35.5 
(34.6-36.4) 
37.1 
(36.1-38.1) 
           
Marital Status           
Single 
25.3 
(24.5-26.1) 
26.1 
(25.4-26.8) 
26.7 
(25.9-27.4) 
26.7 
(25.9-27.5) 
26.7 
(25.9-27.5) 
27.1 
(26.3-27.9) 
27.6 
(26.7-28.5) 
28.0 
(27.2-28.7) 
27.1 
(26.6-27.7) 
28.5 
(27.8-29.3) 
Married 
55.4 
(54.5-56.3) 
55.0 
(54.2-55.9) 
54.6 
(53.5-55.7) 
52.7 
(51.7-53.6) 
52.9 
(51.9-53.9) 
52.6 
(51.7-53.6) 
52.1 
(51.1-53.1) 
51.9 
(51.1-52.7) 
52.7 
(52.0-53.5) 
51.7 
(50.9-52.5) 
Widowed 
6.0 
(5.5-6.5) 
6.0 
(5.6-6.5) 
5.7 
(5.3-6.2) 
6.4 
(5.9-6.9) 
6.0 
(5.5-6.4) 
6.0 
(5.5-6.6) 
6.1 
(5.5-6.8) 
5.8 
(5.4-6.1) 
6.2 
(5.9-6.6) 
5.9 
(5.5-6.3) 
Divorced or Separated 
13.4 
(12.7-14.0) 
12.9 
(12.2-13.6) 
13.0 
(12.4-13.7) 
14.2 
(13.6-14.9) 
14.5 
(13.8-15.1) 
14.3 
(13.7-14.8) 
14.2 
(13.6-14.7) 
14.4 
(13.9-14.9) 
13.9 
(13.4-14.5) 
13.9 
(13.4-14.4) 
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Characteristic 
2007 
(n=37,708) 
2008 
(n=37,504) 
2009 
(n=37,707) 
2010 
(n=38,919) 
2011 
(n=39,133) 
2012 
(n=37,869) 
2013 
(n=37,424) 
2014 
(n=41,671) 
2015 
(n=43,561) 
2016 
(n=42,625) 
Self Rated Health           
Excellent 
23.2 
(22.6-23.9) 
23.2 
(22.4-24.0) 
23.5 
(22.7-24.2) 
23.0 
(22.2-23.7) 
23.2 
(22.4-23.9) 
21.7 
(20.9-22.5) 
22.3 
(21.5-23.0) 
21.4 
(20.8-22.0) 
21.7 
(21.0-22.3) 
21.1 
(20.5-21.6) 
Very Good 
36.1 
(35.3-36.9) 
35.8 
(34.8-36.9) 
36.2 
(35.4-37.1) 
36.6 
(35.7-37.5) 
36.1 
(35.4-36.8) 
36.4 
(35.7-37.2) 
36.2 
(35.5-37.0) 
35.9 
(35.2-36.7) 
35.1 
(34.4-35.9) 
35.8 
(35.1-36.5) 
Good 
27.1 
(26.3-27.9) 
27.5 
(26.7-28.4) 
27.5 
(26.7-28.5) 
26.9 
(26.0-27.8) 
27.0 
(26.4-27.6) 
28.3 
(27.5-29.1) 
28.0 
(27.3-28.8) 
28.7 
(28.0-29.3) 
29.3 
(28.5-30.0) 
29.2 
(28.4-30.0) 
Poor 
13.6 
(12.9-14.4) 
13.5 
(12.7-14.2) 
12.8 
(12.2-13.4) 
13.6 
(12.8-14.4) 
13.7 
(13.1-14.4) 
13.6 
(12.8-14.3) 
13.5 
(12.7-14.3) 
14.0 
(13.5-14.5) 
14.0 
(13.4-14.5) 
14.0 
(13.4-14.6) 
           
Metropolitan Statistical Area Size           
Large Metropolitan 
53.4 
(52.2-54.5) 
53.3 
(52.2-54.4) 
53.1 
(51.9-54.3) 
53.6 
(52.4-54.8) 
53.2 
(52.0-54.3) 
53.4 
(52.3-54.6) 
53.7 
(52.6-54.8) 
55.2 
(54.2-56.1) 
54.6 
(53.5-55.7) 
55.7 
(54.8-56.7) 
Small Metropolitan 
30.2 
(29.0-31.4) 
30.1 
(29.1-31.1) 
30.4 
(29.3-31.7) 
30.4 
(29.2-31.6) 
31.3 
(30.0-32.6) 
30.2 
(28.8-31.6) 
30.1 
(28.8-31.4) 
29.3 
(28.4-30.3) 
30.1 
(29.1-31.2) 
29.9 
(28.9-30.9) 
Non– Metropolitan 
16.4 
(15.7-17.2) 
16.6 
(15.7-17.6) 
16.5 
(15.5-17.5) 
16.1 
(15.3-16.8) 
15.6 
(14.7-16.5) 
16.4 
(15.4-17.4) 
16.2 
(15.2-17.3) 
15.5 
(14.7-16.3) 
15.3 
(14.6-16.0) 
14.4 
(13.5-15.3) 
           
Health Insurer           
Private 
69.1 
(68.2-70.1) 
69.4 
(68.4-70.4) 
67.9 
(67.0-68.7) 
65.9 
(64.8-66.9) 
65.0 
(64.1-66.0) 
64.6 
(63.6-65.6) 
65.7 
(64.7-66.6) 
66.1 
(65.1-67.1) 
66.3 
(65.6-66.9) 
67.2 
(66.5-67.9) 
Medicare 
6.6 
(6.0-7.3) 
7.3 
(6.7-8.0) 
7.0 
(6.5-7.5) 
7.5 
(6.9-8.2) 
8.2 
(7.6-8.8) 
8.8 
(8.2-9.4) 
8.2 
(7.5-8.9) 
8.9 
(8.4-9.5) 
8.6 
(8.2-9.1) 
9.0 
(8.5-9.5) 
Medicaid 
5.6 
(5.2-5.9) 
5.2 
(4.8-5.48) 
5.7 
(5.4-6.1) 
6.2 
(5.8-6.6) 
6.9 
(6.5-7.3) 
6.5 
(6.1-6.9) 
6.9 
(6.5-7.3) 
8.6 
(8.1-9.0) 
10.1 
(9.7-10.5) 
10.3 
(9.9-10.7) 
Tricare & VA 
1.6 
(1.4-1.8) 
1.5 
(1.3-1.7) 
1.7 
(1.5-1.9) 
1.6 
(1.4-1.9) 
1.8 
(1.6-2.2) 
2.0 
(1.8-2.3) 
1.9 
(1.6-2.1) 
2.0 
(1.8-2.2) 
1.9 
(1.7-2.1) 
1.9 
(1.7-2.1) 
Other 
1.8 
(1.6-2.1) 
1.5 
(1.4-1.7) 
1.8 
(1.6-2.1) 
2.0 
(1.8-2.3) 
1.8 
(1.6-2.0) 
2.0 
(1.8-2.3) 
1.7 
(1.5-1.8) 
2.1 
(2.0-2.3) 
2.6 
(2.4-2.8) 
2.2 
(2.0-2.4) 
Uninsured 
15.4 
(14.6-16.1) 
15.1 
(14.5-15.8) 
15.9 
(15.3-16.6) 
16.8 
(16.3-17.4) 
16.3 
(15.8-16.9) 
16.0 
(15.4-16.7) 
15.7 
(15.1-16.3) 
12.3 
(11.9-12.8) 
10.6 
(10.2-11.0) 
9.5 
(9.1-10.0) 
           
Receives Government Assistance           
No 
85.4 
(84.8-86.0) 
86.0 
(85.3-86.8) 
84.4 
(83.8-85.0) 
82.6 
(81.9-83.2) 
80.6 
(79.9-81.3) 
79.6 
(78.9-80.3) 
79.3 
(78.5-80.1) 
79.8 
(79.2-80.4) 
80.3 
(79.7-80.8) 
81.3 
(80.7-81.8) 
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Characteristic 
2007 
(n=37,708) 
2008 
(n=37,504) 
2009 
(n=37,707) 
2010 
(n=38,919) 
2011 
(n=39,133) 
2012 
(n=37,869) 
2013 
(n=37,424) 
2014 
(n=41,671) 
2015 
(n=43,561) 
2016 
(n=42,625) 
Yes 
14.6 
(14.0-15.2) 
14.0 
(13.2-14.8) 
15.6 
(15.0-16.2) 
17.4 
(16.8-18.1) 
19.4 
(18.7-20.1) 
20.4 
(19.7-21.1) 
20.7 
(19.9-21.5) 
20.2 
(19.6-20.8) 
19.7 
(19.2-20.3) 
18.7 
(18.2-19.3) 
           
Income as % of Federal Poverty 
Level 
          
<100% FPL 
11.6 
(11.0-12.2) 
11.4 
(10.9-12.0) 
12.1 
(11.6-12.6) 
12.8 
(12.2-13.4) 
14.0 
(13.4-14.7) 
15.9 
(15.3-16.5) 
14.7 
(14.1-15.4) 
15.1 
(14.6-15.6) 
15.2 
(14.7-15.7) 
14.5 
(14.0-15.1) 
100– 199% FPL 
17.9 
(17.1-18.6) 
18.3 
(17.6-19.0) 
19.6 
(18.9-20.3) 
20.9 
(20.1-21.7) 
20.7 
(20.0-21.4) 
19.2 
(18.5-19.9) 
19.6 
(18.8-20.4) 
19.7 
(19.0-20.3) 
20.2 
(19.5-20.9) 
20.1 
(19.5-20.8) 
>= 200% FPL 
70.5 
(69.6-71.5) 
70.3 
(69.4-71.2) 
68.3 
(67.3-69.2) 
66.3 
(65.3-67.4) 
65.3 
(64.4-66.2) 
64.9 
(64.0-65.8) 
65.7 
(64.6-66.7) 
65.3 
(64.3-66.3) 
64.7 
(63.8-65.5) 
65.3 
(64.5-66.2) 
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Table 3 Unadjusted and adjusted multiple logistic regression of generational cohort associated with past-month substance use and poly-use for adults, 
2007-16 
  Millennial Gen X 
Baby 
Boomer 
 Unadjusted  Adjusted* 
  
(n = 
237,910) 
(n = 
88,402) 
(n = 
67,809) 
 Millennial Gen X Baby Boomer  Millennial Gen X Baby Boomer 
  % % %   OR 95% CI OR 
95% 
CI 
OR 95% CI   OR 95% CI OR 
95% 
CI 
OR 95% CI 
Binge Alcohol 37.83 27.04 14.66  1.64† 
(1.60– 
1.68) 
1  0.46† 
(0.45– 
0.48) 
 1.51† 
(1.46– 
1.56) 
1  0.56† 
(0.54– 
0.58) 
Cocaine 1.31 0.7 0.27  1.88† 
(1.68– 
2.12) 
1  0.38† 
(0.31– 
0.47) 
 1.19† 
(1.03– 
1.37) 
1  0.44† 
(0.35– 
0.56) 
Crack 0.15 0.28 0.12  0.54† 
(0.42– 
0.70) 
1  0.45† 
(0.34– 
0.60) 
 0.33† 
(0.25– 
0.43) 
1  0.54† 
(0.37– 
0.79) 
Heroin 0.26 0.11 0.04  2.28† 
(1.76– 
2.97) 
1  0.35† 
(0.22– 
0.58) 
 1.39† 
(1.01– 
1.91) 
1  0.37† 
(0.21– 
0.64) 
Oxycontin 0.37 0.14 0.06  2.68 
(1.98– 
3.62) 
1  0.44 
(0.27– 
0.72) 
 2.33† 
(1.74– 
3.11) 
1  0.42 
(0.24– 
0.72) 
Methamphetamine 0.28 0.26 0.09  1.09 
(0.89– 
1.34) 
1  0.36† 
(0.27– 
0.49) 
 0.89 
(0.67– 
1.18) 
1  0.36† 
(0.26– 
0.52) 
Poly– Use 0.31 0.34 0.15  0.90 
(0.73– 
1.10) 
1  0.44† 
(0.33– 
0.58) 
 0.56 
(0.45– 
0.70) 
1  0.50† 
(0.36– 
0.71) 
†Denotes statistical significance (i.e. p<0.05) 
*Adjusted for year, age cohort, sex, ethnicity, employment, education, income, marital status, self rated health, metropolitan statistical area size, health insurer, receipt of government 
assistance and income as a % of federal poverty level  
  
Chapter 4: Binge alcohol and substance use across birth cohorts and the global financial crisis in the United States 
Justin Christopher Yang- March 2019   69 
Table 4 Adjusted multiple logistic regression of vulnerability factors associated with past-month substance use and poly-use for adults, 2007-16 
  Vulnerability 
Adjusted 
 0 1 2 3 4 5 
 n 187,749 102,149 56,507 35,194 11,586 936 1 2 3 4 5 
  % % % % % % OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
Binge 
Alcohol 
24.7 25.8 25.0 24.1 26.9 32.0 1 
(1.0 - 
1.0) 
0.91† 
(0.88 - 
0.95) 
0.89† 
(0.85 - 
0.93) 
1.07 
(0.99 - 
1.16) 
1.23 
(0.99 - 
1.53) 
Cocaine 0.4 0.8 1.2 1.5 2.2 2.9 1.90† 
(1.69 - 
2.13) 
2.65† 
(2.26 - 
3.11) 
3.63† 
(3.04 - 
4.33) 
5.4† 
(4.49 - 
6.48) 
6.50† 
(3.56 - 
11.86) 
Crack <0.1 0.2 0.4 0.6 1.1 2.3 3.96† 
(2.49 - 
6.3) 
10.45† 
(6.75 - 
16.18) 
17.42† 
(10.68 - 
28.42) 
28.68† 
(17.4 - 
47.27) 
55.32† 
(24.63 - 
124.28) 
Heroin <0.1 0.1 0.3 0.5 0.5 2.1 2.65† 
(2.01 - 
3.48) 
6.88† 
(5.1 - 
9.28) 
11.58† 
(8.48 - 
15.82) 
11.42† 
(7.55 - 
17.28) 
47.29† 
(21.22 - 
105.39) 
Oxycontin 0.1 0.2 0.3 0.4 0.7 0.3 1.92† 
(1.34 - 
2.75) 
3.74† 
(2.57 - 
5.42) 
4.60† 
(3.14 - 
6.73) 
9.35† 
(5.38 - 
16.26) 
3.33† 
(1.01 - 
10.91) 
Metham-
phetamine 
0.1 0.2 0.5 0.5 0.8 1.7 3.04† 
(2.21 - 
4.17) 
8.56† 
(6.24 - 
11.72) 
8.69† 
(6.15 - 
12.28) 
14.46† 
(8.89 - 
23.54) 
28.91† 
(13.41 - 
62.33) 
Poly- Use 0.1 0.2 0.6 0.8 1.4 2.9 2.78† 
(2.01 - 
3.84) 
8.19 
(5.94 - 
11.29) 
12.02 
(8.43 - 
17.14) 
19.02 
(13.02 - 
27.80) 
37.74 
(18.93 - 
75.24) 
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Table 5 Adjusted multiple logistic regression of socioeconomic, demographic, and health 
variables associated with past-month substance use and any-use for adults, 2007-16 
 
 Any Past– Month Substance Use 
Adjusted*  No Yes 
 
(n = 303,311;  
76.96%) 
(n = 90,810;  
23.04%) 
 % % OR 95% CI 
Sex     
 Male 98.59 1.41 1.00  
 Female 99.33 0.67 0.48† (0.43 – 0.52) 
     
Ethnicity     
 White 98.95 1.05 1.00  
 Black 98.88 1.12 0.57† (0.49 – 0.67) 
 Native American 99.00 1.00 0.56† (0.48 – 0.64) 
 Asian & Pacific Islander 99.59 0.41 0.34† (0.25 – 0.46) 
 Hispanic 98.41 1.60 0.92† (0.66 – 1.29) 
 Other 98.39 1.61 0.98 (0.79 – 1.20) 
     
Employment     
 Full– Time 99.10 0.90 1.00  
 Part– Time 98.78 1.22 1.14† (1.01 – 1.29) 
 Unemployed 97.14 2.86 1.56† (1.37 – 1.78) 
 Other (including not in 
labour force) 
99.15 0.85 1.11 (0.97 – 1.26) 
     
Education     
 Elementary 99.49 0.51 1.00  
 Secondary 98.71 1.29 1.89† (1.30 – 2.74) 
 Tertiary 99.13 0.87 1.92† (1.32 – 2.81) 
     
Income     
 Less than 20,000 98.13 1.87 1.00  
 20,000 to 49,999 98.94 1.07 0.64† (0.53 – 1.29) 
 50,000 to 74,999 99.19 0.81 0.60† (0.46 – 0.78) 
 More than 75,000 99.37 0.63 0.58† (0.46 – 0.74) 
     
Marital Status     
 Single 97.72 2.28 1.00  
 Married 99.64 0.36 0.30† (0.25 – 0.35) 
 Widowed 99.69 0.31 0.36† (0.22 – 0.57) 
 Divorced or Separated 98.54 1.46 0.94 (0.82 – 1.08) 
     
Self Rated Health     
 Excellent 99.36 0.64 1.00  
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 Any Past– Month Substance Use 
Adjusted*  No Yes 
 
(n = 303,311;  
76.96%) 
(n = 90,810;  
23.04%) 
 % % OR 95% CI 
 Very Good 99.06 0.94 1.50† (1.33 – 1.69) 
 Good 98.82 1.18 1.94† (1.71 – 2.21) 
 Poor 98.43 1.57 2.86† (2.41 – 3.38) 
     
Metropolitan Statistical Area 
Size 
    
 Large Metropolitan 98.89 1.11 1.00  
 Small Metropolitan 98.98 1.03 0.84† (0.76 – 0.92) 
 Non– Metropolitan 99.26 0.74 0.56† (0.48 – 0.64) 
     
Health Insurer     
 Private 99.36 0.64 1.00  
 Medicare 99.23 0.77 1.21 (0.94 – 1.56) 
 Medicaid 97.89 2.11 1.61† (1.38 – 1.87) 
 Tricare & VA 98.87 1.13 1.45† (1.06 – 1.98) 
 Other 98.32 1.68 1.57† (1.22 – 2.01) 
 Uninsured 97.68 2.32 1.94† (1.74 – 2.17) 
     
Receives Government 
Assistance 
    
 No 99.17 0.83 1.00  
 Yes 98.08 1.92 1.46† (1.32 – 1.63) 
     
Income as % of Federal 
Poverty Level 
    
 <100% FPL 98.18 1.82 1.00  
 100– 199% FPL 98.70 1.30 1.26† (1.09 – 1.45) 
 >= 200% FPL 99.22 0.78 1.58† (1.29 – 1.93) 
*Adjusted for year, age cohort, sex, ethnicity, employment, education, income, marital status, self 
rated health, metropolitan statistical area size, health insurer, receipt of government assistance 
and income as a % of federal poverty level
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4.4 Discussion 
Existing knowledge regarding the effects of economic recessions, particularly the GFC, 
and health have previously been linked to worsening in mental health, reductions in 
road traffic deaths, and short-term associations with cancer and heart disease (129). Our 
analysis extends this by highlighting major differences in binge alcohol and substance 
use, including poly-use, between Millennials and other generational cohorts. Millennials 
exhibited statistically significant higher odds of substance use over the study period, 
2007-16, with especially worrisome patterns of increase in heroin and oxycontin use, a 
trend which is particularly concerning in the context of the recent prescription opioid 
and heroin epidemic (130) and the measures introduced by the Obama administration to 
address this crisis such as improved access to naloxone and improved training among 
law enforcement agencies (131). These differences appear to be exacerbated by the 
impact of austerity and a high degree of socioeconomic vulnerability, including: being 
uninsured or insured on Medicaid, receiving government assistance, income less than 
100% FPL, poor self rated health, and unemployment. Increased social and economic 
vulnerability after the 2007 crisis is associated significantly with higher rates of 
substance use.  
A limitation of this study is the use of survey data to ascertain both 
socioeconomic and demographic characteristics of the study population as well as the 
use of self reported substance use as an outcome variable. As we are unable to ascertain 
specific birth years for individuals, we infer generational cohort membership based on a 
combination of self reported age and year of data collection. Moreover, underreporting 
of substance use may affect the accuracy of prevalence estimates for past-month binge 
alcohol and substance use as no objective or clinical measure of substance use was 
collected with the survey. Moreover, small samples for specific subpopulations in this 
Chapter 4: Binge alcohol and substance use across birth cohorts and the global financial crisis in the United 
States 
Justin Christopher Yang- March 2019   73 
study, such as Asian & Pacific Islander, those with an elementary education level or 
less, or those insured by Tricare & VA, limit our ability to detect specific patterns of 
substance use in these populations. The design of the NSDUH as a household survey, 
moreover, does not permit for the ability to sample homeless or institutionalised persons 
who may exhibit markedly different patterns of substance use. Finally, the use of 
repeated, cross-sectional data does not allow for an assessment of individuals over time 
and, consequently, no causality can be established between the outcome variables and 
the exposures of interest. Despite these limitations, the NSDUH remains a robust source 
of epidemiological data for assessing the prevalence of substance use. It has been shown 
to provide comparable findings to other validated health studies such as the National 
Comorbidity Survey Replication (NCS-R) and remains the only survey in the United 
States which provides nationally representative statistics on substance use over the life 
course, from adolescence through to adulthood (28). Its relatively large annual sample 
size (>65,000), deeply stratified sampling design to ensure representation among and 
within states, and face-to-face modality further highlight its strengths as a source of data 
for our analyses (123).  
These analyses highlight how a major macroeconomic downturn, the GFC, is 
associated with disproportionately adverse outcomes among Millennials vs. Gen X and 
Baby Boomers with respect to binge alcohol and substance use. We highlight several 
social, health, and economic correlates of substance use and highlight the link between 
social and economic vulnerability and substance use. These findings suggest a need for 
greater attention towards the ways in which macroeconomy and population health are 
linked and how these effects may disproportionately affect generational subpopulations 
with implications for health equity, health services provision, and policymaking. A 
growing body of literature has emerged, for instance, documenting the efficacy of 
differential health interventions to alleviate binge alcohol use among young (132) and 
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older (133) adults; comparable work to identify the unique needs of socioeconomically 
disadvantaged Millennials vis-à-vis advantaged Baby Boomers with respect to binge 
alcohol and substance use to help address ongoing problems such as the ongoing 
prescription opioid crisis. Further work may elucidate the relative merits of a harm 
reduction approach for Millennials, for example, rather than abstinence. These findings 
also signal a need to address economic inequalities with persist between Millennials and 
older generational cohorts while alleviating the direct causes of vulnerability, chiefly 
caused by weak macroeconomic conditions, poor career prospects despite high 
educational attainment, and government policies which have exacerbated austerity and 
inequality. 
Existing economic research has shown that demand for some substances, such as 
cocaine, heroin, and methamphetamine is highly elastic which can help explain, in part, 
some characteristics of first-time substance users, depending on macroeconomic 
conditions and prices of substances (121). As income decreases, particularly in times of 
economic hardship, we would expect substance use to decline and so our findings are 
consistent with this earlier research. Nevertheless, more research is needed to better 
characterize the ways in which macroeconomy and first-time substance use or increase 
rate of consumption are linked.  
Our results signal the urgent need for much greater attention to the link between 
intergenerational inequality and population health, particularly in a global 
macroeconomic climate recovering from the GFC. While governments have sought to 
apply monetary levers to alleviate the worst effects of this global recession, our findings 
underscore the fact that Millennials have suffered disproportionately, exhibiting 
increased socioeconomic vulnerability and increased use of binge alcohol and substance 
use as compared to Gen X and Baby Boomers. Though the long-term effects of 
sustained socioeconomic vulnerability and intergenerational inequality have yet to 
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manifest, policymakers should devote greater attention and sensitivity to the ways in 
which public policy can be further levered to ameliorate the social, economic, and 
health condition of Millennials. 
Research is also needed to consider whether the findings presented here are 
consistent among other developed countries, such as the United Kingdom, to both 
characterize the ways in which macroeconomy, intergenerational inequality, and binge 
alcohol & substance use are related. In addition, given the different economic policies 
that countries have used to address the impacts of the GFC and the varying severity with 
which the crisis affected individual countries, there is an opportunity to directly observe 
the relationship between the severity of macroeconomic shocks and measures of 
population health such as substance use and mental health. 
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5 DEMOGRAPHIC, 
SOCIOECONOMIC, AND 
HEALTH CORRELATES OF 
UNMET NEED FOR MENTAL 
HEALTH TREATMENT IN THE 
UNITED STATES, 2002-16 
5.1 Background 
Mental disorders are the leading contributor to years lived with disability in the 
United States (10,150,407 years lived with disability in 2016, or 3,143 per 100,000 
population) (134). They are common, with data from the National Survey on Drug Use 
and Health (2010-2012) finding that, in the past year, 18.4% of adults had a mental 
illness and 8.6% reported substance abuse/dependence, while 2.2% had both (135). 
Federal policymakers have responded with a variety of legislative approaches, notably 
the Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA), while the 
Patient Protection and Affordable Care Act of 2010 (ACA) includes specific provisions 
for mental health (136). Yet, despite these policies, there are large and persisting 
disparities in access to and receipt of mental health services. Individual studies have 
identified a range of underserved populations, which include certain ethnic minorities 
(137) and those lacking insurance (138). 
However, describing those whose needs for care are unmet is only a first step. It 
is also necessary to understand why, if an appropriate policy response is to be 
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developed. Possible explanations may lie with the individual affected (138), influenced 
by their social environment, such as stigma or lack of awareness of the seriousness of 
the condition or potential for treatment (139), or with the health system, for example 
unaffordability due to lack of insurance coverage (69, 140) or lack of access to facilities 
(140, 141).  
In this study, I characterise the demographic, socioeconomic, and health 
correlates of unmet need for mental health care among Americans, using data from the 
period 2002 to 2016 and to understand the reasons their needs are not being met, for 
example because of cost, perceived stigma, minimisation of symptoms, low perceived 
effectiveness of treatment, and structural barriers.  
5.2 Methods 
5.2.1 Data Source 
This study utilises data from the 2002-16 waves of the NSDUH, a nationally 
representative, annual household survey of civilian, non-institutionalised individuals 
aged 12 and above in the United States (95, 142-155).The NSDUH collects data on 
measures of mental health, including substance use and unmet need for mental health 
treatment, as well as a range of demographic, socioeconomic, and health-related 
variables (95, 142-155). Households are selected from all 50 states and the District 
Columbia, excluding individuals with no fixed address, active duty military personnel, 
and individuals living in institutionalised facilities (95, 142-155). Sampling and 
analytical weights for the NSDUH datasets, provided by the Substance Abuse and 
Mental Health Services Administration (SAMHSA) to address unit- and individual-
level non-response (95, 142-155). In the current study, the only exclusion criterion 
applied to the dataset was to exclude respondents aged 17 or below given in the focus 
on the adult population. 
Social disparities in the epidemiology and treatment of substance-related use disorders in the United States, 
2002-16 
78  Justin Christopher Yang – March 2019 
5.2.2 Study Variables 
Age at time of survey was categorised as: 18-25, 26-34, 35-49, and 50 or over. Sex was 
coded as either male or female. Ethnicity was coded as non-Hispanic White, non-
Hispanic Black, non-Hispanic Native American or Alaskan Native, non-Hispanic 
Native Hawaiian or Pacific Islander, non-Hispanic Asian, non-Hispanic mixed, or 
Hispanic. Marital status was coded as never married, married, widowed, divorced, or 
separated. Population density was coded as metropolitan statistical area (MSA) or core 
based statistical area (CBSA) 1 million or more, MSA or CBSA with fewer than 1 
million, or non-MSA/CBSA based on data from the 2000 or 2010 census and 
information from the Core Based Statistical Area classifications compiled by the Office 
of Management and Budget (OMB) (95, 142-155). 
Education was coded as the highest level reached from among elementary 
school, middle school, high school or college and higher. Employment was coded as 
full-time employed, part-time employed, unemployed, or other (defined as those not in 
the labour force such as students, retirees, or disabled individuals). Annual household 
income was coded as less than $20,000, between $20,000 and $49,999, between 
$50,000 and $74,999, and $75,000 or greater. A dichotomous variable was created to 
indicate whether the respondent was a recipient of a government assistance program 
(i.e. Supplemental Security Income [SSI], food stamps, cash assistance, and/or non-cash 
assistance). Insurance provider was coded as privately insured, insured by Medicare, 
insured by Medicaid, insured by Tricare or Veterans Administration (VA), uninsured, or 
other. 
Self-rated health was dichotomised into two categories: those reporting 
excellent, very good, or good self-rated health and those reporting fair, poor, or very 
poor self-rated health. Dichotomous variables indicating past-year substance abuse or 
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dependence were coded for each of alcohol, pain relievers, cocaine, hallucinogens, 
heroin, inhalants, marijuana, sedatives, stimulants, and tranquilizers. 
Expressed unmet need for mental health treatment (“unmet need”) was defined 
as meeting both the following conditions: (a) perceiving of a need for mental health 
treatment in the past year and (b) perceiving receipt of insufficient mental health 
treatment in the past year, including those adults who had received mental health 
treatment in the past year but perceived a further need that was unmet (95, 142-155). A 
dichotomous variable was created to code for responses to the question, “During the 
past 12 months, was there any time when you needed mental health treatment or 
counselling for yourself but didn't get it?” (95, 142-155). Among individuals expressing 
unmet need for mental health treatment, further dichotomous variables were coded to 
indicate whether the unmet need was due to one or more of the following reasons: cost, 
stigma, minimisation, low perceived treatment effectiveness, structural barriers or other 
reasons using definitions set by SAMHSA (95, 142-155) and from established literature 
(138). These variables were specified as follows: cost indicates when a respondent 
selected at least one of the following reasons for unmet need: could not afford the costs 
of treatment, health insurance does not cover mental health treatment, or health 
insurance does not cover enough for mental health treatment; stigma indicates when a 
respondent selected at least one of the following reasons: might cause neighbours to 
have a negative opinion, might have a negative effect on job, did not want others to find 
out, concerned about confidentiality, or concerned about being committed/medicated; 
minimisation indicates when a respondent either did not feel that they needed treatment 
or that they could handle the problem without treatment; low perceived treatment 
effectiveness indicates respondents who did not feel that mental health treatment would 
help; structural barriers indicate that respondents selected at least one of the following 
reasons: did not know where to go for mental health treatment, did not have the time, or 
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it was inconvenient to attend mental health treatment; and other reasons indicates when 
a respondent responded that mental health treatment was not received due to other 
reasons not indicated above (138). 
5.2.3 Statistical Analysis 
Item non-response was addressed using imputation based on predictive mean 
neighbourhood (PMN), as has been done with NSDUH datasets since 1999 (95, 142-
155), most extensively for variables pertaining to ethnicity and government assistance 
and slightly less for education, marital status, income, and health insurer (95, 142-155). 
Statistical analyses were performed in Stata 14. Bivariate descriptive analysis of 
primary dichotomous variable of interest, unmet need for mental health treatment, and 
multiple maximum-likelihood logit regression with weighted least squares on social, 
economic, and health correlates, with and without adjustment, was used to assess the 
demographic, socioeconomic, and health correlates of unmet mental health treatment 
both individually and simultaneously adjusting for all other correlates. Further analyses 
of secondary dichotomous variables of interest indicating reason(s) for unmet need were 
also conducted using multiple maximum-likelihood logit regressions with weighted 
least squares on social, economic, and health correlates, with and without adjustment, to 
assess the demographic, socioeconomic, and health correlates of unmet need due to: 
cost, perceived stigma, minimisation, low perceived treatment effectiveness, structural 
barriers, and other reasons. All analyses were weighted using analytical weights 
provided by SAMHSA with each annual dataset. 
5.3 Results 
Descriptive characteristics of our sample are shown in Table 6. From 2002-16, between 
36,000-43,000 adults aged 18 or above were surveyed annually, yielding a total study 
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population of 579,017. Table 7 shows the reasons respondents gave for past-year unmet 
need for mental health treatment from 2002-16. 
5.3.1 Unmet Need 
Unadjusted and adjusted odds of reporting unmet need among those perceiving a need 
for mental health treatment in the past year according to a range of demographic, 
socioeconomic, and health characteristics are shown in Table 8. The probability of 
expressing unmet need declined progressively with age, until it was about 65% lower 
among those aged over 50. Women were more than twice as likely to report unmet need 
than men. All ethnic groups aside from non-Hispanic mixed showed lower odds of 
expressed unmet need than the baseline non-Hispanic White group while non-Hispanic 
mixed showed about 25% higher odds of expressed unmet need. Those who were 
married or widowed were less likely to express unmet need than those reporting having 
never married. Those not living in an MSA/CBSA showed about 15% lower odds of 
expressed unmet need than those living in an MSA/CBSA with a population of 1 
million or more. Individuals with at least some college education showed over double 
the odds of expressing unmet need than those attaining only an elementary school 
education. Compared to those who were employed full time, individuals who were part-
time employed, unemployed, or otherwise not in the labour force showed approximately 
10-20% higher odds of expressing past-year unmet need. Compared to those earning 
less than $20,000 annually, those earning $50,000 or more showed modestly lower odds 
of expressing unmet need. Recipients of government assistance expressed about 45% 
higher odds of expressing unmet need in the past year. Compared to those indicating 
good, very good, or excellent self-rated health, respondents with fair, poor, or very poor 
self-rated health showed 2.5 times higher odds of expressed unmet need. As expected, 
compared to those with private health insurance, individuals insured by Medicaid, 
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Tricare or VA, or were uninsured showed higher odds of unmet need in the past year. 
Finally, compared to individuals with no past-year substance abuse or dependence, 
individuals with past year abuse or dependence of almost all substances included in this 
study, namely alcohol, pain relievers, cocaine, heroin, inhalants, marijuana, stimulants, 
and tranquilizers showed higher odds of unmet need. Only those individuals indicating 
past year abuse or dependence of hallucinogens and sedatives did not show statistically 
significantly different odds of expressed unmet need compared to those who had not 
abused or depended upon these substances. 
5.3.2 Reasons for Unmet Need 
Table 9 shows the results of adjusted logistic regression of individual 
demographic, socioeconomic, and health characteristics associated with reported 
reasons for unmet need among respondents indicating past-year unmet need for mental 
health treatment. In the following paragraphs we summarise the key findings. 
5.3.2.1 Cost 
Compared to respondents aged 18-25, respondents aged 26-34 and respondents aged 35-
49 showed higher odds of indicating cost as a reason for unmet need. Respondents who 
were non-Hispanic Black, non-Hispanic Native American or Alaskan Native, or 
Hispanic showed lower odds of indicating cost as a reason for unmet need than non-
Hispanic White respondents. Moreover, those with an employment status of other 
(including those not in the labour force) showed lower odds of indicating cost as a 
reason for unmet need compared to those who were full-time employed. As expected, 
those with an annual household income of at least $50,000 showed lower odds of citing 
cost as a reason for unmet need compared to those earning less than $20,000. All 
respondents with a self rated health other than excellent (i.e. very good, good, fair, poor 
or very poor) other than showed higher odds of citing cost as a reason for unmet need 
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compared to respondents who responded with excellent self rated health. Finally, 
compared to respondents who were privately insured, respondents who were insured by 
Medicaid or Tricare or VA showed lower odds of indicating cost as a reason for unmet 
need while respondents who were insured by other (i.e. not private, Medicare, 
Medicaid, or Tricare or VA) or uninsured showed higher odds of indicating cost as a 
reason for unmet need. 
5.3.2.2  Perceived Stigma 
Respondents of all age groups other than 18-25 showed lower odds of reporting 
perceived stigma as a reason for unmet need. In addition, women were less likely to 
report perceived stigma as a reason for unmet need compared to men. Compared to 
respondents living in an MSA/CBSA of one million or more, those living in an 
MSA/CBSA of less than one million or a non-MSA/CBSA area showed higher odds of 
indicating perceived stigma as a reason for unmet need. Respondents reporting part-time 
employment showed lower odds of citing perceived stigma as a cause for unmet need 
compared to those who were full-time employed. Compared to those with excellent self 
rated health, respondents with fair self rated health showed 25% higher odds of 
indicating perceived stigma as a reason for unmet need. Finally, respondents who 
indicated past year abuse or dependence on either alcohol or pain relievers showed 
higher odds of indicating perceived stigma as a reason for unmet need while those who 
indicated past year abuse or dependence on heroin showed lower odds. 
5.3.2.3 Minimisation 
Compared to respondents aged 18-25, respondents aged 26-49 showed lower odds of 
indicating minimisation as a reason for unmet need. Odds were higher among 
respondents living in MSA/CBSAs with populations less than one million or non-
MSA/CBSA areas showed higher odds of citing minimisation as a cause of unmet need 
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compared to those living in an MSA/CBSA with a population of at least one million. In 
addition, respondents who were unemployed showed lower odds of indicating 
minimisation as a reason for unmet need compared to their full-time employed 
counterparts. Compared to those earning less than $20,000, respondents with a 
household income of $50,000-$74,999 showed about 30% higher odds of indicating 
minimisation as a reason for unmet need while respondents with a household income of 
$75,000 or more showed about 10% lower odds. All respondents indicating a non-
excellent self rated showed lower odds of indicating minimisation as a reason for unmet 
need compared to respondents who reported an excellent self rated health. In addition, 
respondents who were insured by Medicare, insured by Medicaid, insured by other, or 
uninsured showed lower odds of indicating minimisation as a reason for unmet need 
compared to those who were privately insured. Finally, individuals with past-year abuse 
or dependence on alcohol, pain reliever, or stimulants also showed lower odds of 
indicating minimisation as a reason for unmet need. 
5.3.2.4 Low Perceived Effectiveness of Treatment 
Respondents aged 26-49 showed lower odds of citing low perceived effectiveness of 
treatment as a cause for unmet need compared to those aged 18-25. Moreover, both non-
Hispanic Black respondents and Hispanic respondents showed lower odds of citing low 
perceived effectiveness of treatment as a reason for unmet need compared to their non-
Hispanic White counterparts. Interestingly, respondents who were either married or 
divorced/separated showed lower odds of indicating low perceived effectiveness of 
treatment as a cause of unmet need. Compared to those earning less than $20,000, 
respondents earning $50,000-$74,999 showed about 20% higher odds of indicating low 
perceived effectiveness of treatment as a reason for unmet need. Respondents who were 
uninsured showed about 35% lower odds of indicating low perceived effectiveness as a 
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reason for unmet need compared to respondents who were privately insured. Finally, 
respondents who indicated past-year abuse or dependence on pain relievers or cocaine 
showed lower odds of citing low perceived effectiveness as a reason for unmet need. 
5.3.2.5 Structural Barriers 
The odds of reporting structural barriers as a reason for unmet need was lower among 
those aged 26-49 compared to those aged 18-25 while the odds were about 25% higher 
among those aged 50 or over. Compared to non-Hispanic White respondents, non-
Hispanic Asian respondents showed about 35% higher odds of indicating structural 
barriers as a reason for unmet need. Those living in an MSA/CBSA with less than one 
million showed lower odds of indicating structural barriers as a reason for unmet need 
than those living in an MSA/CBSA of at least one million. The odds of citing structural 
barriers as a reason for unmet need were about 50% higher among those reporting at 
least some high school education and about double among those reporting at least some 
college education as compared to respondents with only an elementary school 
education. Compared to those reporting full-time employment, those reporting part-time 
employment or unemployment showed lower odds of citing structural barriers as a 
reason for unmet need. Moreover, compared to those earning less than $20,000, 
respondents reporting earning $20,000-$49,999 showed lower odds of indicating 
structural barriers as a reason for unmet need while those earning at least $75,000 
shower higher odds. Those who were uninsured showed lower odds of reporting 
structural barriers as a cause for unmet need compared to those who were privately 
insured. Finally, respondents with past-year abuse or dependence on marijuana or 
sedatives exhibited lower odds of citing structural barriers as a reason for unmet need. 
5.3.2.6 Other Reason(s) 
Several groups showed higher odds of indicating reasons other than those shown above 
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as a cause for unmet need. Respondents aged 26-49 were more likely to express that 
unmet need was caused by some other reason than those aged 18-25. In addition, non-
Hispanic mixed respondents showed higher odds of citing reason not listed above as a 
cause of unmet need compared to non-Hispanic White respondents. Notably, those with 
at least some high school education showed much higher odds of indicating a reason not 
listed above as a cause of unmet need than those with an elementary school education. 
Compared to those reporting full-time employment, all other groups showed higher 
odds of indicating a reason not listed above as a cause of unmet need. Those insured by 
Tricare or VA showed higher odds of citing a reason not listed above as a cause of 
unmet need compared to those who were privately insured. Finally, individuals who 
reported past-year tranquilizer abuse or dependence showed higher odds of indicating a 
reason not listed above as a reason for unmet need. 
5.4 Discussion 
This analysis of the demographic, socioeconomic, and health correlates of unmet 
need yielded insights into subpopulations at increased risk of unmet need. In summary, 
we found a complex picture in which some of the findings were intuitive but others not. 
Unmet need was higher in younger people, women, non-Hispanic whites or mixed race, 
and those who had never married or were divorced or separated. It was also higher in 
those with higher education, who were in other than full-time employment, who had 
low income or receive government assistance. It was also higher in those with poor 
health or in receipt of Medicaid or coverage by the Veterans Administration. Most 
forms of substance abuse were associated with increased unmet need, other than 
hallucinogens and sedatives. Our further analyses of the demographic, socioeconomic, 
and health correlates with reasons for unmet need provide additional information about 
which subpopulations express unmet need for reasons of cost, perceived stigma, 
Chapter 5: Demographic, socioeconomic, and health correlates of unmet need for mental health treatment in 
the United States, 2002-16 
Justin Christopher Yang- March 2019   87 
minimisation, low perceived effectiveness of treatment, structural barriers, or other 
reasons not specified. Increased odds of citing cost as a reason for unmet need were 
observed among: respondents aged 26-49, respondents indicating fair, poor, or very 
poor self-rated health, and respondents insured by other or uninsured. By contrast, 
increased odds of reporting perceived stigma as a cause of unmet need was observed 
among those living in an MSA/CBSA of fewer than one million or a non- MSA/CBSA 
area and respondents indicating past-year abuse or dependence on alcohol or pain 
relievers. Minimisation was indicated as a reason for unmet need with higher odds 
among respondents living in MSA/CBSA with fewer than one million or a non-
MSA/CBSA area and respondents with an annual household income of $50,000-
$74,999. The odds of reporting low perceived effectiveness as a reason for unmet need 
was only higher among respondents earning at least $75,000. Additionally, increased 
odds of reporting structural barriers as a cause of unmet need were seen among 
respondents aged 50 and over, non-Hispanic Asian respondents, respondents with at 
least some high school education, and respondents earning at least $75,000. The higher 
rate of unmet need among women seems to be driven by structural barriers, an area that 
clearly requires more exploration. Finally, the odds of citing another reason not 
specified above as a reason for unmet need were higher among respondents aged 26-49, 
non-Hispanic mixed respondents, respondents with at least some high school education, 
respondents who did not report working full-time, respondents insured by Tricare or 
VA, and respondents reporting past-year abuse or dependence on tranquilizers. 
The study has some limitations such as using household survey data to assess 
unmet need as well as demographic, socioeconomic, and health characteristics of the 
sample population. Perceived unmet need is also a self-reported variable which was not 
validated using psychiatric diagnostic information; consequently, underreporting or 
over-reporting of perceived unmet need would affect the accuracy of prevalence 
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estimates for unmet need. Indeed, perceived unmet need is subjective, based on 
sociocultural factors such as patient expectations and Allin and Masseria suggest that 
analyses of unmet need are contingent upon the specific phrasing of questions (156). 
Small samples for specific subpopulations in this study limit the ability to identify 
specific patterns of unmet need in these populations. Moreover, the NSDUH excludes 
individuals with no fixed household address and those living in institutional premises, 
such as prisons, precluding conclusions on unmet need among these vulnerable 
populations. Finally, given the repeated, cross-sectional nature of the NSDUH, we are 
not able to conduct analyses of individuals over time and, therefore, we are unable to 
determine causality between unmet need and the demographic, socioeconomic, and 
health correlates under examination. Nevertheless, the NSDUH has been shown to 
provide comparable findings to other validated health studies such as the National 
Comorbidity Survey Replication (NCS-R) and is the only source of data in the United 
States which provides information on unmet need for a nationally representative sample 
of adults living in the United States (28). 
These results are consistent with recent and established literature which identify 
disparities in expressed unmet need based upon age (157), gender (70, 158), economic 
disadvantage (159), urban/rural status (160), health insurer (161), illicit substance use 
(162). The study extends our understanding of these disparities by not only considering 
demographic, socioeconomic, and health characteristics of those expressing unmet need 
from 2002-16 but also identifying how these correlate with reasons for unmet need. As 
expected, cost was a major cause of unmet need among respondents aged 26-49 and 
those who were uninsured; though the ACA has attempted to reduce the number of 
uninsured young adults, provisions only provide for continued enrolment of dependent 
children until age 25 and, consequently, this may partly explain this observed pattern of 
expressed unmet need due to cost among these subgroups (163). Of the reasons for 
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unmet need examined in this study, only perceived stigma and minimisation appear to 
increase the odds of expressed unmet need among those living in suburban or rural 
areas, controlling for other demographic, socioeconomic, and health characteristics, 
highlighting a potential opportunity to develop health promotion interventions for these 
subpopulations to address unmet need consistent with established literature (164-167). 
That the odds of indicating structural barriers as a reason for unmet need were not 
statistically significantly higher among those living in suburban or rural areas is 
somewhat surprising, given existing research which indicate that availability of 
adequate mental health care is a cause for concern (168, 169) which suggests that 
further research is needed to fully understand the availability or lack thereof of mental 
health treatment in suburban or rural areas which can inform new initiatives focused on 
access, such as telemedicine approaches (170, 171). In addition, the large number of 
subpopulations expressing unmet need for reasons not specified in this study (i.e. cost, 
perceived stigma, minimisation, low perceived effectiveness of treatment, and structural 
barriers) suggests a need to investigate the reasons why these subpopulations express 
unmet need to address the causal factors underlying why these subpopulations do not 
receive adequate mental health care. 
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Table 6 Sample characteristics for adults age 18 and over by percentage (%), 2002-16 
Year 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 
n 36370 37026 37308 37227 36965 37708 37504 37707 38919 39133 37869 37424 41671 43561 42625 
Age                
 18-25 48.7 49.6 49.5 49.6 48.5 48.6 50.4 49.8 49.0 49.0 49.2 48.5 31.4 33.4 32.0 
 26-34 15.2 15.0 15.3 14.8 14.9 15.5 14.8 14.9 15.1 14.4 14.5 14.6 20.1 20.9 20.5 
 35-49 22.8 21.9 21.6 21.8 20.8 21.8 20.8 20.7 21.4 19.5 19.5 20.1 27.0 25.6 26.7 
 >50 13.2 13.5 13.6 13.8 15.8 14.2 14.1 14.7 14.5 17.1 16.8 16.9 21.5 20.1 20.8 
                
 Female 53.5 53.1 53.4 54.0 53.0 53.5 53.5 53.3 53.3 52.8 53.1 54.0 53.4 54.5 53.4 
                
Ethnicity                
 Non-Hispanic White 70.4 67.7 66.6 65.6 65.8 65.6 63.3 63.2 64.0 62.9 62.0 61.1 62.4 59.7 60.9 
 Non-Hispanic Black 11.6 11.7 11.9 11.9 12.1 11.6 12.4 12.3 12.1 12.8 12.7 13.0 11.8 12.6 12.8 
 Non-Hispanic Native American or 
Alaskan Native 
1.1 1.3 1.3 1.5 1.4 1.4 1.5 1.4 1.6 1.6 1.4 1.4 1.6 1.5 1.5 
 Non-Hispanic Native Hawaiian or Pacific 
Islander 
0.5 0.4 0.4 0.5 0.5 0.5 0.5 0.4 0.5 0.4 0.6 0.6 0.5 0.5 0.5 
 Non-Hispanic Asian 2.9 3.2 3.5 3.5 3.2 3.7 3.8 3.9 3.8 3.6 4.1 4.4 4.4 4.7 4.4 
 Non-Hispanic Mixed 1.6 2.0 2.3 2.3 2.3 2.5 2.5 2.9 2.7 3.0 2.9 3.1 3.0 3.3 3.2 
 Hispanic 11.9 13.8 14.0 14.7 14.7 14.7 15.9 15.8 15.3 15.6 16.2 16.5 16.2 17.6 16.6 
                
Marital Status                
 Never married 48.3 49.1 49.6 50.3 49.7 50.5 52.8 53.1 53.0 52.9 53.3 53.7 42.7 43.7 44.8 
 Married 40.1 39.4 38.7 38.0 38.8 37.9 35.9 35.6 35.4 35.1 34.6 34.4 42.7 41.4 41.0 
 Widowed 2.5 2.3 2.4 2.4 2.8 2.4 2.3 2.3 2.5 2.5 2.6 2.5 3.1 3.7 3.0 
 Divorced or Separated 9.1 9.2 9.3 9.3 8.7 9.2 8.9 9.0 9.2 9.4 9.5 9.3 11.5 11.1 11.2 
                
MSA/CBSA Size                
 1 million or more 34.8 34.1 34.4 42.1 42.1 41.7 42.1 42.5 41.9 40.7 41.5 42.4 43.1 43.2 42.5 
 Fewer than 1 million 38.9 39.0 38.3 49.2 48.9 49.9 49.4 49.7 50.4 51.1 50.6 49.6 49.0 49.3 49.9 
Chapter 5: Demographic, socioeconomic, and health correlates of unmet need for mental health treatment in the United States, 2002-16 
Justin Christopher Yang- March 2019   91 
Year 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 
n 36370 37026 37308 37227 36965 37708 37504 37707 38919 39133 37869 37424 41671 43561 42625 
 Not an MSA/CBSA 26.3 26.9 27.2 8.7 9.0 8.4 8.5 7.8 7.7 8.2 7.9 7.9 7.8 7.5 7.6 
                
Educational Attainment                
 Elementary School 0.9 1.1 1.0 1.1 1.1 1.2 1.1 1.0 0.9 0.9 1.0 0.9 1.1 0.9 0.9 
 Middle School 2.8 3.0 2.9 3.2 3.0 2.9 2.6 2.6 2.6 2.4 2.2 2.3 2.4 2.5 2.0 
 High School 47.5 48.8 48.1 47.3 47.3 46.2 47.4 45.9 45.2 45.0 45.2 43.7 40.2 38.1 36.6 
 College or Higher 48.8 47.0 48.0 48.5 48.5 49.7 48.9 50.5 51.2 51.7 51.6 53.0 56.4 58.5 60.6 
                
Employment Status                
 Full Time 56.0 53.4 53.1 54.3 54.3 54.1 52.1 46.8 47.1 46.4 47.5 47.8 52.9 50.9 51.7 
 Part Time 17.9 18.6 18.5 18.3 17.9 18.2 18.7 19.8 19.7 19.4 19.1 19.7 16.4 16.1 15.8 
 Unemployed 5.1 6.2 5.8 5.4 5.5 5.6 6.9 10.1 9.6 9.2 8.9 8.1 6.1 6.6 6.1 
 Other (including not in labour force) 21.0 21.8 22.6 22.0 22.3 22.2 22.4 23.3 23.6 25.0 24.4 24.3 24.6 26.4 26.3 
                
Annual Household Income                
 Less than $20,000 25.0 26.4 27.5 26.2 25.7 24.8 24.4 25.1 26.2 26.6 26.1 26.1 22.2 22.3 21.0 
 $20,000-$49,999 39.5 38.8 37.6 36.9 36.1 35.1 34.9 34.6 33.9 34.6 34.6 33.2 31.8 32.2 31.7 
 $50,000-$74,999 16.8 16.4 15.9 16.3 16.1 16.9 17.2 16.1 15.9 15.0 15.2 15.5 16.4 15.5 15.4 
 $75,000 or more 18.7 18.4 19.1 20.6 22.1 23.2 23.5 24.2 24.1 23.8 24.2 25.2 29.6 30.0 32.0 
                
Receives Government Assistance 13.7 15.9 17.2 18.0 17.5 17.7 18.1 19.8 21.7 24.5 25.7 25.9 22.9 23.0 21.6 
                
Self Rated Health                
 Excellent 28.1 28.2 27.5 26.4 25.7 26.1 25.7 26.0 26.1 25.6 24.4 24.5 23.5 23.3 23.3 
 Very Good 39.2 38.4 38.2 38.7 38.6 38.6 38.6 38.6 39.1 38.8 39.0 38.9 38.0 37.3 37.9 
 Good 24.9 25.0 25.3 25.6 26.3 25.9 26.2 25.9 25.4 25.6 26.5 26.6 27.1 27.9 27.6 
 Fair 6.5 7.1 7.5 7.7 8.0 7.9 7.8 8.0 7.9 8.2 8.5 8.3 9.4 9.5 9.3 
 Poor or Very Poor 1.3 1.4 1.5 1.5 1.5 1.6 1.6 1.6 1.5 1.8 1.7 1.8 2.0 1.9 1.9 
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Year 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 
n 36370 37026 37308 37227 36965 37708 37504 37707 38919 39133 37869 37424 41671 43561 42625 
Health Insurer                
 Private 69.2 65.5 64.3 63.3 63.4 62.2 61.2 59.7 59.5 59.1 59.6 60.2 63.6 62.6 63.9 
 Medicare 2.9 2.7 2.8 3.0 3.1 3.0 3.3 3.3 3.3 4.0 4.0 3.9 5.1 4.9 4.9 
 Medicaid 6.9 8.0 8.6 9.0 8.5 9.0 9.8 10.2 10.7 11.4 11.3 11.6 11.7 14.3 14.7 
 Tricare or VA 1.4 1.7 1.6 1.7 1.6 1.6 1.7 1.8 2.0 2.1 2.1 2.1 2.1 2.0 2.2 
 Other 1.8 2.4 2.4 2.4 2.5 2.8 2.6 2.8 2.9 2.8 3.0 2.9 3.0 3.7 3.0 
 Uninsured 17.7 19.8 20.2 20.7 21.0 21.5 21.4 22.2 21.7 20.6 20.0 19.3 14.6 12.5 11.4 
                
Past-Year Substance Abuse or 
Dependence 
               
 Alcohol 12.8 12.4 12.6 12.6 12.3 12.1 12.2 12.0 11.4 10.7 10.5 9.9 8.4 7.9 7.7 
 Pain Reliever 0.9 0.8 0.9 1.1 1.0 1.2 1.3 1.3 1.2 1.2 1.3 1.1 0.9 1.0 0.9 
 Cocaine 1.0 1.0 1.1 1.1 1.0 1.0 0.9 0.7 0.5 0.5 0.5 0.5 0.4 0.4 0.4 
 Hallucinogen 0.4 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.2 0.2 0.2 0.1 0.2 0.2 
 Heroin 0.1 0.1 0.2 0.2 0.2 0.2 0.2 0.3 0.2 0.3 0.4 0.4 0.3 0.3 0.4 
 Inhalant 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 <0.1 <0.1 <0.1 <0.1 <0.1 
 Marijuana 3.4 3.5 3.6 3.3 3.3 3.2 3.4 3.3 3.2 3.1 3.2 3.0 2.3 2.3 2.3 
 Sedative 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 <0.1 0.1 0.1 0.1 0.1 0.1 
 Stimulant 0.3 0.3 0.3 0.3 0.2 0.3 0.2 0.3 0.2 0.2 0.3 0.3 0.3 0.3 0.3 
 Tranquilizer 0.3 0.3 0.4 0.3 0.3 0.3 0.3 0.3 0.3 0.2 0.3 0.3 0.2 0.3 0.3 
                
Past-Year Unmet Need for Mental Health 
Treatment 
7.4 7.1 7.2 7.2 6.4 6.8 6.8 7.1 6.6 6.6 6.7 6.6 6.4 6.3 6.8 
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Table 7 Reason(s) for Unmet Need Among Adults Reporting Unmet Need for Mental Health Treatment in the Past Year by Percentage (%), 2002-16 
Year 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 
n 2680 2640 2665 2678 2368 2557 2530 2687 2556 2564 2537 2463 2652 2718 2891 
Reason for Unmet Need                
 Cost 61.8 62.3 63.8 63.0 47.3 47.3 48.7 50.8 50.9 51.6 48.4 48.5 48.5 44.5 43.8 
 Perceived Stigma 31.2 32.1 30.8 30.2 29.7 31.8 31.1 30.5 32.1 29.5 31.0 30.2 30.4 32.8 34.9 
 Minimisation 13.8 34.8 34.5 32.3 31.5 32.5 30.3 30.6 30.0 27.9 29.9 29.2 28.4 31.6 33.0 
 Low Perceived Effectiveness 1.6 11.8 11.3 10.8 10.4 11.8 10.0 11.0 10.9 10.3 10.3 9.9 10.1 12.6 11.6 
 Structural Barriers 28.8 34.8 32.9 31.7 29.9 31.9 32.5 31.9 32.1 32.2 33.6 35.8 35.8 41.8 42.2 
 Other Reason(s) 4.4 8.3 7.4 7.9 7.3 7.8 7.4 7.6 7.3 7.7 7.2 7.9 8.3 9.2 9.7 
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Table 8 Unadjusted and adjusted multiple logistic regression of demographic, 
socioeconomic, and health characteristics associated with unmet need for mental health 
treatment for adults, 2002-16 
 Unadjusted ORs Adjusted ORs 
Age   
 18-25 years old 1  1  
 26-34 years old 0.89 (0.85 - 0.92) 1.03 (0.99 - 1.08) 
 35-49 years old 0.70 (0.68 - 0.72) 0.84 (0.80 - 0.89) 
 50 or older 0.29 (0.28 - 0.31) 0.33 (0.30 - 0.36) 
     
Female 2.03 (1.95 - 2.11) 2.32 (2.23 - 2.42) 
     
Ethnicity     
 Non-Hispanic White 1  1  
 Non-Hispanic Black 0.84 (0.79 - 0.90) 0.57 (0.53 - 0.61) 
 Non-Hispanic Native American or Alaskan Native 1.32 (1.14 - 1.53) 0.78 (0.66 - 0.92) 
 Non-Hispanic Native Hawaiian or Pacific Islander 0.64 (0.46 - 0.88) 0.46 (0.33 - 0.65) 
 Non-Hispanic Asian 0.41 (0.35 - 0.47) 0.37 (0.32 - 0.43) 
 Non-Hispanic Mixed 1.70 (1.50 - 1.93) 1.22 (1.07 - 1.39) 
 Hispanic 0.73 (0.69 - 0.78) 0.55 (0.51 - 0.58) 
     
Marital Status     
 Never married 1  1  
 Married 0.43 (0.41 - 0.45) 0.76 (0.72 - 0.80) 
 Widowed 0.32 (0.28 - 0.36) 0.61 (0.52 - 0.70) 
 Divorced or Separated 0.96 (0.91 - 1.01) 1.21 (1.13 - 1.28) 
     
MSA/CBSA Size     
 1 million or more 1  1  
 Fewer than 1 million 1.09 (1.06 - 1.13) 0.97 (0.94 - 1.01) 
 Not an MSA/CBSA 0.95 (0.90 - 1.00) 0.84 (0.79 - 0.89) 
     
Educational Attainment     
 Elementary School 1  1  
 Middle School 1.31 (0.97 - 1.76) 1.08 (0.79 - 1.46) 
 High School 1.71 (1.32 - 2.21) 1.31 (1.00 - 1.71) 
 College or Higher 2.06 (1.60 - 2.66) 2.15 (1.65 - 2.81) 
     
Employment Status     
 Full Time 1  1  
 Part Time 1.55 (1.48 - 1.63) 1.19 (1.13 - 1.26) 
 Unemployed 1.91 (1.78 - 2.05) 1.22 (1.13 - 1.32) 
 Other (including not in labour force) 1.12 (1.07 - 1.17) 1.09 (1.03 - 1.15) 
     
Annual Household Income     
 Less than $20,000 1  1  
 $20,000-$49,999 0.69 (0.66 - 0.72) 0.96 (0.91 - 1.01) 
 $50,000-$74,999 0.58 (0.55 - 0.61) 0.92 (0.86 - 0.98) 
 $75,000 or more 0.48 (0.45 - 0.50) 0.83 (0.79 - 0.89) 
     
Receives Government Assistance 2.05 (1.97 - 2.12) 1.41 (1.34 - 1.49) 
     
Self Rated Health     
 Excellent 1  1  
 Very Good 1.54 (1.46 - 1.62) 1.54 (1.47 - 1.62) 
 Good 1.90 (1.80 - 2.00) 2.17 (2.06 - 2.29) 
 Fair 2.63 (2.48 - 2.79) 3.53 (3.31 - 3.76) 
 Poor or Very Poor 4.44 (4.07 - 4.84) 6.92 (6.27 - 7.63) 
     
Health Insurer     
 Private 1  1  
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 Unadjusted ORs Adjusted ORs 
 Medicare 0.99 (0.91 - 1.08) 1.02 (0.91 - 1.13) 
 Medicaid 2.45 (2.34 - 2.57) 1.15 (1.07 - 1.23) 
 Tricare or VA 1.66 (1.48 - 1.87) 1.54 (1.36 - 1.75) 
 Other 1.63 (1.46 - 1.82) 1.07 (0.95 - 1.20) 
 Uninsured 1.83 (1.75 - 1.92) 1.28 (1.21 - 1.35) 
     
Past-Year Substance Abuse or Dependence     
 Alcohol 3.63 (3.47 - 3.80) 2.58 (2.45 - 2.71) 
 Pain Relievers 8.44 (7.70 - 9.26) 2.50 (2.20 - 2.84) 
 Cocaine 7.34 (6.65 - 8.10) 2.06 (1.79 - 2.37) 
 Hallucinogens 8.15 (6.78 - 9.79) 1.28 (0.97 - 1.69) 
 Heroin 7.66 (6.49 - 9.04) 1.48 (1.11 - 1.97) 
 Inhalants 9.19 (6.23 - 13.55) 2.29 (1.34 - 3.91) 
 Marijuana 4.68 (4.38 - 4.99) 1.90 (1.75 - 2.06) 
 Sedatives 16.73 (11.90 - 23.5) 1.54 (0.84 - 2.83) 
 Stimulants 12.77 (10.60 - 15.37) 2.15 (1.62 - 2.85) 
 Tranquilizers 12.35 (10.37 - 14.70) 1.78 (1.35 - 2.34) 
*Adjusted for year, age, sex, ethnicity, marital status, MSA/CBSA size, educational 
attainment, employment status, annual household income, receipt of government 
assistance, self rated health, health insurer and past-year substance abuse or dependence 
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Table 9 Adjusted multiple logistic regression of demographic, socioeconomic, and health characteristics associated with reasons for past-year unmet 
need for mental health treatment for adults, 2002-16 
  Cost Perceived Stigma Minimisation 
Low Perceived 
Effectiveness 
Structural Barriers Other 
 OR AOR OR AOR OR AOR OR AOR OR AOR OR AOR 
Age             
 18-25 years old 1  1  1  1  1  1  
 26-34 years old 1.41 (1.29-1.54) 0.67 (0.61-0.74) 0.76 (0.69-0.84) 0.72 (0.62-0.83) 0.88 (0.81-0.96) 1.14 (0.97-1.34) 
 35-49 years old 1.48 (1.33-1.64) 0.57 (0.51-0.64) 0.66 (0.59-0.73) 0.61 (0.52-0.72) 0.73 (0.66-0.80) 1.25 (1.07-1.45) 
 50 or older 1.11 (0.97-1.27) 0.38 (0.32-0.45) 0.72 (0.62-0.84) 0.69 (0.54-0.88) 0.59 (0.50-0.69) 1.40 (1.08-1.81) 
             
Female 1.07 (0.99-1.15) 0.75 (0.69-0.80) 1.01 (0.93-1.11) 0.89 (0.78-1.02) 1.27 (1.18-1.36) 0.96 (0.83-1.11) 
             
Ethnicity             
 Non-Hispanic White 1  1  1  1  1  1  
 Non-Hispanic Black 0.70 (0.61-0.80) 1.07 (0.94-1.21) 1.09 (0.94-1.26) 0.67 (0.54-0.84) 0.89 (0.78-1.01) 0.80 (0.62-1.03) 
 Non-Hispanic Native American or Alaskan Native 0.53 (0.41-0.70) 1.07 (0.79-1.45) 0.91 (0.61-1.34) 0.60 (0.35-1.02) 1.01 (0.73-1.39) 1.36 (0.81-2.29) 
 Non-Hispanic Native Hawaiian or Pacific Islander 0.74 (0.36-1.50) 2.07 (0.93-4.63) 1.86 (0.91-3.77) 1.15 (0.54-2.48) 1.44 (0.66-3.16) 0.89 (0.36-2.22) 
 Non-Hispanic Asian 0.83 (0.62-1.12) 1.18 (0.95-1.48) 1.11 (0.87-1.40) 1.05 (0.69-1.59) 1.35 (1.06-1.71) 0.86 (0.50-1.45) 
 Non-Hispanic Mixed 0.89 (0.71-1.12) 0.95 (0.77-1.18) 0.92 (0.73-1.17) 1.02 (0.79-1.33) 1.15 (0.90-1.46) 1.85 (1.26-2.72) 
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  Cost Perceived Stigma Minimisation 
Low Perceived 
Effectiveness 
Structural Barriers Other 
 OR AOR OR AOR OR AOR OR AOR OR AOR OR AOR 
 Hispanic 0.74 (0.65-0.84) 1.06 (0.93-1.21) 0.99 (0.87-1.13) 0.69 (0.55-0.87) 1.01 (0.90-1.15) 0.89 (0.72-1.11) 
             
Marital Status             
 Never married 1  1  1  1  1  1  
 Married 0.95 (0.86-1.05) 0.95 (0.85-1.05) 1.05 (0.94-1.16) 0.75 (0.65-0.87) 1.04 (0.94-1.14) 0.78 (0.64-0.95) 
 Widowed 0.85 (0.65-1.11) 0.74 (0.54-1.03) 0.93 (0.67-1.30) 0.58 (0.31-1.09) 0.81 (0.58-1.13) 0.69 (0.45-1.05) 
 Divorced or Separated 1.12 (1.00-1.25) 0.91 (0.80-1.05) 0.98 (0.86-1.12) 0.79 (0.64-0.98) 0.98 (0.86-1.12) 0.92 (0.75-1.12) 
             
MSA/CBSA Size             
 1 million or more 1  1  1  1  1  1  
 Fewer than 1 million 0.99 (0.91-1.06) 1.17 (1.08-1.26) 1.09 (1.01-1.17) 1.05 (0.92-1.19) 0.85 (0.78-0.92) 1.14 (0.98-1.32) 
 Not an MSA/CBSA 0.93 (0.82-1.05) 1.44 (1.27-1.65) 1.18 (1.03-1.34) 0.99 (0.77-1.27) 0.92 (0.81-1.03) 0.84 (0.64-1.09) 
             
Educational Attainment             
 Elementary School 1  1  1  1  1  1  
 Middle School 1.08 (0.60-1.93) 1.09 (0.57-2.07) 1.22 (0.47-3.14) 0.88 (0.25-3.13) 1.16 (0.66-2.04) 2.02 (0.93-4.39) 
 High School 1.10 (0.65-1.85) 0.94 (0.52-1.68) 1.43 (0.59-3.47) 0.89 (0.32-2.50) 1.62 (1.03-2.56) 4.05 (1.90-8.64) 
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  Cost Perceived Stigma Minimisation 
Low Perceived 
Effectiveness 
Structural Barriers Other 
 OR AOR OR AOR OR AOR OR AOR OR AOR OR AOR 
 College or Higher 1.19 (0.71-2.00) 1.00 (0.56-1.81) 1.65 (0.68-3.98) 1.11 (0.40-3.09) 2.16 (1.37-3.39) 5.10 (2.38-10.93) 
             
Employment Status             
 Full Time 1  1  1  1  1  1  
 Part Time 1.06 (0.96-1.16) 0.89 (0.80-0.99) 1.01 (0.93-1.10) 1.01 (0.89-1.15) 0.88 (0.80-0.97) 1.37 (1.16-1.62) 
 Unemployed 1.13 (0.98-1.30) 0.93 (0.81-1.07) 0.79 (0.69-0.92) 0.79 (0.61-1.02) 0.84 (0.72-0.97) 1.53 (1.20-1.94) 
 Other (including not in labour force) 0.80 (0.73-0.88) 0.93 (0.84-1.03) 1.06 (0.95-1.18) 1.12 (0.97-1.29) 0.91 (0.83-1.01) 1.95 (1.66-2.30) 
             
Annual Household Income             
 Less than $20,000 1  1  1  1  1  1  
 $20,000-$49,999 1.09 (0.99-1.21) 0.95 (0.87-1.04) 0.96 (0.86-1.07) 0.96 (0.83-1.11) 0.90 (0.82-0.98) 1.05 (0.89-1.24) 
 $50,000-$74,999 0.88 (0.79-0.99) 1.01 (0.89-1.14) 1.07 (0.95-1.21) 1.23 (1.00-1.52) 0.94 (0.84-1.06) 0.91 (0.71-1.16) 
 $75,000 or more 0.58 (0.52-0.64) 1.05 (0.93-1.19) 1.32 (1.17-1.49) 1.22 (1.01-1.48) 0.98 (0.88-1.10) 1.10 (0.87-1.39) 
             
Receives Government Assistance 1.00 (0.90-1.11) 0.98 (0.89-1.09) 0.88 (0.79-0.98) 0.93 (0.80-1.09) 1.11 (1.00-1.23) 1.05 (0.90-1.23) 
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  Cost Perceived Stigma Minimisation 
Low Perceived 
Effectiveness 
Structural Barriers Other 
 OR AOR OR AOR OR AOR OR AOR OR AOR OR AOR 
Self Rated Health             
 Excellent 1  1  1  1  1  1  
 Very Good 1.18 (1.06-1.32) 1.07 (0.96-1.20) 0.84 (0.74-0.95) 0.93 (0.79-1.10) 1.04 (0.93-1.15) 1.07 (0.86-1.32) 
 Good 1.21 (1.09-1.36) 1.11 (0.99-1.23) 0.79 (0.70-0.90) 0.97 (0.80-1.17) 1.02 (0.92-1.14) 1.04 (0.85-1.27) 
 Fair 1.43 (1.25-1.63) 1.25 (1.10-1.42) 0.66 (0.57-0.78) 0.98 (0.77-1.26) 0.94 (0.83-1.08) 1.18 (0.93-1.51) 
 Poor or Very Poor 1.54 (1.26-1.88) 1.14 (0.91-1.42) 0.53 (0.42-0.67) 0.93 (0.66-1.31) 0.84 (0.68-1.02) 1.06 (0.79-1.44) 
             
Health Insurer             
 Private 1  1  1  1  1  1  
 Medicare 0.85 (0.72-1.01) 1.14 (0.93-1.42) 0.66 (0.51-0.85) 0.71 (0.47-1.06) 0.96 (0.81-1.16) 1.12 (0.84-1.51) 
 Medicaid 0.79 (0.70-0.90) 1.09 (0.97-1.23) 0.80 (0.70-0.93) 1.00 (0.81-1.23) 1.04 (0.91-1.19) 1.21 (0.98-1.48) 
 Tricare or VA 0.48 (0.38-0.61) 1.17 (0.89-1.53) 1.08 (0.80-1.45) 0.99 (0.69-1.41) 1.10 (0.81-1.49) 1.70 (1.21-2.40) 
 Other 1.60 (1.34-1.92) 0.86 (0.71-1.04) 0.78 (0.65-0.93) 0.79 (0.54-1.14) 0.82 (0.66-1.03) 0.79 (0.57-1.11) 
 Uninsured 3.64 (3.24-4.09) 0.62 (0.57-0.68) 0.50 (0.45-0.56) 0.65 (0.54-0.77) 0.69 (0.62-0.76) 0.91 (0.77-1.08) 
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  Cost Perceived Stigma Minimisation 
Low Perceived 
Effectiveness 
Structural Barriers Other 
 OR AOR OR AOR OR AOR OR AOR OR AOR OR AOR 
Past-Year Substance Abuse or Dependence             
 Alcohol 1.03 (0.95-1.12) 1.16 (1.07-1.27) 0.88 (0.80-0.98) 1.03 (0.90-1.18) 0.97 (0.88-1.08) 0.85 (0.73-0.99) 
 Pain Relievers 1.00 (0.84-1.18) 1.35 (1.14-1.61) 0.72 (0.58-0.89) 0.71 (0.52-0.97) 0.85 (0.72-1.01) 0.86 (0.65-1.13) 
 Cocaine 0.93 (0.74-1.16) 1.18 (0.95-1.47) 1.07 (0.80-1.44) 0.63 (0.41-0.97) 0.82 (0.61-1.10) 0.77 (0.54-1.10) 
 Hallucinogens 1.05 (0.74-1.49) 1.06 (0.76-1.48) 1.07 (0.72-1.59) 0.81 (0.43-1.54) 0.77 (0.55-1.09) 0.48 (0.27-0.84) 
 Heroin 1.09 (0.78-1.52) 0.52 (0.38-0.70) 0.93 (0.59-1.48) 0.70 (0.40-1.24) 1.03 (0.70-1.51) 0.67 (0.36-1.25) 
 Inhalants 1.20 (0.68-2.14) 0.62 (0.32-1.20) 0.82 (0.43-1.57) 0.60 (0.28-1.29) 0.64 (0.31-1.32) 0.60 (0.23-1.61) 
 Marijuana 1.03 (0.92-1.16) 0.96 (0.83-1.10) 0.89 (0.77-1.03) 0.97 (0.80-1.17) 0.80 (0.71-0.91) 1.14 (0.91-1.43) 
 Sedatives 0.92 (0.53-1.62) 1.54 (0.86-2.77) 0.67 (0.41-1.12) 0.97 (0.48-1.97) 0.55 (0.33-0.93) 0.69 (0.30-1.62) 
 Stimulants 0.99 (0.76-1.30) 1.64 (1.18-2.29) 0.60 (0.45-0.80) 1.14 (0.73-1.79) 1.12 (0.77-1.63) 0.85 (0.50-1.46) 
 Tranquilizers 1.06 (0.78-1.43) 1.27 (0.90-1.78) 0.78 (0.57-1.07) 0.98 (0.64-1.48) 0.92 (0.65-1.30) 1.69 (1.07-2.66) 
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6 VARIATIONS IN SUBSTANCE 
ABUSE TREATMENT FACILITY 
SERVICES BY GEOGRAPHY, 
OWNERSHIP, AND PAYMENT 
CHARACTERISTICS, 2007-14 
6.1 Background 
The ongoing and sustained opioid epidemic in the United States has manifested as one 
of the most urgent contemporary public health problems such that the United States 
Centers for Disease Control and Prevention (CDC) added the crisis to its list of the top 
five public health challenges in 2014 (130). Opioid overdose deaths have increased at an 
alarming and accelerated rate; from 2015-16, for instance, deaths due to opioid overdose 
increased 27.7% (172). Opioid overdose mortality and its associated economic burden 
have been among the major consequences of this epidemic; in 2014, for instance, 61% 
of drug overdose deaths involved opioids (173) while health care spending among 
individuals with opioid abuse averages eight times higher than individuals without 
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opioid abuse (174).  
The burden of the opioid epidemic has not manifested uniformly across the 
United States. One study found that drug poisoning mortality and opioid consumption 
rates varied significantly by state and region with drug poisoning rates highest in the 
Southwest and lowest in the Midwest (175). Moreover, opioid analgesic sales have 
varied significantly by state as well, with Alaska showing a 13 times higher methadone 
distribution than Nebraska in 2002 (175). Another study has found that prescription 
drug abuse of oxycodone has been unevenly concentrated in eastern and south-eastern 
states with a pattern of migration from the northeast and Appalachia towards the 
southeast and west (176). 
Despite the self-evident need for effective opioid misuse treatment, systemic 
barriers to treatment persist (70, 177), particularly with respect to the type and mode of 
treatment (178, 179). Because of the strict regulatory oversight of pharmacotherapies 
for the treatment of opioid misuse, the accessibility or lack thereof of treatments such as 
buprenorphine and methadone has come under heightened scrutiny (180) especially as 
the American Psychiatric Association (APA) has endorsed the use of pharmacotherapy 
combined with psychotherapy as best practice (181, 182) while the American Society of 
Addiction Medicine (ASAM) has established their use as practice guideline (183). 
Indeed, some have called for increased access to buprenorphine in the outpatient setting 
(184). In addition, even as the broader patterns of macroeconomy have experienced a 
downturn at the start of the millennium, providers have responded with respect to 
changes to patient mix by provider operating entity and acceptance of private health 
insurance (73). 
In this study, I make use of a routine, annual survey of all substance abuse 
treatment (SAT) facilities in the United States to characterise the ways in which 
pharmacotherapeutic approaches to managing opioid use disorders, specifically 
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buprenorphine and methadone, have or have not varied during ten recent years of the 
opioid epidemic from 2007-16, based on geographic, operational, and payment 
characteristics. By doing so, I seek to describe ongoing trends in SAT facility operations 
and whether or not disparities exist based on geographic, operational, and payment 
characteristics with respect to buprenorphine and methadone treatment, particularly 
given the clinical evidence supporting their use in opioid abuse treatment (77). Finally, I 
provide some recommendations for policymakers to address issues facing the treatment 
of opioid use disorders based on our findings. 
6.2 Methods 
6.2.1 Data Source 
This study used data from the 2007-16 waves of the National Survey of Substance 
Abuse Treatment Services (N-SSATS), an annually repeated, survey of all known drug 
and alcohol abuse treatment facilities, both public and private, in the United States (96, 
185-193). Given that the N-SSATS is a point-prevalence survey, facilities are surveyed 
year after year (96, 185-193). The N-SSATS collects data regarding the location and 
characteristics of each substance abuse treatment (SAT) facility as well as the types of 
services offered (96, 185-193). Data are collected through mailed questionnaires, 
telephone interviews, and web-based surveys (96, 185-193). No adjustment is made for 
the approximately 5-10% facility nonresponse (96, 185-193). 
6.2.2 Study Variables 
N-SSATS respondent location was categorized using Census Bureau Divisions 
(“division”) (194): New England; Mid-Atlantic; East North Central; West North 
Central; South Atlantic; East South Central; West South Central; Mountain; and Pacific. 
SAT facility operating entities were defined as one of: private for-profit; private non-
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profit; state government; local government; tribal government; Department of Veterans 
Affairs (VA); Department of Defense (DoD); Indian Health Service (IHS); or other 
Federal agency (96, 185-193). SAT facility payment characteristics were also obtained 
from the N-SSATS. Dichotomous variables were coded to indicate whether a SAT 
facility provided no charge or free treatment, offered a sliding fee scale to patients, 
accepted cash payments, accepted private insurance, accepted Medicare, accepted 
Medicaid, accepted state (non-Medicaid) insurance, and accepted federal Military 
insurance (96, 185-193).  
The outcome variables of interest were dichotomous variables coded to indicate 
whether a SAT facility offered specific pharmacotherapies: buprenorphine (with or 
without naltrexone) and methadone (96, 185-193). For analyses of SAT facilities 
offering methadone, only facilities indicating the presence of an opioid treatment 
program (OTP) were assessed, as methadone dispensing is strictly regulated by Federal 
regulations and limited to OTPs (195). 
6.2.3 Study Variables 
All statistical analyses were performed in Stata 14 (196). Bivariate descriptive analyses 
were conducted for our outcome variables of interest regarding service types and 
pharmacotherapies compared to facility characteristics, including geography, operating 
entity, and payment characteristics. Multiple maximum-likelihood logit regressions 
weighted least squares were performed on these outcome variables, with and without 
adjustment, to yield odds ratios associated with SAT facility characteristics, 
specifically, geography, operating entity, and payment characteristics. The baseline 
characteristics used for logistic regressions were: New England for division, private for-
profit for operating entity, and the counterfactual condition for payment characteristics 
(e.g. the counterfactual for “offers free or no charge treatment” would be “does not offer 
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free or no charge treatment”).  
6.3 Results 
Descriptive characteristics for our study population are shown in Table 10.  
 
Figure 10 Number of SAT Facilities by Census Bureau Division, 2007-16, and 
Percentage of SAT Facilities by Operating Entity by Census Bureau Division, 2007-16. 
As shown in Figure 10, the number of SAT facilities generally increased from 
2007-16 across divisions except for Pacific where a decline in the number of SAT 
facilities from 2008 is observed. SAT facilities across all regions were mostly operated 
by private entities from 2007-16, ranging from 86.5% of all surveyed SAT facilities in 
2007 to 88.6% in 2016.  
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Figure 11 Percentage of SAT Facilities Offering Buprenorphine by Census Bureau 
Division, 2007-16, and Percentage of SAT Facilities Offering Buprenorphine by 
Operating Entity, 2007-16. 
The percentage of SAT facilities offering buprenorphine increased from 2007-
16, nearly doubling from 14.4% of all SAT facilities to 27.2%, across all divisions as 
shown in Figure 2; nevertheless, less than half of SAT facilities in New England and 
Mid-Atlantic, and South Atlantic offered buprenorphine in 2016 and less than 25% did 
so in other divisions. Also shown in Figure 11, the percentage of SAT facilities offering 
buprenorphine increased from 2007-16 among SAT facilities whose operating entities 
were private-for-profit, private non-profit, state government, and VA, markedly so in 
the latter case where buprenorphine was offered at approximately three-quarters of SAT 
facilities operated by the VA in 2016. By contrast, less than 25% of SAT facilities 
operated by tribal governments, DoD or IHS offered buprenorphine from 2007-16. 
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Figure 12 Number of SAT Facilities with OTPs by Census Bureau Division, 2007-16, 
and Percentage of SAT Facilities with OTPs Offering Methadone by Census Bureau 
Division, 2007-16. 
Overall, the number of SAT facilities which operated an OTP remained stable 
from 2007-16, just below 10%. The number of SAT facilities which ran an OTP 
increased in South Atlantic and remained relatively constant in most other divisions as 
shown in Figure 3. In Mid-Atlantic, we observed an increase in the number of SAT 
facilities running an OTP in 2008, then declining until 2012 before increase again 
through to 2015. Reflecting broader patterns in facility operation noted above, SAT 
facilities running an OTP were predominantly operated by private entities.  
Table 11 shows the results of unadjusted and adjusted results of logistic 
regression of geographic, operational, and payment characteristics associated with 
whether SAT facilities offered buprenorphine and methadone pharmacotherapies from 
2007-16. These results are also shown graphically in Figure 13 and Figure 14. SAT 
facilities in most divisions, except for Mid-Atlantic (AOR: 1.15; 95% CI: 1.08 – 1.22), 
showed lower odds of offering buprenorphine treatment when compared to New 
England. SAT facilities operated by private non-profit entities (AOR: 0.85; 95% CI: 
0.82 – 0.88), local, county, or community governments (AOR: 0.71; 95% CI: 0.66 – 
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0.77), tribal governments (AOR: 0.53; 95% CI: 0.45 – 0.62), or IHS (AOR: 0.65; 95% 
CI: 0.45 – 0.95) showed lower odds of offering buprenorphine while those operated by 
state government (AOR: 1.22; 95% CI: 1.11 – 1.35) or VA (AOR: 9.58; 95% CI: 8.40 – 
10.93) showed higher odds of offering buprenorphine. SAT facilities offering any type 
of payment assistance, either charity care or a sliding fee scale, showed lower odds of 
offering buprenorphine than those that did not offer any form of payment assistance. 
SAT facilities accepting cash or self-payment (AOR: 2.09; 95% CI: 1.94 – 2.25), 
private health insurance (AOR: 2.01; 95% CI: 1.93 – 2.25), Medicare (AOR: 1.46; 95% 
CI: 1.40 – 1.52), or Medicaid (AOR: 1.09; 95% CI: 1.05 – 1.13) all showed higher odds 
of offering buprenorphine than those not accepting.  
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Figure 13 Unadjusted and adjusted effects on buprenorphine offering by SAT facility characteristics, 2007-16. 
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Figure 14 Unadjusted and adjusted effects on methadone offering by SAT facility characteristics (among SAT facilities reporting an OTP), 2007-16.
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For methadone treatment, different trends among geographic, operational, and 
payment characteristics were found among SAT facilities operating an OTP. Compared 
to SAT facilities in New England, SAT facilities in Pacific showed higher odds of 
offering methadone treatment (AOR: 6.40; 95% CI: 2.93 – 13.98). Of the SAT facilities 
which responded to the N-SSATS from 2007-16, no SAT facilities operated by DoD ran 
an OTP and no SAT facilities operated by IHS or another Federal government agency 
offered methadone treatment. SAT facilities operated by a private non-profit entity 
(AOR: 0.57; 95% CI: 0.40 – 0.83) or by tribal government (AOR: <0.01) showed lower 
odds of offering methadone treatment than SAT facilities operated by a private-for-
profit entity, particularly so in the latter case. SAT facilities accepting private health 
insurance (AOR: 0.16; 95% CI: 0.10 – 0.25) and Medicare (AOR: 0.70; 95% CI: 0.51 – 
0.95) showed lower odds of offering methadone treatment than those that did not accept 
those forms of payment while SAT facilities accepting Medicaid showed double the 
odds of offering methadone treatment than SAT facilities not accepting Medicaid 
(AOR: 2.04; 95% CI: 1.37 – 3.02). 
6.4  Discussion 
These results show changes in the SAT facility landscape from 2007-16 and highlight 
differences in buprenorphine and methadone treatment availability based upon 
geographic, operational, and payment characteristics. Firstly, though it is promising to 
see that buprenorphine is increasingly offered at SAT facilities among all divisions, 
uptake remains low outside of the northeast. Moreover, though SAT facilities across a 
range of operational entities are increasingly offering buprenorphine treatment, the 
percentage of SAT facilities run by tribal governments or IHS which offer 
buprenorphine remains low, highlighting a potential disparity in treating Native 
Americans. Though SAT facilities operated by the VA which offer buprenorphine have 
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rapidly increased, growth has been more attenuated among facilities run by other 
operational entities as shown by the odds of SAT facilities offering buprenorphine 
among these SAT facilities. We observe that all regions, except for Mid-Atlantic, 
showed lower odds of SAT facilities offering buprenorphine treatment. The odds of 
SAT facilities operated by tribal governments or IHS offering buprenorphine were 
markedly lower than those operated by private for-profit entities. The odds of offering 
buprenorphine among facilities offering payment assistance was lower than those 
without payment assistance. For methadone, on the other hand, we observed that SAT 
facilities accepting Medicaid payments showed higher odds of offering methadone 
treatment. 
This set of analyses do have limitations, particularly the shortcomings of data 
drawn from the N-SSATS. Given major changes to survey design in 2007, namely the 
exclusion of questions capturing the independent and dependent variables of interest, 
inclusion of prior waves of the N-SSATS which could have extended the study period 
was not possible. Moreover, the N-SSATS does not collect information regarding client 
mix among SAT facilities. As client mix and needs contribute to the determination of 
individual SAT facility service offerings, this omission may contribute to omitted 
variables bias. Nevertheless, that the N-SSATS is intended to be a comprehensive 
annual survey of all SAT facilities in the United States strengthens the analysis as 
nearly all SAT facilities are included rather than relying on a generalizable sample (96, 
185-193). Use of a ten-year long study period further contributes to attempts to mitigate 
bias. In addition, to my knowledge, no other dataset currently exists which documents 
SAT facilities on a national level to the extent that the N-SSATS provides. 
Given the magnitude of the opioid epidemic and its sustained impact on 
population health, these findings suggest that greater attention towards the provision of 
pharmacotherapies for the treatment of opioid-related use disorders is warranted, 
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including understanding the reasons why uptake of pharmacotherapies for the treatment 
of opioid-related use disorders has been moderate among civilian healthcare providers. 
This would complement ongoing and sustained efforts to alter prescribing practices 
(197) and to generate novel formulations of abuse-deterrent opioid analgesics (198). 
The relatively low numbers of civilian SAT facilities reporting the availability of 
buprenorphine therapy is concerning, given research which suggests that drug-free 
treatments may contribute towards greater patient mortality than medication-assisted 
therapy (199). Though buprenorphine prescription has hitherto been strictly limited by 
law, researchers have called on lawmakers to consider relaxing such restrictions as they 
may contribute to greater patient harm (200). Previous research has found a similar 
trends regarding the supply of waivered physicians in the northeast relative to other 
regions (201) and though some have offered explanations for this with respect to health 
care reform (202) or regional variations in opioid mortality (203), more research is 
needed to understand the factors which have led to the relatively low uptake of 
buprenorphine treatment outside of the northeast. Additionally, the findings are 
consistent with other analyses of pharmacotherapy among providers primarily focused 
on Native Americans which have also identified low rates of pharmacotherapy 
implementation for substance abuse treatment (204). In the case of opioids specifically, 
some qualitative research suggests that the high prevalence of oxycodone use among a 
tribal community has led to heightened sensitivity regarding opioid misuse (205), 
suggesting that approaches to increasing the use of pharmacotherapy for opioid-related 
substance use disorders must be culturally appropriate and contextual to the needs of 
Native Americans (206). Developing cultural competence and capacity for evidence-
based treatment of opioid-related substance disorders will contribute greatly to 
addressing the disparities we have identified. With respect to methadone treatment, the 
consistent number of SAT facilities with OTPs is concerning as the number of 
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individuals with opioid-related use disorders increases. One study assessing the gap 
between treatment need and capacity for OTPs found that 96% of states showed opioid 
abuse or dependence rates higher than their OTP capacity rates with 38 states reporting 
at least 75% of their OTPs were operating at 80% capacity or more (180). One way of 
addressing the lack of growth of OTPs is by devoting greater resources towards 
expanding the number of waivered physicians who can provide buprenorphine in the 
physician office setting, particularly among rural areas which have been underserved 
with respect to opioid-related substance disorder treatment (207). Another approach is 
to relax the patient limits set on waivered physicians which can be a less resource-
intensive method of increasing capacity for care without the need to increasing the 
number of SAT facilities, OTP programs, or waivered physicians (208).
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Table 10 Characteristics of Study Population by Percentage (%), 2007-16 
  2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 
  n=13352 n=13404 n=13233 n=13066 n=13462 n=14056 n=13873 n=13914 n=13621 n=14162 
Census Division            
 New England 6.4 6.5 6.3 6.3 6.5 6.7 6.5 6.6 6.5 6.8 
 Mid-Atlantic 13.4 13.7 13.8 14.2 13.9 13.2 13.0 13.2 13.2 12.8 
 East North Central 15.8 15.5 15.3 15.0 15.1 14.9 15.1 15.1 14.9 14.8 
 West North Central 8.4 8.3 8.2 8.6 8.8 8.8 8.6 8.9 9.0 9.0 
 South Atlantic 15.6 16.0 16.0 15.5 15.8 16.0 16.4 16.7 17.0 17.2 
 East South Central 5.6 5.4 5.4 5.6 5.7 5.9 5.8 5.7 5.8 5.8 
 West South Central 6.8 6.6 6.6 6.6 6.5 6.7 6.8 6.7 6.5 6.8 
 Mountain 8.6 8.9 8.8 9.3 9.2 9.9 10.1 10.0 10.3 10.4 
 Pacific 19.4 19.1 19.6 18.9 18.6 17.9 17.6 17.1 16.8 16.4 
Operating Entity            
 Private-for-Profit 28.5 29.3 29.3 30.0 30.6 31.1 32.3 33.0 33.6 35.4 
 Private Non-Profit 58.0 58.0 57.9 57.5 57.3 56.3 55.3 55.2 54.6 53.2 
 State Government 3.1 3.0 2.9 2.7 2.4 2.4 2.3 2.3 2.4 2.2 
 
Local, County, or 
Community 
Government 
6.6 6.1 6.0 5.7 5.5 5.4 5.3 5.1 5.1 5.0 
 Tribal Government 1.4 1.3 1.4 1.4 1.6 2.3 2.1 2.0 1.9 1.8 
 Department of Veterans 
Affairs 
1.4 1.3 1.6 1.7 1.7 1.5 1.6 1.5 1.5 1.5 
 Department of Defense 0.7 0.7 0.7 0.7 0.7 0.6 0.6 0.6 0.6 0.6 
 Indian Health Service 0.3 0.3 0.3 0.3 0.2 0.4 0.3 0.2 0.2 0.2 
 Other Federal 
Government Agency 
0.1 <0.05 <0.05 <0.05 <0.05 <0.05 0.1 0.1 0.1 <0.05 
Facility Characteristic            
 Operate an Opioid 
Treatment Program 
8.3 8.4 9.3 8.8 8.8 8.2 9.2 9.4 9.8 9.2 
Types of Payment 
Assistance Offered 
           
 
Offers no charge or free 
treatment 
52.6 52.1 51.5 49.6 49.3 49.5 48.3 47.1 46.6 45.5 
 Sliding fee scale 62.8 62.9 62.8 62.6 62.7 62.2 62.4 61.4 60.6 59.6 
Accepted Payment 
Types 
           
 Cash or Self-Payment 91.3 90.1 91.1 91.5 91.6 90.7 91.3 90.8 90.5 90.4 
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  2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 
  n=13352 n=13404 n=13233 n=13066 n=13462 n=14056 n=13873 n=13914 n=13621 n=14162 
 
Private Health 
Insurance 
66.1 64.7 64.8 65.8 66.2 66.8 67.3 68.7 69.4 70.5 
 Medicare 35.8 35.9 34.2 33.9 34.1 34.6 34.6 34.6 35.1 35.6 
 Medicaid 56.0 55.5 56.0 57.0 58.8 60.3 61.0 62.1 63.6 63.8 
 
State-Financed Health 
Insurance 
37.5 41.3 41.1 42.0 42.0 43.4 44.4 47.4 48.4 49.2 
 
Federal Military 
Insurance 
35.7 35.4 35.6 35.5 36.0 36.5 35.9 36.7 36.1 36.5 
Pharmacotherapies 
Offered 
           
 
Buprenorphine (with or 
without naloxone) 
14.4 15.2 17.2 18.6 19.9 20.7 22.2 23.4 24.8 27.2 
 Methadone 11.2 8.4 11.4 11.5 11.3 11.3 11.7 11.8 12.1 12.5 
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Table 11 Unadjusted and adjusted multiple logistic regression of SAT facility characteristics associated with pharmacotherapies offered. 
 Buprenorphine Methadone* 
 Unadjusted OR Adjusted OR** Unadjusted OR Adjusted OR** 
Census Bureau Division     
New England 1  1  1  1  
Mid-Atlantic 1.05 (0.99 - 1.11) 1.15 (1.08 - 1.22) 0.98 (0.71 - 1.35) 0.62 (0.42 - 0.91) 
East North Central 0.52 (0.49 - 0.56) 0.47 (0.44 - 0.50) 1.73 (1.13 - 2.64) 1.14 (0.70 - 1.86) 
West North Central 0.34 (0.31 - 0.36) 0.28 (0.26 - 0.30) 2.99 (1.28 - 6.98) 3.98 (1.38 - 11.44) 
South Atlantic 0.76 (0.72 - 0.80) 0.75 (0.70 - 0.80) 1.82 (1.27 - 2.62) 0.91 (0.58 - 1.42) 
East South Central 0.35 (0.33 - 0.38) 0.32 (0.29 - 0.35) 2.57 (1.16 - 5.66) 0.88 (0.35 - 2.20) 
West South Central 0.45 (0.42 - 0.49) 0.45 (0.42 - 0.49) 5.74 (2.61 - 12.62) 2.77 (1.00 - 7.69) 
Mountain 0.55 (0.52 - 0.59) 0.56 (0.52 - 0.60) 2.30 (1.28 - 4.14) 1.66 (0.79 - 3.49) 
Pacific 0.42 (0.40 - 0.44) 0.51 (0.48 - 0.55) 5.21 (2.95 - 9.21) 6.40 (2.93 - 13.98) 
Private-for-Profit 1  1  1  1  
Private Non-Profit 0.70 (0.68 - 0.73) 0.85 (0.82 - 0.88) 0.29 (0.23 - 0.38) 0.57 (0.40 - 0.83) 
State Government 0.95 (0.88 - 1.04) 1.22 (1.11 - 1.35) 0.32 (0.17 - 0.63) 0.48 (0.22 - 1.01) 
Local, County, or Community Government 0.59 (0.55 - 0.63) 0.71 (0.66 - 0.77) 0.48 (0.26 - 0.89) 1.26 (0.54 - 2.93) 
Tribal Government 0.37 (0.33 - 0.43) 0.53 (0.45 - 0.62) 0.05 (0.03 - 0.112 0.01 (<0.01 - 0.02) 
Department of Veterans Affairs 6.41 (5.84 - 7.05) 9.58 (8.40 - 10.93) 0.20 (0.12 - 0.31) 0.91 (0.43 - 1.89) 
Department of Defense 0.47 (0.38 - 0.57) 1.32 (1.06 - 1.64) **  **  
Indian Health Service 0.35 (0.25 - 0.49) 0.65 (0.45 - 0.95) **  **  
Other Federal Government Agency 0.95 (0.52 - 1.73) 1.29 (0.66 - 2.52) **  **  
Offers no charge or free Tx 0.68 (0.67 - 0.70) 0.84 (0.81 - 0.87) 0.51 (0.41 - 0.64) 1.00 (0.74 - 1.36) 
Uses sliding fee scale 0.57 (0.55 - 0.58) 0.46 (0.45 - 0.48) 0.67 (0.54 - 0.84) 0.99 (0.73 - 1.35) 
Accepts cash or self-payment 1.84 (1.74 - 1.94) 2.09 (1.94 - 2.25) 1.84 (1.08 - 3.13) 2.01 (1.03 - 3.93) 
Accepts private health insurance 2.27 (2.20 - 2.34) 2.01 (1.93 - 2.10) 0.11 (0.08 - 0.17) 0.16 (0.10 - 0.25) 
Accepts Medicare payments 1.65 (1.60 - 1.69) 1.46 (1.40 - 1.52) 0.30 (0.24 - 0.38) 0.70 (0.51 - 0.95) 
Accepts Medicaid payments 1.29 (1.26 - 1.33) 1.09 (1.05 - 1.13) 0.52 (0.40 - 0.69) 2.04 (1.37 - 3.02) 
Accepts state-financed health insurance 1.30 (1.27 - 1.34) 0.98 (0.94 - 1.02) 0.31 (0.25 - 0.40) 0.77 (0.56 - 1.06) 
Accepts Federal military insurance 1.54 (1.50 - 1.58) 0.95 (0.92 - 0.99) 0.23 (0.18 - 0.29) 0.58 (0.43 - 0.78) 
*Only among facilities operating an OTP 
**Adjusted for year, census bureau division, operating entity, type of payment assistance offered, accepted payment types 
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7 REGIONAL DISPARITIES IN 
OPIOID AGONIST 
TREATMENT AND DELAYS 
TO ENTER TREATMENT FOR 
OPIOID MISUSE IN THE 
UNITED STATES, 2003-14 
7.1 Background 
In 2010 the global burden of disease attributable to opioid dependence was 9.2 
million disability-adjusted life years (DALYs) with 15.5 million individuals suffering 
from opioid dependence and a significantly high burden of premature mortality 
affecting North America and Eastern Europe (209). In 2015, over 33,000 deaths from 
overdoses were recorded in the United States, nearly equal to the number of deaths from 
traffic accidents for the same period, with deaths from heroin alone exceeding those 
from homicides involving firearms (130). The opioid misuse epidemic in the United 
States has been one of the most pressing public health challenges identified by the 
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United States Centers for Disease Control and Prevention (CDC) (130), involving both 
heroin use, proved to be exacerbated by socioeconomic vulnerability (210), as well as 
ease of accessibility and over prescription of synthetic opioids such as oxycodone and 
fentanyl, respectively, which appear to fuel the increasing abuse, toxicity, and mortality 
of these substances (211). The effects of this increasing prevalence has been an upsurge 
in opioid-related overdose deaths that have tripled between 1999-2014, with 60.9% of 
drug-related deaths involving an opioid (173). Moreover, misuse and addiction to 
prescription and synthetic opioids has steadily increased; from 1997-2011, the number 
of individuals seeking treatment for opioid addiction increased by 900% (130). Despite 
the urgent need for additional capacity and health system responsiveness for opioid 
misuse treatment, individuals with opioid addictions continue to face barriers to 
evidence based treatment such as psychotherapy and opioid agonist treatments (OATs) 
(70, 177). One national study in 2013 found, for instance, that lifetime cumulative 
probability of treatment-seeking among individuals with opioid addiction was only 42% 
with a median delay of 3.83 years from onset of disorder to first treatment (212). These 
findings, in conjunction with research that show that opiate-dependent patients waiting 
for treatment are at heightened risk for mortality (213), indicate a need for greater 
scrutiny of barriers to treatment. In addition to barriers to treatment, the type and mode 
of treatment received by opioid users has also been at the centre of the access barriers 
debate (178, 179). OATs, such as methadone (182) or buprenorphine (181), are cost-
effective, evidence-based treatments for opioid misuse, especially compared against 
abstinence-based treatments for opioid dependence (181, 182). Nevertheless, OATs 
have historically been subject to heightened scrutiny in the United States; the use of 
OATs is strictly regulated by the Drug Addiction Treatment Act (DATA) of 2000 and 
limited only to certified Opioid Treatment Programs (OTPs) (214). The use of 
buprenorphine in physician office setting has only been approved since 2002 for 
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waivered physicians with strict limitations on the quantity of buprenorphine which may 
be dispensed (215). Given the stringent regulatory oversight of OATs for the treatment 
of opioid misuse amid the opioid crisis, the accessibility of OATs and the capacity to 
treat opioid misuse has come under heightened scrutiny (180) with some calling for 
increased access to buprenorphine in the outpatient setting (184). Moreover, given the 
urgency of prescription opioid misuse, some attention has also been devoted to the 
timely receipt of care for opioid misuse (216). 
The aim here was to examine and identify opioid misuse patient subpopulations 
at risk of not receiving OAT as well as delayed entry to treatment based on 
demographic, socioeconomic, institutional, and behavioural characteristics. In addition, 
this analysis explores possible disparities among major geographic regions of the United 
States associated with differential receipt of OAT and delay to enter treatment. This 
analysis extends beyond the position endorsed by the American Psychiatric Association 
(APA) and American Society of Addiction Medicine that OAT, combined with 
psychosocial therapy, is the most effective treatment for opioid misuse disorders (181-
183). In this study, the Treatment Episode Dataset (TEDS), an administrative dataset of 
annual admissions to substance abuse treatment facilities is used to analyse the 
differential use of OAT among admitted patients by geographic region and patient 
characteristics as well as factors underlying delays to enter treatment. Patient subgroups 
at potential heightened risk of disparately long waiting times to enter treatment as well 
as those at higher risk of not receiving OAT are also described to provide guidance to 
policymakers and care providers for improved care for opioid misuse. 
7.2 Methods 
7.2.1 Data Source 
Data were used from the Treatment Episode Data Set – Admissions (TEDS-A), a 
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national administrative dataset coordinated and maintained by the Center for Behavioral 
Health Statistics and Quality at the Substance Abuse and Mental Health Service 
Administration (SAMHSA), for admissions from 2003-14 (97). TEDS-A captures 
information at intake on all publicly-funded admissions to public and private substance 
abuse treatment facilities in all 50 States, the District of Columbia, and Puerto Rico, as 
well as some privately-funded admissions to facilities which receive public funding, 
depending on whether State regulations require this information or not (97). The unit of 
analysis in TEDS-A is admission, not an individual; consequently, an individual may be 
represented as multiple admissions in TEDS-A (97). Nevertheless, the TEDS-A data file 
excludes admissions known to be transfers from one level of care to another within a 
single treatment episode for the same provider (97). Collected information includes: 
demographic and socioeconomic characteristics of admitted patients, such as sex, age, 
and primary source of income, and their substance use behaviours, such as types of 
substances used, institutional information pertaining to the admission, and indicators of 
behavioural health of admitted patients (97).  
These analyses included all admissions for opioid treatment (not detoxification) 
where at least one of: heroin, non-prescription methadone, or other opiates was reported 
as the primary, secondary, or tertiary substance of abuse at time of admission. As 
outcome variables of interest were whether or not an admitted patient received opioid 
agonist therapy and days waiting to enter treatment, states were excluded which 
reported no patients receiving opioid agonist therapy (Indiana, Mississippi, Nevada, 
Ohio, and West Virginia) or states reporting every patient having waited over 365 days 
to enter treatment (Colorado, Idaho, Kansas, Mississippi, New Jersey, New Mexico, 
Oklahoma, Pennsylvania, Utah, Virginia, Vermont, and Wisconsin) as these were likely 
to represent reporting errors or non-response for optional modules of TEDS-A. This 
approach has been adopted elsewhere (217).  
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7.2.2 Study Variables  
The primary outcome variables were whether an admitted patient received OAT, coded 
as a dichotomous variable; and days waiting to enter treatment, coded as a continuous 
variable capped at 996 days. Independent variables were categorized as demographic, 
socioeconomic, institutional, or behavioural. Demographic independent variables 
included age, sex, ethnicity, marital status, living arrangement, and veteran status. 
Socioeconomic variables included years of education, employment status, primary 
source of income, and health insurer. Institutional characteristics included census 
division, service setting at time of admission, and primary source of referral. Census 
divisions in the United States include: New England; Mid-Atlantic; East North Central; 
West North Central; South Atlantic; East South Central; West South Central; Mountain; 
and Pacific (194). Details on which states categorization by census division are 
available in Table 12. 
Table 12 States by Census Division. 
Census 
Division 
States 
New England Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont 
Mid-Atlantic New Jersey, New York, and Pennsylvania 
East North 
Central 
Illinois, Indiana, Michigan, Ohio, and Wisconsin 
West North 
Central 
Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, and South Dakota 
South Atlantic 
Delaware, the District of Columbia, Florida, Georgia, Maryland, North Carolina, South 
Carolina, Virginia, and West Virginia 
East South 
Central 
Alabama, Kentucky, Mississippi, and Tennessee 
West South 
Central 
Arkansas, Louisiana, Oklahoma, and Texas 
Mountain Arizona, Colorado, Idaho, Montana, Nevada, New Mexico, Utah, and Wyoming 
Pacific Alaska, California, Hawaii, Oregon, and Washington 
 
Behavioural characteristics included a patient’s DSM criteria diagnosis (if applicable) 
and a dichotomous indicating the presence or absence of a psychiatric disorder in 
addition to alcohol and/or drug use. In addition to variables already provided in TEDS-
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A, namely demographic, socioeconomic, and behavioural characteristics of admitted 
patients and institutional characteristics pertaining to admission, two additional 
explanatory variables were coded. Firstly, new dichotomous variable was created to 
indicate whether a patient was being admitted for the first time or whether a patient was 
a repeat admission. A further dichotomous variable was created to indicate the reported 
use of alcohol or benzodiazepines on admission, both of which contraindicate the use of 
OAT for opioid substance abuse (218) and could confound the analysis of receipt of 
OAT. 
7.2.3 Statistical Analysis 
All statistical analyses were performed in Stata 14 (196). For analyses of OAT, a 
dichotomous outcome variable indicating whether an admitted patient received OAT, I 
conducted multiple maximum-likelihood logit regressions with weighted least squares 
to simultaneously model how demographic, socioeconomic, and behavioural 
characteristics of admitted patients and institutional characteristics pertaining to 
admission were related to OAT. For analyses of days waiting to enter treatment, a 
continuous outcome variable, I conducted multiple maximum-likelihood censored linear 
regressions to simultaneously model how predictor variables were related to days 
waiting to enter treatment. Censored linear regression was selected for this portion of 
our study as the outcome variable of interest, days waiting to enter treatment, was a 
right-censored continuous variable with a cap of 996 days.  
7.3 Results 
Descriptive sample characteristics are presented in Table 13 and Table 14. Use of OAT 
among patients admitted for opioid-related substance abuse by state, census division, 
and year from 2003-14 is shown in Figure 15. 
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Figure 15 Use of Opioid Agonist Therapy Among Patients Admitted for Opioid-Related Substance Abuse by State, Census Bureau Division, and Year, 
2003-14. A small random jitter has been applied to the data points to show overlapping states within the same year.
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Generally low use of OAT is observed among most census divisions over the study 
period, 2003-14, with the notable exception of Middle Atlantic, chiefly due to OAT use 
in New York and New Jersey, and Pacific, primarily due to California. Among states in 
New England, a consistently high number of patients were admitted for opioid-related 
substance abuse as well as a high number of patients receiving opioid agonist therapy. 
7.3.1 Use of Opioid Agonist Therapy 
The unadjusted and adjusted results of logistic regression of patient 
characteristics on receipt of OAT are shown in Table 15. These results are also shown 
graphically in Figure 16. 
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Figure 16 Unadjusted and adjusted effects on opioid agonist therapy for patients admitted for opioid-related substance misuse by patient and 
institutional characteristics, 2003-14.
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7.3.1.1 Demographic Characteristics 
We observed higher odds of receipt of OAT among all age groups relative to the 
reference group. Women showed higher odds of receiving opioid agonist therapy than 
men. Native Americans showed lower odds of receiving OAT than White Americans 
while Black or African Americans showed higher odds. Compared to those who were 
never married, those who were married, separated, or divorced/widowed all showed 
lower odds of receiving OAT. Those who were homeless also showed much lower odds 
of receiving opioid agonist therapy. No statistically significant difference in receipt of 
opioid agonist treatment was observed between veterans and non-veterans, holding 
other demographic, socioeconomic, institutional, and behavioural characteristics 
constant. 
7.3.1.2 Socioeconomic Characteristics 
Those reporting more than 13 years of education showed lower odds of receiving opioid 
agonist therapy compared to those who received 8 or fewer years of education with 
much lower odds, about 30% lower, among those receiving over 16 years of education. 
Those who were unemployed or otherwise not in the labour force also showed lower 
odds of receiving opioid agonist therapy. Recipients of public assistance were at slightly 
higher odds of receiving opioid agonist therapy. The odds of receiving opioid agonist 
therapy were about 10% lower among admitted patients whose primary health insurer 
was Medicaid compared with those whose primary health insurer was private insurance. 
7.3.1.3 Institutional Characteristics 
Compared with New England which served as our reference group, admitted patients in 
East North Central, West North Central, and Pacific showed slightly higher odds of 
receiving OAT while those in Mid-Atlantic and Mountain showed twice the odds of 
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those in New England. By comparison, patients in South Atlantic showed about 20% 
lower odds of receiving OAT while those in East South Central showed nearly 0.75% 
lower odds. Patients admitted to non-hospital settings showed much lower odds of 
receiving opioid agonist therapy. Similarly, patients who we referred by any source 
other than individual (including self-referral) exhibited much lower odds of receiving 
OAT, especially for those who were referred by employers.  
7.3.1.4 Behavioural Characteristics 
Those reporting a DSM diagnosis, except for those diagnosed with opioid dependence, 
and those reporting a psychiatric problem in addition to an alcohol or drug problem 
showed lower odds of receiving opioid agonist therapy. 
7.3.2 Days Waiting to Enter Treatment 
The unadjusted and adjusted results of Tobit censored linear regression of 
patient characteristics on days waiting to enter treatment for opioid substance abuse are 
shown in Table 16. These results are also shown graphically in Figure 17.
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Figure 17 Unadjusted and adjusted effects on days waiting to enter treatment for patients admitted for opioid-related substance misuse by patient and 
institutional characteristics, 2003-14.
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7.3.2.1 Demographic Characteristics 
Neither age nor sex were associated with statistically significant differences in days 
waiting to enter treatment for patients admitted for opioid substance abuse. Black or 
African Americans entered treatment sooner than White Americans by just over one 
day. Compared to those admitted patients who reported living independently, those in a 
dependent living arrangement waited just over a day longer while those who were 
homeless entered treatment sooner by more than half a day. No difference was observed 
in days waiting to enter treatment between veterans and non-veterans. 
7.3.2.2 Socioeconomic Characteristics 
No statistically significant difference in days waiting to enter treatment was observed 
among patients with differing years of education. Admitted patients who were 
unemployed or otherwise not in the labour force waited one day more to enter treatment 
compared to admitted patients who reported full-time employment. Those reporting a 
primary source of income other than wages/salary showed slightly fewer days waiting 
to enter treatment. Moreover, patients whose primary health insurer was Medicaid, 
Medicare or other, or who were uninsured waited about one-and-a-half days more to 
enter treatment than those who were privately insured.  
7.3.2.3 Institutional Characteristics 
Compared to the baseline group of patients admitted in New England, patients in all 
other census divisions reported less time to enter treatment except for Mid-Atlantic 
which reported just over one day more to enter treatment. Patients who were admitted at 
long-term care facilities reported waiting about a week longer to enter treatment than 
patients who were admitted to the hospital setting. Patients referred by an alcohol or 
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drug abuse care provider or other health care provider reported 4-5 fewer days waiting 
to enter treatment compared with those who were individually referred, including self-
referrals, while those referred through the criminal justice system waited just over two 
days longer enter treatment.  
7.3.2.4 Behavioural Characteristics 
Compared with patients with no DSM diagnosis, those with a DSM diagnosis 
either exhibited more days waiting to enter treatment or no statistically significant 
difference in days waiting to enter treatment.  
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Table 13 Characteristics of admitted patients either receiving or not receiving opioid 
agonist therapy for opioid substance abuse, 2003-14. 
Characteristic 
Opioid Agonist Therapy 
Total 
No Yes 
No. % No. % No. % 
Age       
18-20 120,878 85.0 21,290 15.0 142,168 100 
21-24 284,571 78.6 77,454 21.4 362,025 100 
25-29 348,099 74.1 121,456 25.9 469,555 100 
30-34 253,536 71.8 99,374 28.2 352,910 100 
35-39 192,672 69.8 83,464 30.2 276,136 100 
40-44 170,274 67.8 81,025 32.2 251,299 100 
45-49 139,431 63.9 78,613 36.1 218,044 100 
50-54 89,085 58.1 64,320 41.9 153,405 100 
55+ 56,545 48.8 59,392 51.2 115,937 100 
Total 1,655,091 70.7 686,388 29.3 2,341,479 100        
Sex       
Male 961,363 71.3 386,226 28.7 1,347,589 100 
Female 693,410 69.8 300,023 30.2 993,433 100 
Total 1,654,773 70.7 686,249 29.3 2,341,022 100        
Race       
White 1,255,743 72.8 468,650 27.2 1,724,393 100 
Black or African American 268,651 66.7 134,269 33.3 402,920 100 
Asian or Pacific Islander 9,280 58.7 6,528 41.3 15,808 100 
Native American 16,039 68.6 7,353 31.4 23,392 100 
Other 83,199 56.5 64,054 43.5 147,253 100 
Total 1,632,912 70.6 680,854 29.4 2,313,766 100        
Marital Status       
Never Married 947,570 74.7 321,760 25.3 1,269,330 100 
Married 194,188 69.4 85,552 30.6 279,740 100 
Separated 94,607 73.7 33,765 26.3 128,372 100 
Divorced or Widowed 207,670 72.9 77,040 27.1 284,710 100 
Total 1,444,035 73.6 518,117 26.4 1,962,152 100        
Living Arrangement       
Independent 918,587 64.9 496,709 35.1 1,415,296 100 
Dependent 369,970 76.8 111,815 23.2 481,785 100 
Homeless 176,715 83.9 33,826 16.1 210,541 100 
Total 1,465,272 69.5 642,350 30.5 2,107,622 100        
Veteran Status       
No 1,346,667 70.7 558,104 29.3 1,904,771 100 
Yes 41,436 69.8 17,886 30.2 59,322 100 
Total 1,388,103 70.7 575,990 29.3 1,964,093 100        
Education       
<8 Years 102,810 66.4 52,033 33.6 154,843 100 
9-11 Years 391,219 69.7 170,434 30.3 561,653 100 
12 Years 755,094 70.4 316,946 29.6 1,072,040 100 
13-15 Years 316,027 72.9 117,331 27.1 433,358 100 
16+ Years 61,924 72.9 22,978 27.1 84,902 100 
Total 1,627,074 70.5 679,722 29.5 2,306,796 100        
Employment Status       
Full-Time 190,709 62.9 112,538 37.1 303,247 100 
Part-Time 100,858 63.9 57,066 36.1 157,924 100 
Unemployed 779,196 74.1 271,667 25.9 1,050,863 100 
Not in Labour Force 565,452 70.2 239,815 29.8 805,267 100 
Total 1,636,215 70.6 681,086 29.4 2,317,301 100        
Source of Income/Support      
Wages/Salary 275,346 73.1 101,462 26.9 376,808 100 
Public Assistance 92,591 61.6 57,706 38.4 150,297 100 
Retirement/Pension or Disability 96,237 68.7 43,806 31.3 140,043 100 
Other 174,488 78.2 48,774 21.8 223,262 100 
None 463,763 85.0 81,947 15.0 545,710 100 
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Characteristic 
Opioid Agonist Therapy 
Total 
No Yes 
No. % No. % No. % 
Total 1,102,425 76.8 333,695 23.2 1,436,120 100        
Health Insurance       
Private 117,169 75.2 38,733 24.8 155,902 100 
Medicaid 261,492 61.5 163,575 38.5 425,067 100 
Medicare or Other 87,931 79.1 23,215 20.9 111,146 100 
Uninsured 585,091 77.1 173,380 22.9 758,471 100 
Total 1,051,683 72.5 398,903 27.5 1,450,586 100        
Census Division       
New England 171,350 60.0 114,361 40.0 285,711 100 
Mid-Atlantic 278,335 70.1 118,576 29.9 396,911 100 
East North Central 372,178 75.9 117,873 24.1 490,051 100 
West North Central 90,563 91.6 8,284 8.4 98,847 100 
South Atlantic 313,837 72.8 116,969 27.2 430,806 100 
East South Central 50,561 95.7 2,268 4.3 52,829 100 
West South Central 105,747 87.6 14,977 12.4 120,724 100 
Mountain 97,337 73.7 34,689 26.3 132,026 100 
Pacific 175,183 52.5 158,391 47.5 333,574 100 
Total 1,655,091 70.7 686,388 29.3 2,341,479 100        
Service Setting at Admission      
Hospital 3,935 92.2 335 7.8 4,270 100 
Short-Term 309,077 95.8 13,673 4.2 322,750 100 
Long-Term 278,228 95.6 12,947 4.4 291,175 100 
Ambulatory, Intensive Outpatient 308,985 88.7 39,357 11.3 348,342 100 
Ambulatory, Non-Intensive Outpatient 754,698 54.9 619,400 45.1 1,374,098 100 
Total 1,654,923 70.7 685,712 29.3 2,340,635 100        
Principal Source of Referral      
Individual (including Self-Referral 500,421 49.4 512,001 50.6 1,012,422 100 
Alcohol/Drug Abuse Care Provider 298,371 78.8 80,291 21.2 378,662 100 
Other Health Care Provider 110,171 77.2 32,492 22.8 142,663 100 
Educational Institution 1,205 88.3 160 11.7 1,365 100 
Employer 5,352 93.4 378 6.6 5,730 100 
Other Community Referral 155,450 85.4 26,475 14.6 181,925 100 
Court/Criminal Justice Referral/DUI 566,484 95.6 26,035 4.4 592,519 100 
Total 1,637,454 70.7 677,832 29.3 2,315,286 100        
One or More Prior Treatment Episode(s)    
No 483,735 74.5 165,285 25.5 649,020 100 
Yes 1,171,356 69.2 521,103 30.8 1,692,459 100 
Total 1,655,091 70.7 686,388 29.3 2,341,479 100        
Alcohol or Benzodiazepines Reported at Admission    
Substance Not Reported 1,046,956 64.3 580,855 35.7 1,627,811 100 
Substance Reported 608,135 85.2 105,533 14.8 713,668 100 
Total 1,655,091 70.7 686,388 29.3 2,341,479 100        
DSM Diagnosis       
No Diagnosis 5,088 70.1 2,170 29.9 7,258 100 
Alcohol-Induced Disorder 466 97.3 13 2.7 479 100 
Substance-Induced Disorder 4,664 93.4 330 6.6 4,994 100 
Alcohol Intoxication 991 97.6 24 2.4 1,015 100 
Alcohol Dependence 55,427 97.6 1,386 2.4 56,813 100 
Opioid Dependence 448,267 71.0 182,810 29.0 631,077 100 
Cocaine Dependence 32,814 96.0 1,377 4.0 34,191 100 
Cannabis Dependence 24,551 97.9 529 2.1 25,080 100 
Other Substance Dependence 97,503 95.2 4,865 4.8 102,368 100 
Alcohol Abuse 8,147 96.8 271 3.2 8,418 100 
Cannabis Abuse 5,865 96.6 206 3.4 6,071 100 
Other Substance Abuse 4,193 96.9 136 3.1 4,329 100 
Opioid Abuse 24,598 89.0 3,043 11.0 27,641 100 
Cocaine Abuse 3,343 94.6 190 5.4 3,533 100 
Anxiety Disorders 1,492 86.2 238 13.8 1,730 100 
Depressive Disorders 4,861 91.4 456 8.6 5,317 100 
Schizophrenia / Other Psychotic Disorder 979 92.9 75 7.1 1,054 100 
Bipolar Disorders 2,999 89.6 347 10.4 3,346 100 
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Characteristic 
Opioid Agonist Therapy 
Total 
No Yes 
No. % No. % No. % 
Attention Deficit / Disruptive Behaviour 178 93.7 12 6.3 190 100 
Other Mental Health Condition 1,809 92.6 145 7.4 1,954 100 
Other Condition 11,850 92.7 928 7.3 12,778 100 
Total 740,085 78.8 199,551 21.2 939,636 100        
Psychiatric Problem in Addition to Alcohol/Drug Problem   
No 908,357 67.4 438,497 32.6 1,346,854 100 
Yes 448,349 73.0 165,651 27.0 614,000 100 
Total 1,356,706 69.2 604,148 30.8 1,960,854 100 
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Table 14 Characteristics of admitted patients by days waiting to enter treatment for opioid substance abuse, 2003-14. 
Characteristic 
Days Waiting to Enter Treatment  
No wait 
Within one 
day 
Within one 
week 
Within one 
month 
Within three 
months 
Within six 
months 
Within one 
year 
More than 
one year 
No. % No. % No. % No. % No. % No. % No. % No. % 
Age                 
18-20 55,683 37.3 10,664 7.1 21,709 14.5 15,016 10.1 3,693 2.5 723 0.5 268 0.2 41,572 27.8 
21-24 145,541 38.2 26,095 6.9 52,980 13.9 37,848 9.9 9,884 2.6 2,073 0.5 712 0.2 105,661 27.7 
25-29 198,440 40.2 33,355 6.8 67,272 13.6 49,388 10.0 12,910 2.6 2,771 0.6 1,153 0.2 128,649 26.0 
30-34 151,854 41.0 24,589 6.6 49,196 13.3 35,752 9.7 9,780 2.6 2,130 0.6 840 0.2 96,301 26.0 
35-39 117,251 40.8 18,781 6.5 36,971 12.9 26,041 9.1 6,702 2.3 1,506 0.5 637 0.2 79,659 27.7 
40-44 110,032 42.2 17,174 6.6 33,465 12.8 22,742 8.7 5,533 2.1 1,326 0.5 544 0.2 69,897 26.8 
45-49 102,070 45.2 14,408 6.4 28,190 12.5 18,733 8.3 4,500 2.0 1,024 0.5 529 0.2 56,399 25.0 
50-54 78,868 49.6 10,184 6.4 19,077 12 12,251 7.7 3,042 1.9 711 0.4 375 0.2 34,507 21.7 
55+ 68,032 56.8 7,142 6.0 13,188 11 8,207 6.8 2,046 1.7 473 0.4 278 0.2 20,477 17.1 
Total 1,027,771 42.0 162,392 6.6 322,048 13.2 225,978 9.2 58,090 2.4 12,737 0.5 5,336 0.2 633,122 25.9 
                                  
Sex                                 
Male 584,481 41.5 92,331 6.6 182,708 13.0 129,530 9.2 34,130 2.4 7,423 0.5 2,981 0.2 373,247 26.5 
Female 443,071 42.6 70,027 6.7 139,286 13.4 96,406 9.3 23,948 2.3 5,311 0.5 2,355 0.2 259,749 25.0 
Total 1,027,552 42.0 162,358 6.6 321,994 13.2 225,936 9.2 58,078 2.4 12,734 0.5 5,336 0.2 632,996 25.9 
                                  
Race                                 
White 726,139 40.0 124,521 6.9 248,751 13.7 176,484 9.7 46,092 2.5 10,181 0.6 4,115 0.2 478,907 26.4 
Black or African American 195,501 47.6 28,968 7.0 55,408 13.5 35,889 8.7 8,025 2.0 1,755 0.4 947 0.2 84,470 20.6 
Asian or Pacific Islander 7,961 48.8 1,198 7.3 1,798 11.0 1,175 7.2 358 2.2 64 0.4 23 0.1 3,747 23.0 
Native American 11,145 46.4 1,130 4.7 2,511 10.4 1,970 8.2 598 2.5 125 0.5 46 0.2 6,505 27.1 
Other 75,528 49.7 5,883 3.9 11,833 7.8 8,918 5.9 2,612 1.7 497 0.3 152 0.1 46,464 30.6 
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Total 1,016,274 42.0 161,700 6.7 320,301 13.2 224,436 9.3 57,685 2.4 12,622 0.5 5,283 0.2 620,093 25.6 
                                  
Marital Status                                 
Never Married 492,732 37.2 97,217 7.3 193,640 14.6 132,804 10.0 32,921 2.5 6,948 0.5 2,931 0.2 367,120 27.7 
Married 124,030 42.0 21,478 7.3 41,229 14.0 27,654 9.4 6,904 2.3 1,428 0.5 696 0.2 71,631 24.3 
Separated 53,682 39.5 9,941 7.3 19,221 14.2 14,376 10.6 3,705 2.7 775 0.6 460 0.3 33,662 24.8 
Divorced or Widowed 126,343 41.9 20,028 6.6 40,505 13.4 28,768 9.5 7,315 2.4 1,403 0.5 578 0.2 76,748 25.4 
Total 796,787 38.7 148,664 7.2 294,595 14.3 203,602 9.9 50,845 2.5 10,554 0.5 4,665 0.2 549,161 26.7 
                                  
Living Arrangement                                 
Independent 650,175 43.7 114,840 7.7 226,228 15.2 148,244 10.0 34,358 2.3 7,444 0.5 3,504 0.2 303,834 20.4 
Dependent 264,472 53.3 29,907 6.0 62,949 12.7 52,499 10.6 16,133 3.3 3,624 0.7 1,308 0.3 65,050 13.1 
Homeless 100,923 46.3 15,347 7.0 29,313 13.5 22,963 10.5 6,765 3.1 1,473 0.7 424 0.2 40,598 18.6 
Total 1,015,570 46.1 160,094 7.3 318,490 14.5 223,706 10.2 57,256 2.6 12,541 0.6 5,236 0.2 409,482 18.6 
                                  
Veteran Status                                 
No 854,770 43.2 126,021 6.4 247,345 12.5 176,446 8.9 47,519 2.4 10,012 0.5 4,427 0.2 511,224 25.8 
Yes 31,554 52.2 4,049 6.7 6,964 11.5 5,096 8.4 1,363 2.3 217 0.4 102 0.2 11,082 18.3 
Total 886,324 43.5 130,070 6.4 254,309 12.5 181,542 8.9 48,882 2.4 10,229 0.5 4,529 0.2 522,306 25.6 
                                  
Education                                 
<8 Years 56,680 35.3 9,670 6.0 18,040 11.2 12,663 7.9 3,656 2.3 706 0.4 255 0.2 58,793 36.6 
9-11 Years 261,200 44.5 39,565 6.7 77,004 13.1 54,875 9.4 14,086 2.4 2,886 0.5 1,406 0.2 135,672 23.1 
12 Years 459,816 41.2 73,937 6.6 148,300 13.3 103,505 9.3 26,575 2.4 5,495 0.5 2,253 0.2 296,850 26.6 
13-15 Years 198,577 43.7 31,118 6.8 63,385 13.9 44,244 9.7 11,231 2.5 2,438 0.5 1,094 0.2 102,308 22.5 
16+ Years 38,243 42.9 6,380 7.2 12,154 13.6 7,799 8.8 1,856 2.1 374 0.4 172 0.2 22,140 24.8 
Total 1,014,516 42.1 160,670 6.7 318,883 13.2 223,086 9.3 57,404 2.4 11,899 0.5 5,180 0.2 615,763 25.6 
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Employment Status                                 
Full-Time 128,195 40.4 23,768 7.5 42,878 13.5 26,468 8.3 5,757 1.8 1,219 0.4 513 0.2 88,718 27.9 
Part-Time 70,869 43.5 10,493 6.4 22,451 13.8 15,812 9.7 3,654 2.2 776 0.5 397 0.2 38,435 23.6 
Unemployed 485,772 44.0 69,547 6.3 146,972 13.3 102,268 9.3 25,532 2.3 5,830 0.5 2,871 0.3 265,082 24.0 
Not in Labour Force 336,683 40.3 56,793 6.8 106,976 12.8 79,907 9.6 22,779 2.7 4,771 0.6 1,459 0.2 226,109 27.1 
Total 1,021,519 42.2 160,601 6.6 319,277 13.2 224,455 9.3 57,722 2.4 12,596 0.5 5,240 0.2 618,344 25.6 
                                  
Source Of Income/Support                                 
Wages/Salary 163,957 42.3 28,084 7.3 55,214 14.3 42,354 10.9 10,319 2.7 2,217 0.6 1,087 0.3 84,011 21.7 
Public Assistance 62,330 39.2 10,316 6.5 23,410 14.7 15,197 9.6 3,829 2.4 701 0.4 337 0.2 42,840 27.0 
Retirement/Pension or 
Disability 
69,316 48.9 9,752 6.9 19,679 13.9 13,552 9.6 3,588 2.5 795 0.6 501 0.4 24,533 17.3 
Other 107,267 46.2 16,851 7.3 32,815 14.1 23,072 9.9 4,983 2.1 904 0.4 305 0.1 45,989 19.8 
None 240,255 43.1 33,890 6.1 62,753 11.3 55,935 10.0 19,392 3.5 4,338 0.8 1,751 0.3 139,205 25.0 
Total 643,125 43.5 98,893 6.7 193,871 13.1 150,110 10.2 42,111 2.8 8,955 0.6 3,981 0.3 336,578 22.8 
                                  
Health Insurance                                 
Private 60,693 37.3 16,064 9.9 30,345 18.6 14,097 8.7 2,161 1.3 365 0.2 76 0 38,973 23.9 
Medicaid 139,609 31.5 33,326 7.5 61,146 13.8 39,801 9.0 10,716 2.4 1,897 0.4 707 0.2 156,464 35.3 
Medicare or Other 33,161 26.7 5,242 4.2 11,712 9.4 8,493 6.8 1,968 1.6 386 0.3 109 0.1 63,111 50.8 
Uninsured 314,303 40.3 55,362 7.1 106,838 13.7 82,659 10.6 22,013 2.8 4,287 0.5 1,394 0.2 193,085 24.8 
Total 547,766 36.3 109,994 7.3 210,041 13.9 145,050 9.6 36,858 2.4 6,935 0.5 2,286 0.2 451,633 29.9 
                                  
Census Division                                 
New England 50,637 17.7 15,175 5.3 33,861 11.9 26,441 9.3 8,421 2.9 1,476 0.5 258 0.1 149,461 52.3 
Mid-Atlantic 65,935 15.8 41,925 10.0 63,159 15.1 31,098 7.4 5,547 1.3 817 0.2 188 0 209,800 50.1 
East North Central 247,240 49.9 27,346 5.5 77,359 15.6 59,478 12.0 15,822 3.2 3,874 0.8 2,973 0.6 61,852 12.5 
West North Central 30,424 30.8 4,893 4.9 12,783 12.9 13,228 13.4 4,072 4.1 588 0.6 130 0.1 32,772 33.1 
South Atlantic 201,286 41.8 49,890 10.4 86,514 18.0 53,134 11.0 9,906 2.1 1,644 0.3 402 0.1 78,602 16.3 
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East South Central 24,347 39.5 1,044 1.7 3,393 5.5 4,389 7.1 1,812 2.9 819 1.3 33 0.1 25,851 41.9 
West South Central 96,167 79.2 3,487 2.9 8,556 7.0 8,164 6.7 2,071 1.7 445 0.4 222 0.2 2,359 1.9 
Mountain 103,718 70.5 6,584 4.5 12,794 8.7 11,152 7.6 4,755 3.2 1,865 1.3 967 0.7 5,241 3.6 
Pacific 208,017 61.8 12,048 3.6 23,629 7.0 18,894 5.6 5,684 1.7 1,209 0.4 163 0 67,184 19.9 
Total 1,027,771 42.0 162,392 6.6 322,048 13.2 225,978 9.2 58,090 2.4 12,737 0.5 5,336 0.2 633,122 25.9 
                                  
Service Setting At Admission                                 
Hospital 794 17.9 157 3.5 138 3.1 70 1.6 29 0.7 13 0.3 14 0.3 3,228 72.7 
Short-Term 137,723 40.7 24,774 7.3 50,407 14.9 35,597 10.5 7,708 2.3 1,209 0.4 329 0.1 80,644 23.8 
Long-Term 103,602 34.5 17,449 5.8 39,097 13.0 41,758 13.9 16,068 5.3 3,442 1.1 665 0.2 78,580 26.1 
Ambulatory, Intensive 
Outpatient 
154,739 42.1 30,475 8.3 60,788 16.5 36,961 10.0 8,569 2.3 1,937 0.5 806 0.2 73,515 20.0 
Ambulatory, Non-Intensive 
Outpatient 
630,634 43.9 89,472 6.2 171,534 12 111,565 7.8 25,711 1.8 6,135 0.4 3,522 0.2 396,715 27.6 
Total 1,027,492 42.0 162,327 6.6 321,964 13.2 225,951 9.2 58,085 2.4 12,736 0.5 5,336 0.2 632,682 25.9 
                                  
Principal Source Of Referral                                 
Individual (including Self-
Referral 
471,045 44.4 80,522 7.6 137,923 13.0 77,922 7.3 18,607 1.8 4,550 0.4 2,333 0.2 269,039 25.3 
Alcohol/Drug Abuse Care 
Provider 
154,045 40.1 23,036 6.0 55,436 14.4 35,481 9.2 7,547 2.0 1,064 0.3 332 0.1 107,072 27.9 
Other Health Care Provider 63,656 41.3 9,115 5.9 19,616 12.7 11,412 7.4 2,537 1.6 696 0.5 671 0.4 46,438 30.1 
Educational Institution 629 43.6 79 5.5 165 11.4 123 8.5 18 1.2 6 0.4 3 0.2 419 29.1 
Employer 2,185 37.2 589 10 1,007 17.1 591 10.1 113 1.9 20 0.3 5 0.1 1,370 23.3 
Other Community Referral 77,813 40.3 15,504 8.0 26,662 13.8 18,934 9.8 4,417 2.3 882 0.5 360 0.2 48,298 25 
Court/Criminal Justice 
Referral/DUI 
246,801 40.2 30,676 5.0 77,560 12.6 78,832 12.8 24,284 4.0 5,342 0.9 1,542 0.3 149,549 24.3 
Total 1,016,174 42.1 159,521 6.6 318,369 13.2 223,295 9.2 57,523 2.4 12,560 0.5 5,246 0.2 622,185 25.8 
                                  
One or More Prior Treatment 
Episode(s) 
                                
No 329,514 48.5 43,215 6.4 82,094 12.1 58,539 8.6 15,074 2.2 3,499 0.5 1,387 0.2 145,460 21.4 
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Yes 698,257 39.5 119,177 6.7 239,954 13.6 167,439 9.5 43,016 2.4 9,238 0.5 3,949 0.2 487,662 27.6 
Total 1,027,771 42.0 162,392 6.6 322,048 13.2 225,978 9.2 58,090 2.4 12,737 0.5 5,336 0.2 633,122 25.9 
                                  
Alcohol or Benzodiazepines 
Reported at Admission 
                                
Substance Not Reported 744,461 43.8 114,209 6.7 216,134 12.7 144,305 8.5 36,895 2.2 8,504 0.5 3,772 0.2 429,723 25.3 
Substance Reported 283,310 37.8 48,183 6.4 105,914 14.1 81,673 10.9 21,195 2.8 4,233 0.6 1,564 0.2 203,399 27.1 
Total 1,027,771 42.0 162,392 6.6 322,048 13.2 225,978 9.2 58,090 2.4 12,737 0.5 5,336 0.2 633,122 25.9 
                                  
DSM Diagnosis                                 
No Diagnosis 2,244 30.8 347 4.8 1,079 14.8 717 9.9 141 1.9 35 0.5 29 0.4 2,686 36.9 
Alcohol-Induced Disorder 203 38.5 103 19.5 63 12.0 70 13.3 19 3.6 3 0.6 0 0 66 12.5 
Substance-Induced Disorder 2,651 48.3 780 14.2 526 9.6 481 8.8 174 3.2 38 0.7 15 0.3 821 15 
Alcohol Intoxication 643 62.3 56 5.4 108 10.5 88 8.5 19 1.8 5 0.5 1 0.1 112 10.9 
Alcohol Dependence 28,328 47.4 3,613 6.1 8,741 14.6 8,012 13.4 2,365 4.0 548 0.9 214 0.4 7,882 13.2 
Opioid Dependence 358,434 53.6 41,100 6.1 88,588 13.2 67,217 10.1 20,066 3.0 5,715 0.9 3,220 0.5 84,294 12.6 
Cocaine Dependence 16,949 47.2 2,353 6.6 4,332 12.1 3,627 10.1 1,154 3.2 257 0.7 96 0.3 7,133 19.9 
Cannabis Dependence 11,583 43.7 1,422 5.4 3,583 13.5 4,326 16.3 1,378 5.2 280 1.1 113 0.4 3,797 14.3 
Other Substance Dependence 58,546 51.5 6,883 6.1 13,988 12.3 12,605 11.1 3,774 3.3 980 0.9 336 0.3 16,567 14.6 
Alcohol Abuse 4,477 49.6 395 4.4 961 10.6 1,158 12.8 347 3.8 86 1.0 43 0.5 1,560 17.3 
Cannabis Abuse 2,972 45.6 291 4.5 662 10.1 841 12.9 272 4.2 50 0.8 23 0.4 1,412 21.6 
Other Substance Abuse 2,677 56.6 270 5.7 493 10.4 501 10.6 176 3.7 47 1.0 18 0.4 545 11.5 
Opioid Abuse 17,030 57.4 1,557 5.2 2,898 9.8 2,830 9.5 937 3.2 253 0.9 125 0.4 4,061 13.7 
Cocaine Abuse 2,054 55.4 168 4.5 274 7.4 313 8.4 93 2.5 22 0.6 21 0.6 762 20.6 
Anxiety Disorders 1,067 43.9 114 4.7 161 6.6 240 9.9 64 2.6 20 0.8 13 0.5 753 31 
Depressive Disorders 3,283 42.7 235 3.1 434 5.6 433 5.6 169 2.2 86 1.1 117 1.5 2,925 38.1 
Schizophrenia / Other 
Psychotic Disorder 
653 50.2 33 2.5 79 6.1 80 6.1 31 2.4 16 1.2 27 2.1 383 29.4 
Bipolar Disorders 2,022 43.2 130 2.8 216 4.6 286 6.1 130 2.8 64 1.4 90 1.9 1,742 37.2 
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Attention Deficit / Disruptive 
Behaviour 
101 41.9 9 3.7 33 13.7 22 9.1 7 2.9 1 0.4 0 0 68 28.2 
Other Mental Health Condition 1,309 51.2 102 4.0 159 6.2 205 8.0 70 2.7 16 0.6 22 0.9 676 26.4 
Other Condition 7,957 60.5 518 3.9 1,261 9.6 1,291 9.8 388 3 103 0.8 38 0.3 1,588 12.1 
Total 525,183 52.3 60,479 6.0 128,639 12.8 105,343 10.5 31,774 3.2 8,625 0.9 4,561 0.5 139,833 13.9 
                                  
Psychiatric Problem In Addition 
To Alcohol/Drug Problem 
                                
No 642,548 46.9 92,980 6.8 190,206 13.9 136,825 10.0 35,262 2.6 8,107 0.6 3,428 0.2 262,073 19.1 
Yes 259,068 40.6 51,498 8.1 101,418 15.9 69,985 11.0 18,347 2.9 3,642 0.6 1,465 0.2 132,358 20.8 
Total 901,616 44.9 144,478 7.2 291,624 14.5 206,810 10.3 53,609 2.7 11,749 0.6 4,893 0.2 394,431 19.6 
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Table 15 Logistic regression estimates for receiving opioid agonist therapy for opioid 
substance abuse among admitted patients, 2003-14. 
Characteristic 
Unadjusted Adjusted* 
OR 95% CI OR 95% CI 
Age     
18-20 1  1  
21-24 1.55 (1.52 – 1.57) 1.74 (1.62 – 1.88) 
25-29 1.98 (1.95 – 2.01) 2.37 (2.20 – 2.55) 
30-34 2.23 (2.19 – 2.26) 2.80 (2.60 – 3.02) 
35-39 2.46 (2.42 – 2.50) 3.11 (2.88 – 3.35) 
40-44 2.70 (2.66 – 2.75) 3.07 (2.85 – 3.32) 
45-49 3.20 (3.15 – 3.26) 3.37 (3.12 – 3.64) 
50-54 4.10 (4.03 – 4.17) 4.23 (3.91 – 4.58) 
55+ 5.96 (5.85 – 6.08) 5.66 (5.21 – 6.15) 
     
Ethnicity     
Male 1  1  
Female 1.08 (1.07 – 1.08) 1.10 (1.07 – 1.12) 
     
Ethnicity     
White 1  1  
Black or African American 1.34 (1.33 – 1.35) 1.37 (1.32 – 1.41) 
Asian or Pacific Islander 1.89 (1.83 – 1.95) 0.96 (0.83 – 1.13) 
Native American 1.23 (1.20 – 1.26) 0.75 (0.66 – 0.86) 
Other 2.06 (2.04 – 2.09) 1.45 (1.37 – 1.54) 
     
Marital Status     
Never Married 1  1  
Married 1.30 (1.29 – 1.31) 0.92 (0.89 – 0.95) 
Separated 1.05 (1.04 – 1.07) 0.92 (0.88 – 0.96) 
Divorced or Widowed 1.09 (1.08 – 1.10) 0.88 (0.85 – 0.91) 
     
Living Arrangement     
Independent 1  1  
Dependent 0.56 (0.56 – 0.56) 1.02 (0.99 – 1.04) 
Homeless 0.35 (0.35 – 0.36) 0.54 (0.52 – 0.57) 
     
Veteran Status     
No     
Yes 1.04 (1.02 – 1.06) 1.00 (0.94 – 1.07) 
     
Years of Education     
<8 Years 1  1  
9-11 Years 0.86 (0.85 – 0.87) 1.09 (1.03 – 1.15) 
12 Years 0.83 (0.82 – 0.84) 1.00 (0.95 – 1.06) 
13-15 Years 0.73 (0.72 – 0.74) 0.92 (0.87 – 0.97) 
16+ Years 0.73 (0.72 – 0.75) 0.69 (0.64 – 0.74) 
     
Employment Status     
Full-Time 1  1  
Part-Time 0.96 (0.95 – 0.97) 1.03 (0.98 – 1.08) 
Unemployed 0.59 (0.59 – 0.60) 0.85 (0.81 – 0.89) 
Not in Labour Force 0.72 (0.71 – 0.73) 0.65 (0.62 – 0.68) 
     
Primary Source of Income     
Wages/Salary 1  1  
Public Assistance 1.69 (1.67 – 1.71) 1.25 (1.19 – 1.32) 
Retirement/Pension or Disability 1.24 (1.22 – 1.25) 0.95 (0.90 – 1.01) 
Other 0.76 (0.75 – 0.77) 1.28 (1.21 – 1.35) 
None 0.48 (0.48 – 0.49) 0.91 (0.87 – 0.95) 
     
Health Insurer     
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Characteristic 
Unadjusted Adjusted* 
OR 95% CI OR 95% CI 
Private 1  1  
Medicaid 1.89 (1.87 – 1.92) 0.89 (0.84 – 0.93) 
Medicare or Other 0.80 (0.78 – 0.81) 0.97 (0.92 – 1.04) 
Uninsured 0.90 (0.89 – 0.91) 0.92 (0.88 – 0.96) 
     
Census Division     
New England 1  1  
Mid-Atlantic 0.64 (0.63 – 0.65) 2.66 (2.40 – 2.94) 
East North Central 0.48 (0.47 – 0.48) 1.13 (1.03 – 1.24) 
West North Central 0.14 (0.13 – 0.14) 1.86 (1.69 – 2.05) 
South Atlantic 0.56 (0.55 – 0.56) 0.80 (0.72 – 0.88) 
East South Central 0.07 (0.06 – 0.07) 0.26 (0.22 – 0.31) 
West South Central 0.21 (0.21 – 0.22) 1.07 (0.97 – 1.18) 
Mountain 0.53 (0.53 – 0.54) 2.91 (2.66 – 3.19) 
Pacific 1.36 (1.34 – 1.37) 1.35 (1.18 – 1.54) 
     
Service Setting at Time of Admission     
Hospital 1  1  
Short-Term 0.52 (0.46 – 0.58) 0.05 (0.04 – 0.07) 
Long-Term 0.55 (0.49 – 0.61) 0.05 (0.03 – 0.07) 
Ambulatory – Intensive Outpatient 1.50 (1.34 – 1.67) 0.13 (0.09 – 0.18) 
Ambulatory – Non-Intensive Outpatient 9.64 
(8.62 – 
10.78) 
0.42 (0.30 – 0.58) 
     
Primary Source of Referral     
Individual (including Self-Referral) 1  1  
Alcohol/Drug Abuse Care Provider 0.26 (0.26 – 0.27) 0.63 (0.61 – 0.65) 
Other Health Care Provider 0.29 (0.29 – 0.29) 0.20 (0.20 – 0.21) 
Educational Institution 0.13 (0.11 – 0.15) 0.32 (0.20 – 0.50) 
Employer 0.07 (0.06 – 0.08) 0.08 (0.05 – 0.11) 
Other Community Referral 0.17 (0.16 – 0.17) 0.32 (0.31 – 0.34) 
Court/Criminal Justice Referral/DUI 0.04 (0.04 – 0.05) 0.10 (0.10 – 0.11) 
     
Repeat Admission     
No Prior Treatment Episode 1  1  
One or More Prior Treatment Episode(s) 1.30 (1.29 – 1.31) 1.41 (1.38 – 1.45) 
     
Alcohol or Benzodiazepines Reported at Admission     
No 1  1  
Yes 0.31 (0.31 – 0.32) 0.64 (0.62 – 0.66) 
     
DSM Diagnosis     
No Diagnosis 1  1  
Alcohol-Induced Disorder 0.07 (0.04 – 0.11) 0.05 (0.01 – 0.21) 
Substance-Induced Disorder 0.17 (0.15 – 0.19) 0.12 (0.08 – 0.17) 
Alcohol Intoxication 0.06 (0.04 – 0.09) 0.43 (0.22 – 0.84) 
Alcohol Dependence 0.06 (0.05 – 0.06) 0.11 (0.10 – 0.13) 
Opioid Dependence 0.96 (0.91 – 1.01) 1.08 (0.98 – 1.20) 
Cocaine Dependence 0.10 (0.09 – 0.11) 0.17 (0.15 – 0.20) 
Cannabis Dependence 0.05 (0.05 – 0.06) 0.19 
(0.160 – 
0.226) 
Other Substance Dependence 0.12 (0.11 – 0.12) 0.27 (0.24 – 0.30) 
Alcohol Abuse 0.08 (0.07 – 0.09) 0.17 (0.13 – 0.21) 
Cannabis Abuse 0.08 (0.07 – 0.10) 0.23 (0.17 – 0.30) 
Other Substance Abuse 0.08 (0.06 – 0.09) 0.09 (0.06 – 0.12) 
Opioid Abuse 0.29 (0.27 – 0.31) 0.30 (0.26 – 0.34) 
Cocaine Abuse 0.13 (0.11 – 0.16) 0.13 (0.09 – 0.17) 
Anxiety Disorders 0.37 (0.32 – 0.43) 0.46 (0.33 – 0.65) 
Depressive Disorders 0.22 (0.20 – 0.25) 0.32 (0.24 – 0.42) 
Schizophrenia / Other Psychotic Disorder 0.18 (0.14 – 0.23) 0.32 (0.18 – 0.59) 
Bipolar Disorders 0.27 (0.24 – 0.31) 0.45 (0.33 – 0.62) 
Attention Deficit / Disruptive Behaviour 0.16 (0.09 – 0.28) 0.71 (0.25 – 1.99) 
Other Mental Health Condition 0.19 (0.16 – 0.22) 0.18 (0.12 – 0.28) 
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Characteristic 
Unadjusted Adjusted* 
OR 95% CI OR 95% CI 
Other Condition 0.18 (0.17 – 0.20) 0.58 (0.49 – 0.69) 
     
Psychiatric Problem in Addition to Alcohol/Drug 
Problem 
    
No 1  1  
Yes 0.77 (0.76 – 0.77) 0.75 (0.73 – 0.78) 
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Table 16 Censored linear regression estimates for days waiting to enter treatment for 
opioid substance abuse among admitted patients, 2003-14. 
Characteristic 
Unadjusted Adjusted* 
Coefficient 95% CI Coefficient 95% CI 
Age     
18-20 0  0  
21-24 -0.22 (-0.44 – 0.01) -0.13 (-0.61 – 0.36) 
25-29 -0.58 (-0.80 – -0.35) <0.01 (-0.47 – 0.48) 
30-34 -0.62 (-0.86 – -0.38) 0.19 (-0.31 – 0.68) 
35-39 -1.52 (-1.77 – -1.26) 0.31 (-0.21 – 0.83) 
40-44 -2.31 (-2.58 – -2.05) -0.28 (-0.81 – 0.26) 
45-49 -2.80 (-3.07 – -2.52) 0.10 (-0.45 – 0.66) 
50-54 -3.54 (-3.86 – -3.23) -0.21 (-0.80 – 0.38) 
55+ -4.38 (-4.74 – -4.03) -0.30 (-0.94 – 0.33) 
     
Sex     
Male 0  0  
Female 0.29 (0.18 – 0.40) 0.06 (-0.14 – 0.26) 
     
Ethnicity     
White 0  0  
Black or African American -4.29 (-4.49 – -4.10) -1.39 (-1.68 – -1.11) 
Asian or Pacific Islander -4.54 (-5.36 – -3.72) 0.06 (-1.20 – 1.31) 
Native American -2.07 (-2.65 – -1.49) -0.6 (-1.46 – 0.33) 
Other -5.75 (-6.06 – -5.44) -1.46 (-2.02 – -0.90) 
     
Marital Status     
Never Married 0  0  
Married -0.42 (-0.61 – -0.23) 0.69 (0.41 – 0.98) 
Separated 2.09 (1.81 – 2.36) 0.46 (0.08 – 0.83) 
Divorced or Widowed -0.98 (-1.16 – -0.79) 0.69 (0.40 – 0.97) 
     
Living Arrangement     
Independent 0  0  
Dependent -0.22 (-0.35 – -0.09) 1.27 (1.05 – 1.49) 
Homeless 0.49 (0.31 – 0.68) -0.38 (-0.74 – -0.02) 
     
Veteran Status     
No 0  0  
Yes 9.91 (9.70 – 10.12) 0.41 (-0.17 – 0.98) 
     
Years of Education     
<8 Years 0  0  
9-11 Years 0.18 (-0.09 – 0.45) 0.31 (-0.17 – 0.78) 
12 Years 0.38 (0.12 – 0.64) 0.08 (-0.39 – 0.54) 
13-15 Years 0.50 (0.22 – 0.78) 0.09 (-0.40 – 0.58) 
16+ Years -0.63 (-1.00 – -0.26) 0.18 (-0.45 – 0.81) 
     
Employment Status     
Full-Time 0  0  
Part-Time 0.75 (0.50 – 1.00) 0.24 (-0.24 – 0.71) 
Unemployed 0.75 (0.58 – 0.92) 0.96 (0.53 – 1.40) 
Not in Labour Force 0.86 (0.68 – 1.03) 0.97 (0.51 – 1.44) 
     
Primary Source of Income     
Wages/Salary 0  0  
Public Assistance -1.61 (-1.92 – -1.31) -1.33 (-1.80 – -0.86) 
Retirement/Pension or Disability -1.30 (-1.62 – -0.98) -1.34 (-1.83 – -0.85) 
Other -4.76 (-5.06 – -4.47) -1.25 (-1.75 – -0.75) 
None 1.69 (1.49 – 1.89) -1.14 (-1.51 – -0.76) 
     
Health Insurer     
Private 0  0  
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Characteristic 
Unadjusted Adjusted* 
Coefficient 95% CI Coefficient 95% CI 
Medicaid 2.47 (2.33 – 2.61) 1.47 (1.03 – 1.90) 
Medicare or Other 2.13 (1.95 – 2.32) 1.29 (0.77 – 1.81) 
Uninsured 2.43 (2.30 – 2.56) 1.44 (1.05 – 1.82) 
     
Census Division     
New England 0  0  
Mid-Atlantic -15.78 
(-16.08 – -
15.48) 
1.20 (0.39 – 2.00) 
East North Central -9.65 (-9.89 – -9.40) -5.39 (-6.04 – -4.73) 
West North Central -12.79 
(-13.24 – -
12.33) 
-3.31 (-3.99 – -2.63) 
South Atlantic -12.14 
(-12.28 – -
12.00) 
-6.48 (-7.20 – -5.75) 
East South Central -13.34 
(-13.94 – -
12.75) 
-7.15 (-7.88 – -6.43) 
West South Central -18.42 
(-18.79 – -
18.06) 
-9.51 
(-10.18 – -
8.84) 
Mountain -14.42 
(-14.77 – -
14.08) 
-11.76 
(-12.43 – -
11.10) 
Pacific -18.47 
(-18.73 – -
18.20) 
-10.29 
(-11.24 – -
9.34) 
     
Service Setting at Admission     
Hospital 0  0  
Short-Term -0.84 (-3.46 – 1.78) 1.98 (-1.45 – 5.41) 
Long-Term 6.59 (3.97 – 9.21) 6.93 (3.48 – 10.37) 
Ambulatory – Intensive Outpatient 0.19 (-2.43 – 2.81) 2.60 (-0.84 – 6.03) 
Ambulatory – Non-Intensive Outpatient 0.64 (-1.98 – 3.25) 2.29 (-1.13 – 5.72) 
     
Primary Source of Referral)     
Individual (including Self-Referral) 0  0  
Alcohol/Drug Abuse Care Provider -1.32 (-1.50 – -1.13) -5.29 (-5.56 – -5.02) 
Other Health Care Provider 8.66 (8.45 – 8.88) -4.09 (-4.45 – -3.73) 
Educational Institution 3.79 (1.88 – 5.70) -2.71 (-5.91 – 0.49) 
Employer 0.69 (-0.25 – 1.63) 1.18 (0.02 – 2.34) 
Other Community Referral 0.51 (0.29 – 0.74) 0.19 (-0.20 – 0.58) 
Court/Criminal Justice Referral/DUI 3.91 (3.77 – 4.05) 2.30 (2.05 – 2.55) 
     
One or More Prior Treatment Episode(s)     
No 0  0  
Yes 1.54 (1.42 – 1.66) 0.60 (0.38 – 0.81) 
     
Alcohol or Benzodiazepines Reported at 
Admission 
    
No 0  0  
Yes 2.21 (2.09 – 2.32) 0.43 (0.21 – 0.66) 
     
DSM Diagnosis     
No Diagnosis 0  0  
Alcohol-Induced Disorder 0.83 (-3.93 – 5.60) 2.20 (-1.74 – 6.13) 
Substance-Induced Disorder -2.46 (-4.98 – 0.07) 3.21 (1.04 – 5.39) 
Alcohol Intoxication -5.35 (-8.99 – -1.72) 0.26 (-4.22 – 4.73) 
Alcohol Dependence -0.78 (-2.76 – 1.20) 3.19 (1.42 – 4.97) 
Opioid Dependence -0.41 (-2.34 – 1.52) 2.56 (0.82 – 4.30) 
Cocaine Dependence 0.81 (-1.18 – 2.79) 2.37 (0.55 – 4.18) 
Cannabis Dependence 1.48 (-0.56 – 3.52) 4.11 (2.28 – 5.94) 
Other Substance Dependence 1.26 (-0.69 – 3.20) 2.74 (0.98 – 4.50) 
Alcohol Abuse 0.64 (-1.56 – 2.85) 4.06 (2.04 – 6.07) 
Cannabis Abuse 0.50 (-1.83 – 2.83) 4.74 (2.58 – 6.91) 
Other Substance Abuse 0.92 (-1.35 – 3.19) 2.73 (0.54 – 4.92) 
Opioid Abuse -1.65 (-3.66 – 0.37) 2.43 (0.61 – 4.25) 
Cocaine Abuse -0.22 (-2.68 – 2.24) 2.97 (0.58 – 5.36) 
Anxiety Disorders 3.60 (-0.12 – 7.31) 1.55 (-1.30 – 4.41) 
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Characteristic 
Unadjusted Adjusted* 
Coefficient 95% CI Coefficient 95% CI 
Depressive Disorders 37.10 
(34.56 – 
39.64) 
0.83 (-1.46 – 3.11) 
Schizophrenia / Other Psychotic Disorder 54.66 
(51.01 – 
58.31) 
5.69 (1.46 – 9.92) 
Bipolar Disorders 45.06 
(42.41 – 
47.72) 
2.46 (-0.25 – 5.16) 
Attention Deficit / Disruptive Behaviour 14.40 (4.44 – 24.37) -1.90 (-10.97 – 7.17) 
Other Mental Health Condition 6.46 (3.56 – 9.36) 0.89 (-1.76 – 3.53) 
Other Condition -3.79 (-5.99 – -1.60) 4.78 (2.82 – 6.74) 
     
Psychiatric Problem in Addition to Alcohol/Drug 
Problem 
    
No 0  0  
Yes 3.40 (3.28 – 3.53) -0.30 (-0.53 – -0.07) 
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7.4 Discussion 
These findings highlight several disparities in the receipt of OAT and timely access to 
care in opioid misuse treatment based on patient socioeconomic, demographic, 
institutional and behavioural characteristics. Firstly, Native Americans are much less 
likely to receive OAT as compared to White Americans, signalling a problematic 
disparity in opioid misuse treatment. In addition, those demonstrating socioeconomic 
vulnerability, specifically the homeless, the unemployed, and those insured on Medicaid 
or uninsured showed lower odds of receipt of OAT, highlighting the role that economic 
and fiscal policy may have in exacerbating disparities in OAT treatment. Nevertheless, 
the fact that recipients of public assistance showed slightly higher odds of OAT is 
promising and further study may help identify the factors contributing to this 
phenomenon which, in turn, may guide future policymaking. Geographic disparities in 
receipt of OAT gesture towards the need for greater coordination at the national level to 
ensure high quality care for all patients presenting in the clinical setting with opioid 
misuse, potentially through clinical pathways or practice guidelines. While differences 
in delays to enter treatment were small in some cases, some disparities emerged in this 
analysis. Patients admitted at long-term care facilities, for instance, were admitted 7 
days later than those admitted to the hospital setting, for instance, while patients who 
were individually referred, including self-referred, waited 4-5 days longer than those 
referred by a health care provider.  
This analysis is necessarily limited by use of the TEDS-A dataset. Firstly, given 
the relative complexity of reporting from the facility to the state to the Federal level, 
variations on reporting mechanisms by state may have downstream effects on the 
quality of data at the national level (219). In addition, information on days waiting to 
enter treatment are collected through TEDS Supplementary Data which is voluntary 
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(97). As such, facilities with longer waiting times may choose not to submit this 
information thereby contributing a level of reporting bias to this analysis leading to the 
underestimation of actual waiting times to enter treatment. Nevertheless, no other 
dataset exists at the national level which provides comparable data to TEDS-A. 
Consequently, despite the limitations presented here, this study draws upon the largest 
extant dataset to provide information on OAT and time waiting to enter treatment.  
Addressing these disparities in treating individuals affected by opioid misuse is a 
major concern for policymakers and care providers. One systematic review of 
determinants of opioid-related mortality in the United States and Canada has found 
opioid-related mortality trends tend to very considerably by sociodemographic 
differences, including ethnicity, gender, age, and socioeconomic status, as we have 
highlighted here (220). Failure to address disparities in treatment have, consequently, 
directly contributed to disparately high rates of mortality among individuals expressing 
a high degree of vulnerability. In addition, the implications of failure to treat opioid 
misuse must be considered for their wider societal effects more widely. Perlman and 
Jordan, for instance, highlight the complex inter-relationships among opioid misuse and 
overdose, hepatitis C, and HIV as a syndemic with disproportionately adverse results 
for individuals at heightened risk (221). As a result, opioid misuse, taken in context of 
wider trends in population health, is increasingly an urgent priority and disparities in 
treatment must be addressed both in the near- and long-term. 
Concerns emerge over the disparately low use of OAT for individuals 
demonstrating heightened socioeconomic vulnerability, particularly individuals who are 
homeless, unemployed, insured on Medicaid or uninsured, referred through the criminal 
justice system, or experiencing a comorbid psychiatric disorder. In addition, time to 
enter treatment was disparately higher among individuals expressing socioeconomic 
vulnerability, namely, those in a dependent living situation, insured on Medicaid or 
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uninsured, referred through the criminal justice system, or experiencing one or more 
prior treatment episodes. Moreover, geographic disparities in the care of patients 
admitted for opioid-related substance disorders are salient; compared to the baseline 
group of admitted patients in New England, admitted patients in South Atlantic and East 
South Central appear to be at disparately high risk of not receiving OAT treatment 
whilst admitted patients in Mid-Atlantic experience higher delays to enter treatment, 
even after adjusting for a variety of demographic, socioeconomic, and behavioural 
factors. These trends are especially worrying considering new data published by the 
CDC which suggest that rates of emergency department visits for suspected opioid 
overdoses has significantly increased in the Southwest, Midwest, and West from 2016-
17 at a rate of approximately 7-11% each annual quarter (172).  
Various policy measures may help bridge the gaps in opioid misuse treatment. 
Firstly, coverage of OAT among health insurers, both public and private, is of crucial 
importance to increasing access to OAT. In one analysis of Medicaid-enrolled 
individuals, for instance, 45% of Medicaid enrolees in opioid addiction treatment used 
OAT among states covering methadone maintenance while only 17% of Medicaid 
enrolees in opioid addiction treatment used OAT among states with no coverage (222). 
Coverage alone, however, is insufficient. Though state Medicaid programs, for instance, 
are increasingly covering OAT for opioid use disorders, the increasing use of prior 
authorization requirements to limit use has had the unintended effect of stymieing the 
wider use of OAT (223). Commercial plans may provide more favourable coverage of 
OATs such as buprenorphine than state Medicaid programs, however, utilization 
management policies limit their use among plan beneficiaries and access to care can be 
limited to in-network providers (224). This reluctance on the part of commercial 
insurers to provide favourable coverage for OAT, especially maintenance therapy is 
surprising given the business case for robust coverage for OAT; evidence suggests that 
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mean total annual costs for patients receiving maintenance therapy for opioid 
dependence are lower than those who do not receive maintenance therapy (225). 
Increasing the number of physicians who can prescribed OAT will also contribute to 
closing the gaps in opioid misuse treatment. One analysis of the effects of permitting 
waivered physicians to prescribe buprenorphine in the physician office setting yielded a 
decrease of counties with a shortage of waivered physicians from 46.8% in 2002 to 
10.4% in 2011, suggesting that an increase in waivered physicians contributed to an 
increase in access to OAT (226).  
The analysis presented here provides direction to policymakers and health 
administrators with respect to patient subpopulations at heightened risk of receiving 
suboptimal care, both in terms of delays to enter treatment and receipt of OAT. 
Particularly in the context of the opioid misuse crisis, these subpopulations represent 
major opportunities to improve access and quality of care. Increasing coverage of OAT, 
decreasing administrative barriers to OAT, and increasing the number of physicians 
authorised to prescribe OAT may contribute to reducing the disparities we have 
observed in the TEDS-A dataset from 2003-14. 
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8 PATTERNS OF SUBSTANCE 
USE AMONG ADULTS AGED 
16-59 IN ENGLAND AND 
WALES, 2006-16 
8.1 Background 
In the UK renewed interest in, and concern over, the subject of illicit substance use has 
been expressed among policymakers very recently. For instance, at the Conservative 
Party Conference in October 2018, Home Secretary Sajid Javid announced a focus on 
drug use among the middle-class in order to reduce serious violent crime (227). In 
addition, new data released by the Office for National Statistics in August 2018 show an 
increase of 29% in the number of deaths attributable to fentanyl (228), prompting 
concerns that the long-standing opioid crisis in the United States may be facing the 
United Kingdom (229). Amid these concerns, the Government has been embroiled in 
ongoing discussions regarding proposals to establish supervised injection sites, a 
measure which had been proposed by Scottish policymakers but vetoed by the Home 
Office in early 2018 (230). These policy discussions have also been informed by new 
research into the ways in which the dark web has facilitated trade in illicit substances 
among highly developed countries, prompting worry over the ways to address this 
problem through traditional law enforcement mechanisms (231).  
Yet despite this intense scrutiny of drug and drug-related issues by policymakers in 
England and Wales, there has been a marked lack of attention towards the social, 
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economic, and demographic correlates of drug use which can elucidate patterns of illicit 
substance use to inform domestic drug policy. In contrast, countries such as the United 
States (210) or Sweden (232) have paid much more attention towards the social 
disparities of substance use disorder, pointing to ways in which such evidence can also 
be developed in the English and Welsh setting. This chapter is a secondary analysis of 
the Crime Survey for England and Wales (CSEW), specifically, the illicit substance use 
self-completion module, from 2006-16, to investigate patterns of substance use over 
time and to analyse the social, economic, and demographic correlates of use with the 
aim of informing practice and public policy. 
8.2 Methods 
8.2.1 Data Source 
The study utilised data from the 2006-16 waves of the CSEW, a nationally-
representative annual household survey of adults aged 16-59 residing in England and 
Wales which measures data on self-reported victimization, attitudes towards crime, the 
police, and justice system, and other related topics (233). As a household survey, CSEW 
does not sample among those living in group or institutional settings, such as 
dormitories or prisons, or those with no fixed household address (233). Each year, to 
gather data for the CSEW, approximately 35,000-45,000 individuals are interviewed 
face-to-face using structured, computer-assisted personal interviewing (CAPI) (233). 
Questions relating to alcohol and illegal drug use, as well as other sensitive questions, 
are administered through a self-completion module to increase the likelihood of honest 
responses (233). 
8.2.2 Study Variables 
Sex was coded as either male or female. Generational cohort was defined using age at 
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time of survey administration according to Eyerman and Turner’s sociocultural 
definitions of generations (124), where respondents aged 18-34 were coded as 
Millennials, respondents aged 35-49 were coded as Generation X (“Gen X”), and 
respondents aged 50-59 were coded as Baby Boomers. Marital status was coded as: 
single and never married, married or civil partnership, separated, divorced, or widowed 
or surviving civil partnership. Ethnicity was coded as: White, Black or Black British, 
Asian or Asian British, mixed, or other. Respondents were also coded based on whether 
they lived in an urban or rural area. Employment status was coded as: employed, 
unemployed, or not in labour force. Annual household income was coded using the 
following categories: less than £5,000, £5,000 to £9,999, £10,000 to £14,999, £15,000 
to £19,999, and £20,000 or more. Educational attainment was coded using the 
respondent’s highest educational qualification, namely: less than O level/GCSE, O 
level/GCSE, apprenticeship or A/AS level, degree or diploma, or other. Self-reported 
health was coded as: very good, good, fair, bad, or very bad. Dichotomous variables 
were coded to reflect whether a respondent indicated past-year use of each of the 
following substance allowing for inclusion of more than one: heavy alcohol use, 
amphetamines, powder cocaine, crack cocaine, MDMA, heroin, ketamine, methadone, 
or methamphetamine. Heavy use of alcohol was defined as respondents who answered 
positively to the following question, “Have you felt very drunk on most days (i.e. more 
than once or twice a week) during the last 12 months?” 
8.2.3 Statistical Analysis 
All statistical analyses were conducted in Stata 14. We applied multiple maximum-
likelihood logit regression with weighted least squares using respondent characteristics 
to identify the correlates associated with past-year substance abuse. 
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8.3 Results 
Sample characteristics are presented in Table 17. In total, 436,878 respondents were 
included in this series of surveys.
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Table 17 Sample characteristics for adults age 18 and over by percentage (%), 2006-16 
Year 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 
n 37486 46406 44081 44563 44798 45938 36196 35032 33126 34134 35118 
Female 54.6 54.7 55.0 55.0 55.2 54.6 54.7 54.7 54.6 54.9 53.7 
            
Generational Cohort            
 Millennials 21.2 21.3 20.9 20.2 20.9 21.5 21.3 21.7 20.8 20.4 20.7 
 Generation X 27.9 28.1 27.6 27.2 26.4 25.6 25.8 25.8 25.1 24.6 25.5 
 Baby Boomer 50.9 50.6 51.5 52.6 52.7 52.9 52.9 52.5 54.1 55.0 53.8 
            
Marital Status            
 Single and never married 25.1 25.5 25.6 25.4 26.4 26.9 28.1 28.7 28.3 28.7 29.9 
 Married or civil partnership 48.8 48.4 48.1 47.9 47.5 47.0 45.7 45.6 45.8 46.1 45.8 
 Separated 3.3 3.3 3.3 3.5 3.6 3.6 3.6 3.7 3.5 3.1 3.2 
 Divorced 11.0 11.0 10.8 11.3 10.9 10.9 11.4 11.3 11.2 11.2 11.0 
 Widowed or surviving civil partnership 11.9 11.9 12.2 11.9 11.7 11.6 11.1 10.7 11.2 10.8 10.1 
            
Ethnicity            
 White 93.5 93.5 92.9 92.7 92.5 92.0 92.1 90.6 90.6 90.9 89.9 
 Black or Black British 1.7 1.8 2.1 2.1 2.1 2.2 2.1 2.7 2.7 2.5 2.8 
 Asian or Asian British 3.2 3.3 3.7 3.6 3.8 4.2 4.4 5.2 5.0 5.0 5.4 
 Mixed 0.6 0.5 0.6 0.7 0.7 0.7 0.6 1.0 0.9 1.0 1.0 
 Other 0.9 0.9 0.8 0.9 1.0 1.0 0.9 0.6 0.8 0.7 0.9 
            
Rural and Urban Classification            
 Urban 75.3 74.6 73.9 74.3 74.8 75.1 76.3 77.4 77.5 33.3 21.9 
 Rural 24.7 25.4 26.1 25.7 25.2 24.9 23.7 22.6 22.5 66.7 78.1 
            
Employment Status            
 Employed 56.5 56.7 56.2 54.6 54.9 54.9 54.6 56.1 55.6 56.2 57.9 
 Unemployed 1.5 1.6 2.2 3.0 3.0 3.2 3.6 3.2 2.4 2.0 1.9 
 Not in labour force 41.9 41.7 41.6 42.4 42.1 41.9 41.8 40.7 42.0 41.8 40.2 
            
Annual Household Income            
 Less than £5,000 8.3 7.1 6.9 5.7 4.8 4.9 5.9 5.2 5.0 4.9 3.7 
 £5,000 to £9,999 14.6 14.7 13.9 14.5 14.6 14.0 13.6 13.1 12.0 10.8 9.7 
 £10,000 to £14,999 12.5 12.3 12.4 13.9 14.1 14.4 14.0 13.5 13.1 12.8 12.5 
 £15,000 to £19,999 10.9 10.2 10.1 10.8 11.3 11.4 11.3 11.0 11.1 10.7 11.2 
 £20,000 or more 53.7 55.7 56.7 55.0 55.2 55.3 55.2 57.2 58.8 60.8 63.0 
            
Educational Attainment            
 Less than O level/GCSE 29.8 28.6 27.7 27.8 26.5 24.6 23.1 21.8 21.4 21.1 21.0 
 O level/GCSE 18.7 19.0 19.0 18.5 18.7 18.9 18.5 18.6 17.9 18.0 17.6 
 Apprenticeship or A/AS level 16.8 17.0 16.8 16.5 17.2 17.9 17.9 18.2 18.2 17.9 17.3 
 Degree or diploma 30.2 31.0 32.4 32.8 33.1 34.3 36.4 37.4 38.4 38.6 40.0 
 Other 4.5 4.4 4.1 4.3 4.5 4.3 4.2 3.9 4.1 4.3 4.1 
            
Self-Reported Health            
 Very good 36.3 36.2 36.2 35.9 35.6 34.6 33.3 33.4 33.7 33.5 32.7 
 Good 39.1 39.3 39.4 39.0 39.0 39.1 40.4 41.1 40.8 40.8 41.9 
 Fair 18.4 18.4 18.0 18.9 19.3 19.2 19.4 18.6 18.8 18.8 18.7 
 Bad 5.1 5.1 5.4 5.3 5.0 5.8 5.6 5.6 5.5 5.6 5.5 
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Year 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 
n 37486 46406 44081 44563 44798 45938 36196 35032 33126 34134 35118 
 Very bad 1.0 0.9 1.0 1.0 1.1 1.4 1.3 1.3 1.3 1.3 1.3 
            
Past-Year Substance Use            
 Heavy alcohol use * 0.6 0.6 0.4 0.3 0.4 0.2 0.2 0.2 * n/a 
 Amphetamines 1.1 1.1 0.9 0.9 0.9 0.8 0.7 0.7 0.6 0.5 0.5 
 Powder cocaine 2.1 2.0 2.1 2.1 1.9 1.9 1.7 2.0 1.9 1.8 2.0 
 Crack cocaine 0.2 0.1 0.2 0.2 0.1 0.2 0.1 0.2 0.2 0.1 0.1 
 MDMA 1.3 1.2 1.2 1.2 1.1 0.9 1.0 1.1 1.1 0.9 1.0 
 Heroin 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 
 Ketamine 0.2 0.3 0.3 0.3 0.4 0.4 0.3 0.4 0.4 0.2 0.2 
 Methadone 0.1 0.1 0.1 0.1 0.2 0.2 0.1 0.2 0.1 0.1 0.1 
 Methamphetamine ** ** 0.1 0.1 0.1 * 0.1 0.1 0.1 * * 
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Table 18 shows the results of adjusted multiple logistic regression of respondent 
characteristics associated with past-year substance use. Women were less likely than 
men to exhibit past-year substance use. Compared to Millennials, Gen X respondents 
were less likely to have used amphetamines, powder cocaine, crack cocaine, MDMA, 
and ketamine in the past year. Baby Boomers were less likely than Millennials to have 
used amphetamines, powder cocaine, crack cocaine, MDMA, heroin, ketamine, and 
methadone. No statistically significant difference was observed in past-year use of 
heavy alcohol and methamphetamine between Millennials and Gen X or Baby 
Boomers. Respondents who were married were less likely to have shown past-year use 
of heavy alcohol, amphetamines, powder cocaine, crack cocaine, MDMA, heroin, 
ketamine, and methadone. Respondents who were separated were less likely to have 
used amphetamines, crack cocaine, heroin, ketamine, and methadone while those who 
were divorced were less likely to have used powder cocaine, crack cocaine, MDMA, 
heroin, ketamine, or methadone. Minority ethnic, mixed, or other respondents were less 
likely to have used amphetamines than White respondents. Black or Black British and 
Asian or Asian British respondents were less likely to have used powder cocaine, 
MDMA, and ketamine while Black or Black British respondents were less likely to 
have used crack cocaine. Respondents from rural areas were less likely to have used 
powder cocaine, MDMA, and ketamine. Respondents earning at least £5,000 were less 
likely to have used heavy alcohol in the past year while those earning at least £10,000 
were less likely to have used MDMA. Respondents earning at least £15,000 were less 
likely to have used amphetamines or ketamine while those earning at least £20,000 were 
less likely to have used crack cocaine, heroin, and methadone. Respondents whose 
highest educational qualification was an apprenticeship or A/AS level were less likely 
to have used heroin while those who obtained a degree or diploma were less likely to 
have used heavy alcohol, or amphetamines.
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Table 18 Adjusted multiple logistic regression of respondent characteristics associated with past-year substance use for adults aged 18-59, 2006-16. 
 
Heavy Alcohol 
Use 
Amphetamine Powder Cocaine Crack Cocaine MDMA Heroin Ketamine Methadone 
Methampheta-
mine 
Sex                   
 Male 1  1  1  1  1  1  1  1  1  
 Women 0.33 
(0.23-
0.47) 
0.51 
(0.43-
0.59) 
0.41 
(0.37-
0.45) 
0.32 
(0.22-
0.47) 
0.38 
(0.33-
0.44) 
0.30 
(0.20-
0.44) 
0.32 
(0.24-
0.43) 
0.36 
(0.24-
0.52) 
0.28 
(0.13-
0.61) 
                   
Generational Cohort                   
 Millennials 1  1  1  1  1  1  1  1  1  
 Generation X 1.09 
(0.75-
1.57) 
0.42 
(0.36-
0.50) 
0.29 
(0.26-
0.32) 
0.48 
(0.33-
0.70) 
0.24 
(0.20-
0.29) 
0.93 
(0.60-
1.44) 
0.26 
(0.19-
0.36) 
0.84 
(0.57-
1.23) 
1.00 
(0.44-
2.30) 
 Baby Boomers 0.74 
(0.44-
1.25) 
0.09 
(0.06-
0.13) 
0.06 
(0.04-
0.08) 
0.10 
(0.04-
0.24) 
0.06 
(0.04-
0.09) 
0.23 
(0.10-
0.54) 
0.05 
(0.02-
0.13) 
0.22 
(0.11-
0.46) 
0.36 
(0.08-
1.61) 
                   
Marital Status                   
 Single and never 
married 
1  1  1  1  1  1  1  1  1  
 Married or civil 
partnership 
0.51 
(0.33-
0.78) 
0.24 
(0.19-
0.29) 
0.27 
(0.24-
0.31) 
0.17 
(0.09-
0.34) 
0.20 
(0.16-
0.24) 
0.17 
(0.08-
0.35) 
0.13 
(0.08-
0.20) 
0.18 
(0.09-
0.37) 
*  
 Separated 1.51 
(0.76-
3.01) 
0.64 
(0.44-
0.93) 
0.81 
(0.57-
1.14) 
0.30 
(0.11-
0.83) 
0.64 
(0.33-
1.22) 
0.35 
(0.13-
0.93) 
0.25 
(0.08-
0.81) 
0.29 
(0.10-
0.80) 
*  
 Divorced 0.91 
(0.54-
1.55) 
0.82 
(0.63-
1.07) 
0.61 
(0.49-
0.76) 
0.54 
(0.31-
0.95) 
0.68 
(0.51-
0.91) 
0.39 
(0.21-
0.74) 
0.42 
(0.23-
0.75) 
0.32 
(0.17-
0.61) 
*  
 Widowed or 
surviving civil 
partnership 
0.16 
(0.02-
1.15) 
0.30 
(0.09-
1.03) 
0.33 
(0.13-
0.82) 
0.56 
(0.11-
2.81) 
0.15 
(0.05-
0.50) 
0.49 
(0.11-
2.27) 
0.13 
(0.02-
0.95) 
0.33 
(0.08-
1.41) 
*  
                   
Ethnicity                   
 White 1  1  1  1  1  1  1  1  1  
 Black or Black 
British 
0.80 
(0.27-
2.41) 
0.09 
(0.04-
0.22) 
0.22 
(0.14-
0.34) 
0.19 
(0.05-
0.76) 
0.17 
(0.09-
0.32) 
0.41 
(0.15-
1.14) 
0.15 
(0.05-
0.44) 
*  *  
 Asian or Asian 
British 
1.41 
(0.61-
3.25) 
0.05 
(0.02-
0.14) 
0.18 
(0.12-
0.26) 
0.35 
(0.12-
1.01) 
0.07 
(0.03-
0.14) 
0.34 
(0.09-
1.29) 
0.27 
(0.13-
0.54) 
*  *  
 Mixed 1.03 
(0.41-
2.63) 
0.47 
(0.25-
0.91) 
0.72 
(0.47-
1.12) 
0.80 
(0.26-
2.47) 
1.00 
(0.64-
1.56) 
0.55 
(0.16-
1.82) 
1.40 
(0.69-
2.85) 
*  *  
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Heavy Alcohol 
Use 
Amphetamine Powder Cocaine Crack Cocaine MDMA Heroin Ketamine Methadone 
Methampheta-
mine 
 Other 1.09 
(0.30-
4.02) 
0.33 
(0.11-
0.94) 
0.29 
(0.15-
0.58) 
0.17 
(0.02-
1.21) 
0.37 
(0.16-
0.84) 
0.96 
(0.29-
3.24) 
0.31 
(0.04-
2.26) 
*  *  
                   
Rural and Urban 
Classification 
                  
 Urban 1  1  1  1  1  1  1  1  1  
 Rural 1.24 
(0.84-
1.81) 
0.94 
(0.77-
1.15) 
0.75 
(0.66-
0.86) 
0.78 
(0.48-
1.27) 
0.68 
(0.57-
0.82) 
0.79 
(0.46-
1.35) 
0.38 
(0.24-
0.58) 
1.08 
(0.67-
1.74) 
1.25 
(0.41-
3.86) 
                   
Employment Status                   
 Employed 1  1  1  1  1  1  1  1  1  
 Unemployed 2.02 
(1.07-
3.81) 
1.61 
(1.24-
2.11) 
1.17 
(0.95-
1.45) 
3.58 
(2.14-
5.99) 
1.18 
(0.91-
1.54) 
5.95 
(3.12-
11.38) 
1.16 
(0.72-
1.86) 
5.93 
(3.18-
11.05) 
1.40 
(0.40-
4.87) 
 Not in labour force 1.71 
(1.00-
2.93) 
1.21 
(0.97-
1.50) 
0.83 
(0.70-
0.98) 
2.05 
(1.35-
3.10) 
0.88 
(0.70-
1.11) 
4.47 
(2.86-
7.00) 
1.09 
(0.72-
1.67) 
4.06 
(2.44-
6.73) 
1.47 
(0.72-
2.98) 
                   
Annual Household 
Income 
                  
 Less than £5,000 1  1  1  1  1  1  1  1  1  
 £5,000 to £9,999 0.58 
(0.35-
0.99) 
0.76 
(0.57-
1.02) 
1.02 
(0.80-
1.30) 
0.73 
(0.46-
1.14) 
0.75 
(0.55-
1.02) 
0.90 
(0.56-
1.44) 
0.59 
(0.35-
1.01) 
0.91 
(0.57-
1.44) 
0.75 
(0.23-
2.47) 
 £10,000 to £14,999 0.46 
(0.24-
0.85) 
0.78 
(0.56-
1.09) 
0.88 
(0.67-
1.16) 
0.63 
(0.36-
1.11) 
0.65 
(0.47-
0.91) 
0.59 
(0.32-
1.09) 
0.74 
(0.41-
1.33) 
0.82 
(0.46-
1.46) 
0.10 
(0.01-
0.93) 
 £15,000 to £19,999 0.46 
(0.22-
0.96) 
0.66 
(0.47-
0.93) 
0.81 
(0.62-
1.06) 
0.54 
(0.28-
1.06) 
0.54 
(0.39-
0.75) 
0.83 
(0.39-
1.76) 
0.48 
(0.25-
0.92) 
0.83 
(0.41-
1.71) 
0.16 
(0.02-
1.46) 
 £20,000 or more 0.43 
(0.22-
0.84) 
0.59 
(0.44-
0.80) 
1.07 
(0.85-
1.35) 
0.38 
(0.23-
0.60) 
0.72 
(0.54-
0.96) 
0.50 
(0.28-
0.88) 
0.60 
(0.37-
0.98) 
0.43 
(0.24-
0.79) 
0.96 
(0.38-
2.44) 
                   
Educational 
Attainment 
                  
 Less than O 
level/GCSE 
1  1  1  1  1  1  1  1  1  
 O level/GCSE 0.88 
(0.57 - 
1.35) 
0.76 
(0.61 - 
0.95) 
1.19 
(1.00 - 
1.41) 
1.09 
(0.68 - 
1.73) 
1.22 
(0.95 - 
1.56) 
0.94 
(0.58 - 
1.52) 
1.16 
(0.69 - 
1.94) 
0.86 
(0.56 - 
1.32) 
1.53 
(0.41 - 
5.73) 
 Apprenticeship or 
A/AS level 
0.68 
(0.43 - 
1.10) 
0.81 
(0.63 - 
1.02) 
1.25 
(1.05 - 
1.50) 
0.70 
(0.40 - 
1.21) 
1.55 
(1.20 - 
1.98) 
0.44 
(0.24 - 
0.80) 
2.25 
(1.36 - 
3.73) 
0.61 
(0.37 - 
1.01) 
1.74 
(0.48 - 
6.33) 
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Heavy Alcohol 
Use 
Amphetamine Powder Cocaine Crack Cocaine MDMA Heroin Ketamine Methadone 
Methampheta-
mine 
 Degree or diploma 0.59 
(0.37 - 
0.94) 
0.72 
(0.57 - 
0.92) 
1.15 
(0.96 - 
1.37) 
1.19 
(0.70 - 
2.01) 
1.72 
(1.35 - 
2.20) 
0.98 
(0.57 - 
1.70) 
2.27 
(1.37 - 
3.74) 
0.71 
(0.41 - 
1.21) 
1.94 
(0.59 - 
6.35) 
 Other 0.74 
(0.27 - 
2.05) 
0.83 
(0.53 - 
1.30) 
0.76 
(0.51 - 
1.13) 
1.06 
(0.45 - 
2.51) 
0.83 
(0.47 - 
1.47) 
1.29 
(0.56 - 
2.93) 
1.16 
(0.42 - 
3.22) 
0.83 
(0.25 - 
2.75) 
2.40 
(0.41 - 
14.05) 
                   
Self-Reported Health                   
 Very good 1  1  1  1  1  1  1  1  1  
 Good 1.33 
(0.91 - 
1.95) 
1.34 
(1.13 - 
1.59) 
1.30 
(1.17 - 
1.45) 
3.36 
(2.14 - 
5.27) 
1.18 
(1.02 - 
1.36) 
2.28 
(1.38 - 
3.77) 
1.37 
(1.04 - 
1.81) 
1.49 
(0.91 - 
2.43) 
*  
 Fair 2.65 
(1.67 - 
4.21) 
1.91 
(1.53 - 
2.39) 
1.62 
(1.39 - 
1.90) 
5.29 
(3.12 - 
8.95) 
1.45 
(1.17 - 
1.80) 
3.25 
(1.91 - 
5.53) 
1.75 
(1.20 - 
2.54) 
2.69 
(1.66 - 
4.37) 
*  
 Bad 5.74 
(3.29 - 
10.00) 
2.24 
(1.61 - 
3.12) 
1.71 
(1.29 - 
2.28) 
10.14 
(5.29 - 
19.43) 
1.43 
(0.97 - 
2.11) 
5.34 
(2.67 - 
10.68) 
1.43 
(0.71 - 
2.88) 
4.46 
(2.42 - 
8.22) 
*  
 Very bad 4.66 
(1.98 - 
10.96) 
2.13 
(1.05 - 
4.32) 
1.80 
(0.94 - 
3.45) 
14.63 
(5.61 - 
38.19) 
0.43 
(0.13 - 
1.46) 
10.62 
(4.15 - 
27.19) 
0.50 
(0.07 - 
3.74) 
6.83 
(2.68 - 
17.42) 
*  
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This analysis identified several risk factors for past-year substance use. Firstly, 
unemployment was more associated with heavy alcohol use, use of amphetamines, use 
of crack cocaine, use of heroin, and use of methadone. In addition, those achieving an 
apprenticeship or A/AS level of education were more likely to have used powder 
cocaine, MDMA, and ketamine. Finally, those with bad or very bad self-reported health 
were more likely to have used heavy alcohol, amphetamines, crack cocaine, heroin, and 
methadone. 
8.4 Discussion 
This analysis shows most illicit substance use is appreciably lower among Generation X 
and Baby Boomer than Millennials. In contrast no statistically significant differences in 
heavy alcohol use and methamphetamines were observed among generational cohorts. 
Minority ethnic populations showed generally lower risk of use of illicit substances than 
White British respondents. Unsurprisingly, indicators of poor socioeconomic wellbeing, 
namely employment status and annual household income, were good predictors of illicit 
substance use. Similarly, poor self-rated health was a major risk factor for illicit 
substance use. Use of MDMA and ketamine were higher among those attaining a degree 
or diploma-level education. 
A limitation of this study was the use of survey data to gather information on 
substance use, including for illicit substances. Though the substance use module is a 
self-completion module which aims to increase the likelihood of honest responses, 
respondents may not answer with full honesty for fear of legal repercussions. Moreover, 
small samples for specific subpopulations in our study attenuate our ability to identify 
specific patterns of substance use in these populations. Finally, as our dataset was a 
repeated, cross-sectional study, we are not able to remark upon causality or 
directionality of risk factors on substance abuse. Despite these drawbacks this analysis 
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makes good use of a routinely collected dataset to provide new information regarding 
the state of substance use in England and Wales. Though estimates are available from 
the Office for National Statistics regarding deaths due to substance use, these are new 
estimates for the prevalence of ongoing substance use and their social, economic, and 
health correlates.  
Compared to data from the United States, these findings are promising and 
suggest potential avenues for policy development (Yang, Roman-Urrestarazu, & 
Brayne, 2018). Firstly, rates of substance abuse in England and Wales are markedly 
lower than those seen in the United States; for instance, use of heroin and 
methamphetamine were both 75-80% lower in England and Wales than in the United 
States. Notwithstanding, this analysis has identified several disparities of note. Use of 
MDMA and ketamine, for instance, was found to be higher among those attaining a 
degree or diploma-level education, suggesting a need for specific research into the 
subcultures into why and how this subpopulation initiates and uses these substances in 
order to develop new policy to curb their use. In the United States, for instance, 
evidence suggests the use of MDMA and ketamine in sexual settings among sexual 
minority young adults (234), particularly among men who have sex with men (MSM) 
with implications for incidence of HIV and Hepatitis B(235). Given the limitations of 
the CSEW dataset, however, such secondary analyses are not possible and further study 
is needed to identify the unique circumstances underlying the use cases for specific 
substances among subpopulations of interest. 
Despite the relatively low rates of substance misuse and abuse in England and 
Wales when compared to the United States, it appears that policymakers are 
increasingly worried about the use of illicit substances, particularly among the middle-
class. The opioid epidemic, the burden of which has been sustained and worsening in 
the United States, may have prompted some of this worry, as well as rates of violent and 
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organised crime which may be linked to the supply and trade in illicit substances. These 
findings highlight social disparities in substance misuse and abuse which can inform 
more nuanced drug policy and suggests a greater need for sensitivity in policy 
discussions which specifically investigate the unique use cases underlying specific 
substances for subpopulations of interest in order to understand and address reasons for 
substance abuse and misuse initiation and maintenance.  
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9 DISCUSSION 
9.1 Summary 
Substance use disorders remain a major and growing contributor to global burden of 
disease (236). Addressing these is a priority of practitioners and policymakers. 
Historical approaches to substance misuse and abuse have predominantly focused on the 
abstinence paradigm or, more recently, the harm reduction paradigm with varying 
degrees of success. Renewed scholarly attention towards the ways in which describing 
and understanding social disparities in substance use disorders, drawing heavily upon 
medical sociology and demography, holds great promise for developing nuanced drug 
policy which accounts for the social factors and environmental milieu in which 
substance misuse and abuse occur. Through the secondary analysis of administrative 
data, this dissertation has sought to characterise and investigate these social disparities 
with respect to the prevalence of substance use misuse and abuse as well as unmet need 
for mental health treatment. Moreover, using the opioid epidemic as a representative 
case study, this dissertation presents an analysis of the disparities in substance abuse 
treatment based upon not only provider characteristics but also patient characteristics 
among those admitted for substance abuse treatment. Finally, this dissertation presents 
comparable data on substance use from England and Wales drawn from analyses of the 
Crime Survey for England and Wales.  
9.1.1 Epidemiology 
As shown in Chapters 4 and 5, social disparities among the prevalence of substance 
misuse and abuse as well as unmet need for mental health treatment are varied. 
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Millennials and young adults consistently show heightened risk of substance use, 
especially for heroin and oxycontin, as well as unmet need for mental health treatment 
due cost. As substance misuse and abuse initiation tends to occur in adolescence and 
early adulthood, these findings highlight the exceptionally vulnerable position which 
young adults find themselves – at the highest risk for substance use disorder as well as 
for unmet need for mental health treatment. As previously mentioned, Federal 
approaches to expanding coverage of mental health treatment through policy levers has 
yielded some positive changes yet these analyses suggest a potential “coverage cliff” 
where young adults age out of their parents’ insurance plans precisely when substance 
use disorders emerge and are diagnosed. In addition, the recent global financial crisis 
and subsequent austerity measures which reduced or scaled back social welfare 
programs may have a role to play as well with respect to the social disparities in 
substance use disorder. Analysis of the reasons for unmet need also highlights the 
important role of urbanicity with respect to mental health treatment; specifically, stigma 
and minimisation among those living in non-Metropolitan Statistical Areas/Core-Based 
Statistical Areas are a much more important reason for unmet need for mental health 
treatment than cost or structural barriers, highlighting the major role that education and 
social interventions can play to increase uptake of treatment. 
9.1.2 Treatment 
Analysis of the N-SSATS dataset in Chapter 6 highlights the major disparities in 
treatment of opioid use disorder, resulting in inequities based on geography and facility 
operational entity. While the number of VA-operated facilities which offer 
buprenorphine-assisted therapy has increased over time, this growth has not been 
reflected among civilian substance abuse treatment facilities. In addition, facilities 
which did not offer payment assistance were also less likely to offer buprenorphine-
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assisted therapy which is worrying, considering this work has highlighted which shows 
that the socioeconomically vulnerable are at heightened risk of substance misuse and 
abuse as well as unmet need for mental health treatment. Findings from Chapter 7 
provide further insights into disparities in the treatment of opioid use disorder. I present 
evidence that Indian Health Service and Tribal government-operated substance abuse 
treatment facilities are less likely to provide opioid agonist treatment, corroborated from 
TEDS which highlights Native Americans as a specific subpopulation at heightened risk 
of not receiving opioid agonist treatment. Geographic disparities emerge from the 
analysis of admissions data, suggesting a greater need for national coordination of 
substance abuse treatment care standards to ensure equitable treatment, regardless of 
geography.  
9.1.3 Context 
Drawing upon England and Wales as a comparison, it is clear the United States faces a 
much more serious problem with substance misuse and abuse with prevalence rates an 
order of magnitude higher. One reason for this major difference could be the different 
structure of the respective health care systems, particularly between the National Health 
Service in England and Wales and the highly disaggregated system in the United States. 
Yet, this difference should not be overstated; Clinical Commissioning Groups (CCGs) 
have decentralised some aspects of care in England and so further study, ideally 
involving patient registries and/or primary data collection, would offer greater insights 
into the reasons why England and Wales have had much fewer problems with substance 
use disorders to date than the United States. The United States, on the other hand, offers 
useful lessons in addressing the opioid epidemic for England and Wales, where statistics 
highlight significantly increasingly mortality due to synthetic opioids, potentially 
signalling the start of an opioid-based crisis. 
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9.2 Limitations 
As noted in Chapter 3 as well as under the methodology sections under each respective 
study, this dissertation is founded upon the secondary use of administrative data for the 
analysis of social disparities in substance use disorders and their treatment. By 
extension, each analysis is limited by the ways in which each administrative dataset is 
collected, methodological and statistical considerations associated with each dataset, 
and, more generally, the use of administrative data in public health research. Firstly, as 
this dissertation does not rely upon primary data collection, all research questions reflect 
the limitations of the NSDUH, N-SSATS, TEDS, and CSEW. Moreover, as these 
datasets do not reflect a formal diagnosis of substance use disorder nor do they provide 
biological samples for analysis, we must infer substance abuse and misuse based on 
existing questions. Nevertheless, this is often the case on substance abuse research 
where most outcome variables are based upon self-reported data. Even in cases where 
the dataset reflects non-self-reported data, as in the case of TEDS, there are risks 
associated with data which are not included in the dataset, particularly for admitted 
patients who are not captured in TEDS (for example, patients seeking care at private 
facilities receiving no public funds). This is a major consideration when using 
household survey data to develop population estimates, especially in the case of 
substance abuse and misuse. Analyses drawn from the two household surveys in this 
thesis, namely, the NSDUH and CSEW, may not accurately reflect true rates of 
substance abuse and misuse among a variety of subpopulations which are excluded 
from these surveys, including those with no fixed household address (86) and those 
living in educational or institutional settings, such as students (237) and prison 
populations (238). These subpopulations often represent groups of disproportionately 
high risk of substance use disorders and other complications arising therefrom; 
consequently, much more attention and resources will be necessary to more fully 
Social disparities in the epidemiology and treatment of substance-related use disorders in the United States, 
2002-16 
168  Justin Christopher Yang – March 2019 
understand the impact of substance use disorders on society as a whole. In addition, as 
previously noted, the use of administrative data presents challenges with respect to 
causal inference as data is routinely collected in a repeated cross-sectional format, rather 
than as longitudinal or panel data. As such, this dissertation cannot provide conclusions 
regarding the causal effect of specific correlates on substance misuse and abuse and 
treatment but identifies important social disparities for further investigation.  
9.3 Strengths 
Notwithstanding the limitations highlighted above, as highlighted in Chapter 2, research 
considering substance use disorders among the general American adult population have 
been limited recently and have understudied the impact of social disparities on 
substance use disorders and their treatment. This dissertation attempts to addressing this 
knowledge deficit by characterising and identifying the demographic, socioeconomic, 
and health correlates of substance use disorders and their treatment by drawing upon 
well-established administrative datasets. The use of administrative datasets for this 
purpose is a noted strength; such analyses are cost-effective, drawing upon data which 
has already been collected and, usually, processed. Moreover, given our interest in 
specifically vulnerable subpopulations, some of which normally comprise only a limited 
selection in normal study design and entail uniquely difficult sampling methods, the 
secondary analysis of administrative datasets provides the necessary sample sizes for 
these subpopulations to power the analyses presented. Moreover, the analyses presented 
in this dissertation highlight trends over large periods of time, work that is not feasible 
without significant resource allocation for data collection and follow-up  
9.4 Results in Context of the Literature 
Most findings were consistent with the established literature on the epidemiology of 
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substance use disorders while others extended our understanding. Firstly, as expected, 
the data show that young adults continue to be a subpopulation of interest given the 
higher prevalence of substance use disorders among this group than older 
subpopulations. Also, the data and analyses presented here provide some evidence 
towards the relationship between low SES and illicit substance use, yet much more 
study is needed to fully elucidate this relationship, its causes and potential opportunities 
for policy interventions. 
With respect to the treatment of substance use disorders, the findings extend 
understanding of why individuals who perceive a need for treatment report unmet need 
for mental health treatment. While the literature suggests that adults with SUDs but no 
other diagnosable health conditions do not seek care as they do not perceive a need for 
treatment, our analysis highlights a myriad of reasons for reporting unmet need among 
those perceiving need for treatment, including cost primarily among those aged 26-49, 
stigma among those living in suburban or rural areas, and structural barriers among a 
number of ethnic minority groups. 
The study of substance abuse treatment facilities and treatment of opioid use 
disorders have highlighted new trends which complement the existing literature. 
Though it has been known that the use of opioid agonists has increased for the treatment 
of opioid use disorder over time, findings presented in chapter 6 have shown that this 
expansion has been relatively low outside of the northeast region, in particular, the 
expanded use of buprenorphine has been relatively lower among facilitated not operated 
by the VA.  
9.5 Implications and Future Directions 
As shown in the preceding analyses, social disparities are abundant with respect to 
substance use disorders in the United States and remain an enduring problem. For 
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practitioners, attention towards the upstream social and economic determinants of health 
have prompted a greater focus on understanding the daily living conditions of patients 
and the settings where they seek care (239). Yet, despite an increasingly consensus 
among practitioners over the importance of considering the upstream determinants of 
health and their implications on health equity, evidence to support the development of 
new interventions and holistic approaches to care has been limited (240). Work in this 
area, to date, has shown wide variations in not only methodology but also 
conceptualization and definition of basic terminology (241). Indeed, agreement on what 
constitutes social determinants of health as well as their causes bears greater scrutiny 
and greater elucidation will do much to guide future policymaking and research in this 
area (242). Nevertheless, evidence suggests that interventions focused on addressing the 
social determinants of health, despite its nebulous definition, have yielded largely 
positive effects on health outcomes, costs, or both (243).  
Further research into substance use disorders and their prevention and treatment 
has also benefitted from advances in our understanding in genetic epidemiology (244, 
245). Such research has elucidated the genetic risk factors for substance use and abuse 
particularly in the case of the dopaminergic system and has highlight further avenues of 
research into variations in drug processing and metabolism at the individual level (244, 
245). Much work remains to be done, nevertheless, to understand the causal pathways 
which explain these genetic risk factors. Further work may provide direction for tailored 
approaches to the treatment and prevention of substance use disorders when considered 
in the overall context of other risk factors, including lifestyle, social environment, and 
material deprivation. In conjunction with a growing evidence base which identifies the 
societally based risk factors for substance use disorders, new advances in genetic 
epidemiology may help practitioners with more effective approaches tailored to 
individuals.  
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Findings from this thesis can also contribute advancing legal practice and 
jurisprudence in the United States with respect to drug treatment courts. Drug treatment 
courts, established to provide an alternative to the criminal justice system for nonviolent 
offenders, adopt a public safety approach to addressing illicit drug use by integrating 
substance use treatment and rehabilitation services with ongoing judicial interaction 
(246). By doing so, these courts have demonstrably reduced criminal behaviour and 
drug use, at least in the short-term (247). Evolving jurisprudence can and should make 
use of best and new evidence which highlight the social determinants of health with 
respect to heightened vulnerability and propensity for substance use and abuse to tailor 
treatment programs which can better address individual pathways to substance use 
initiation and maintenance.  
Nevertheless, despite the successes of drug treatment courts in diverting 
individuals with substance use disorders from the criminal justice system, these cases 
represent only a minority of cases involving substance use disorders; consequently, 
most cases related to substance use disorders involve the criminal justice system and 
result in admission to jails and prisons (248). These institutions, therefore, represent a 
significant opportunity to address substance use disorders among large subpopulations 
of individuals with substance use disorder; yet, the relative lack of research and 
evidence into the characteristics of these individuals has stymied attempts to develop 
new interventions to address substance use, dependence, and abuse among these 
populations. As mentioned earlier, administrative data which provides much 
information regarding non-institutionalised Americans overlooks incarcerated 
populations entirely and this oversight bears further attention if the health of jail and 
prison populations facing substance use disorders is to be addressed more fully.  
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9.6 Conclusion 
Substance use disorders continue to be a major contributor to global morbidity with 
wide-ranging implications on social care and the macroeconomy. Efforts in the past 
which have focused on abstinence as a paradigm for treatment have failed to address the 
root causes of substance misuse and abuse despite rather significant resources devoted 
to the control and enforcement of illicit substances. The increasing focus towards the 
social and economic correlates of adverse health conditions and their outcomes have 
yielded promising possibilities for the development of new interventions to prevent, 
treat, and control substance use disorders in the broader population by identifying the 
risk factors for substance use disorders as well as ways in which the treatment thereof 
may be materially improved and optimised. Already, public health officials and health 
care providers have significantly advanced the harm reduction paradigm in public 
policy and care provision, as shown by the increasing uptake of agonist or tapering 
treatments for substance use disorders, yet stigma and public misunderstanding of 
addiction and dependency continue to influence policymakers and politicians at several 
levels of governance. As highlighted in this dissertation, acknowledging, recognising, 
and addressing the social and economic disparities of substance use disorders and their 
treatment will be necessary in the near- and long-term to fully address this urgent and 
potentially worsening public health crisis.  
 
Chapter 10: References 
Justin Christopher Yang- March 2019   173 
10 REFERENCES 
 
1. Mathew VM. ALCOHOLISM IN BIBLICAL PROPHECY. Alcohol and 
Alcoholism. 1992;27(1):89-90. 
2. Stolberg VB. Historical Images and Reviews of Substance Use and Substance 
Abuse in the Teaching of Addiction Studies. Journal of Teaching in the Addictions. 
2009;8(1-2):65-83. 
3. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, et al. 
Global burden of disease attributable to mental and substance use disorders: findings 
from the Global Burden of Disease Study 2010. Lancet (London, England). 
2013;382(9904):1575-86. 
4. Goodman AJBp. Neurobiology of addiction: An integrative review. 
2008;75(1):266-322. 
5. Ritter A, Ritter A, Cameron J, Ritter A, Cameron JJD, review a. A review of the 
efficacy and effectiveness of harm reduction strategies for alcohol, tobacco and illicit 
drugs. 2006;25(6):611-24. 
6. Bradby HJFiS. Research agenda in medical sociology. 2016;1:14. 
7. Wu LT, Blazer DG. Substance use disorders and psychiatric comorbidity in mid 
and later life: a review. International journal of epidemiology. 2014;43(2):304-17. 
8. Wu LT, Blazer DG. Illicit and nonmedical drug use among older adults: a 
review. J Aging Health. 2011;23(3):481-504. 
9. Wang YP, Andrade LH. Epidemiology of alcohol and drug use in the elderly. 
Curr Opin Psychiatry. 2013;26(4):343-8. 
10. Searby A, Maude P, McGrath I. Dual diagnosis in older adults: a review. Issues 
Ment Health Nurs. 2015;36(2):104-11. 
11. Le Roux C, Tang Y, Drexler K. Alcohol and Opioid Use Disorder in Older 
Adults: Neglected and Treatable Illnesses. Curr Psychiatry Rep. 2016;18(9):87. 
12. Kuerbis A, Sacco P, Blazer DG, Moore AA. Substance abuse among older 
adults. Clin Geriatr Med. 2014;30(3):629-54. 
13. Kalapatapu RK, Paris P, Neugroschl JA. Alcohol use disorders in geriatrics. Int 
J Psychiatry Med. 2010;40(3):321-37. 
14. Gell L, Meier PS, Goyder E. Alcohol consumption among the over 50s: 
international comparisons. Alcohol Alcohol. 2015;50(1):1-10. 
15. Ferreira MP, Weems MK. Alcohol consumption by aging adults in the United 
States: health benefits and detriments. J Am Diet Assoc. 2008;108(10):1668-76. 
16. Doukas N. Older adults prescribed methadone: a review of the literature across 
the life span from opiate initiation to methadone maintenance treatment. Curr Drug 
Abuse Rev. 2014;7(3):165-73. 
17. Donatelli NS, Somes J. Alcohol and aging: the invisible epidemic. J Emerg 
Nurs. 2014;40(2):177-80. 
18. Caputo F, Vignoli T, Leggio L, Addolorato G, Zoli G, Bernardi M. Alcohol use 
disorders in the elderly: a brief overview from epidemiology to treatment options. Exp 
Gerontol. 2012;47(6):411-6. 
19. Berks J, McCormick R. Screening for alcohol misuse in elderly primary care 
patients: a systematic literature review. Int Psychogeriatr. 2008;20(6):1090-103. 
Social disparities in the epidemiology and treatment of substance-related use disorders in the United States, 
2002-16 
174  Justin Christopher Yang – March 2019 
20. Screening for At-Risk Alcohol Use in Older Adults: What Progress Have We 
Made? J Addict Nurs. 2015;26(3):152-6. 
21. Davis TA, Ancis J. Look to the relationship: a review of African American 
women substance users' poor treatment retention and working alliance development. 
Subst Use Misuse. 2012;47(6):662-72. 
22. Greenfield SF, Back SE, Lawson K, Brady KT. Substance abuse in women. 
Psychiatr Clin North Am. 2010;33(2):339-55. 
23. McHugh RK, Wigderson S, Greenfield SF. Epidemiology of substance use in 
reproductive-age women. Obstet Gynecol Clin North Am. 2014;41(2):177-89. 
24. Shahram S. The social determinants of substance use for aboriginal women: A 
systematic review. Women Health. 2016;56(2):157-76. 
25. Wilsnack SC, Wilsnack RW, Kantor LW. Focus on: women and the costs of 
alcohol use. Alcohol Res. 2013;35(2):219-28. 
26. Schulden JD, Thomas YF, Compton WM. Substance abuse in the United States: 
findings from recent epidemiologic studies. Curr Psychiatry Rep. 2009;11(5):353-9. 
27. Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their 
contribution to the global burden of disease. Lancet (London, England). 
2012;379(9810):55-70. 
28. Merikangas KR, McClair VL. Epidemiology of substance use disorders. Hum 
Genet. 2012;131(6):779-89. 
29. Dasgupta N, Creppage K, Austin A, Ringwalt C, Sanford C, Proescholdbell SK. 
Observed transition from opioid analgesic deaths toward heroin. Drug Alcohol Depend. 
2014;145:238-41. 
30. Sharfstein JM. The Opioid Crisis From Research to Practice. Milbank Q. 
2017;95(1):24-7. 
31. Creedon TB, Cook BL. Access to mental health care increased but not for 
substance use, while disparities remain. Health Affairs. 2016;35(6):1017-21. 
32. Green S, Higgins J. Cochrane handbook for systematic reviews of interventions. 
Version; 2005. 
33. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. 
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-
P) 2015 statement. 2015;4(1):1. 
34. Dixon-Woods M, Agarwal S, Jones D, Young B, Sutton A. Synthesising 
qualitative and quantitative evidence: A review of possible methods. Journal of Health 
Services Research & Policy. 2005;10(1):45-53. 
35. Popay J, Roberts H, Sowden A, Petticrew M, Arai L, Rodgers M, et al. 
Guidance on the conduct of narrative synthesis in systematic reviews. 2006;1:b92. 
36. Wechsler H, Austin SBJJosoa. Binge drinking: the five/four measure. 
1998;59(1):122-4. 
37. Hingson RW, Zha W, White AM. Drinking Beyond the Binge Threshold: 
Predictors, Consequences, and Changes in the U.S. Am J Prev Med. 2017;52(6):717-27. 
38. Paul LA, Grubaugh AL, Frueh BC, Ellis C, Egede LE. Associations between 
binge and heavy drinking and health behaviors in a nationally representative sample. 
Addict Behav. 2011;36(12):1240-5. 
39. Patrick ME, Terry-McElrath YM, Miech RA, Schulenberg JE, O'Malley PM, 
Johnston LD. Age-Specific Prevalence of Binge and High-Intensity Drinking Among 
U.S. Young Adults: Changes from 2005 to 2015. Alcohol Clin Exp Res. 
2017;41(7):1319-28. 
40. Blazer DG, Wu LT. The epidemiology of at-risk and binge drinking among 
middle-aged and elderly community adults: National Survey on Drug Use and Health. 
Am J Psychiatry. 2009;166(10):1162-9. 
Chapter 10: References 
Justin Christopher Yang- March 2019   175 
41. Choi NG, Dinitto DM. Heavy/binge drinking and depressive symptoms in older 
adults: gender differences. International journal of geriatric psychiatry. 2011;26(8):860-
8. 
42. Han BH, Moore AA, Sherman S, Keyes KM, Palamar JJ. Demographic trends of 
binge alcohol use and alcohol use disorders among older adults in the United States, 
2005-2014. Drug Alcohol Depend. 2017;170:198-207. 
43. Otiniano Verissimo AD, Gee GC, Ford CL, Iguchi MY. Racial discrimination, 
gender discrimination, and substance abuse among Latina/os nationwide. Cultur Divers 
Ethnic Minor Psychol. 2014;20(1):43-51. 
44. Lee HK, Han B, Gfroerer JC. Differences in the prevalence rates and correlates 
of alcohol use and binge alcohol use among five Asian American subpopulations. 
Addict Behav. 2013;38(3):1816-23. 
45. Wong CF, Kipke MD, Weiss G. Risk factors for alcohol use, frequent use, and 
binge drinking among young men who have sex with men. Addict Behav. 
2008;33(8):1012-20. 
46. Mack KA, Jones CM, Ballesteros MF. Illicit Drug Use, Illicit Drug Use 
Disorders, and Drug Overdose Deaths in Metropolitan and Nonmetropolitan Areas - 
United States. MMWR Surveill Summ. 2017;66(19):1-12. 
47. Han B, Gfroerer JC, Colliver JD. Associations between duration of illicit drug 
use and health conditions: results from the 2005-2007 national surveys on drug use and 
health. Ann Epidemiol. 2010;20(4):289-97. 
48. Carliner H, Delker E, Fink DS, Keyes KM, Hasin DS. Racial discrimination, 
socioeconomic position, and illicit drug use among US Blacks. Social psychiatry and 
psychiatric epidemiology. 2016;51(4):551-60. 
49. John WS, Wu LT. Trends and correlates of cocaine use and cocaine use disorder 
in the United States from 2011 to 2015. Drug Alcohol Depend. 2017;180:376-84. 
50. Jones CM, Logan J, Gladden RM, Bohm MK. Vital Signs: Demographic and 
Substance Use Trends Among Heroin Users - United States, 2002-2013. MMWR Morb 
Mortal Wkly Rep. 2015;64(26):719-25. 
51. Palamar JJ, Davies S, Ompad DC, Cleland CM, Weitzman M. Powder cocaine 
and crack use in the United States: an examination of risk for arrest and socioeconomic 
disparities in use. Drug Alcohol Depend. 2015;149:108-16. 
52. Calcaterra S, Glanz J, Binswanger IA. National trends in pharmaceutical opioid 
related overdose deaths compared to other substance related overdose deaths: 1999-
2009. Drug Alcohol Depend. 2013;131(3):263-70. 
53. Hasegawa K, Espinola JA, Brown DF, Camargo CA, Jr. Trends in U.S. 
emergency department visits for opioid overdose, 1993-2010. Pain Med. 
2014;15(10):1765-70. 
54. Han B, Compton WM, Jones CM, Cai R. Nonmedical Prescription Opioid Use 
and Use Disorders Among Adults Aged 18 Through 64 Years in the United States, 
2003-2013. JAMA. 2015;314(14):1468-78. 
55. Jones CM. The paradox of decreasing nonmedical opioid analgesic use and 
increasing abuse or dependence - An assessment of demographic and substance use 
trends, United States, 2003-2014. Addict Behav. 2017;65(10):229-35. 
56. Han B, Compton WM, Blanco C, Crane E, Lee J, Jones CM. Prescription Opioid 
Use, Misuse, and Use Disorders in U.S. Adults: 2015 National Survey on Drug Use and 
Health. Ann Intern Med. 2017;167(5):293-301. 
57. Centers for Disease C, Prevention. Vital signs: overdoses of prescription opioid 
pain relievers and other drugs among women--United States, 1999-2010. MMWR Morb 
Mortal Wkly Rep. 2013;62(26):537-42. 
Social disparities in the epidemiology and treatment of substance-related use disorders in the United States, 
2002-16 
176  Justin Christopher Yang – March 2019 
58. Kozhimannil KB, Graves AJ, Levy R, Patrick SW. Nonmedical Use of 
Prescription Opioids among Pregnant U.S. Women. Womens Health Issues. 
2017;27(3):308-15. 
59. Morley KI, Lynskey MT, Moran P, Borschmann R, Winstock AR. 
Polysubstance use, mental health and high-risk behaviours: Results from the 2012 
Global Drug Survey. Drug Alcohol Rev. 2015;34(4):427-37. 
60. McCabe SE, West BT, Jutkiewicz EM, Boyd CJ. Multiple DSM-5 substance use 
disorders: A national study of US adults. Hum Psychopharmacol. 2017;32(5). 
61. Jarlenski M, Barry CL, Gollust S, Graves AJ, Kennedy-Hendricks A, 
Kozhimannil K. Polysubstance Use Among US Women of Reproductive Age Who Use 
Opioids for Nonmedical Reasons. Am J Public Health. 2017;107(8):1308-10. 
62. Gilder DA, Stouffer GM, Lau P, Ehlers CL. Clinical characteristics of alcohol 
combined with other substance use disorders in an American Indian community sample. 
Drug Alcohol Depend. 2016;161:222-9. 
63. Hartzler B, Dombrowski JC, Crane HM, Eron JJ, Geng EH, Christopher 
Mathews W, et al. Prevalence and Predictors of Substance Use Disorders Among HIV 
Care Enrollees in the United States. AIDS Behav. 2017;21(4):1138-48. 
64. Cicero TJ, Ellis MS, Surratt HLJNEJoM. Effect of abuse-deterrent formulation 
of OxyContin. 2012;367(2):187-9. 
65. Jones CM. Heroin use and heroin use risk behaviors among nonmedical users of 
prescription opioid pain relievers - United States, 2002-2004 and 2008-2010. Drug 
Alcohol Depend. 2013;132(1-2):95-100. 
66. Martins SS, Santaella-Tenorio J, Marshall BD, Maldonado A, Cerda M. 
Racial/ethnic differences in trends in heroin use and heroin-related risk behaviors 
among nonmedical prescription opioid users. Drug Alcohol Depend. 2015;151:278-83. 
67. Martins SS, Segura LE, Santaella-Tenorio J, Perlmutter A, Fenton MC, Cerda 
M, et al. Prescription opioid use disorder and heroin use among 12-34 year-olds in the 
United States from 2002 to 2014. Addict Behav. 2017;65:236-41. 
68. Unick GJ, Ciccarone D. US regional and demographic differences in 
prescription opioid and heroin-related overdose hospitalizations. Int J Drug Policy. 
2017;46:112-9. 
69. Ali MM, Teich JL, Mutter R. The role of perceived need and health insurance in 
substance use treatment: implications for the Affordable Care Act. J Subst Abuse Treat. 
2015;54:14-20. 
70. Chen LY, Strain EC, Crum RM, Mojtabai R. Gender differences in substance 
abuse treatment and barriers to care among persons with substance use disorders with 
and without comorbid major depression. J Addict Med. 2013;7(5):325-34. 
71. Blanco C, Iza M, Rodriguez-Fernandez JM, Baca-Garcia E, Wang S, Olfson M. 
Probability and predictors of treatment-seeking for substance use disorders in the U.S. 
Drug Alcohol Depend. 2015;149:136-44. 
72. Mulvaney-Day N, DeAngelo D, Chen CN, Cook BL, Alegria M. Unmet need 
for treatment for substance use disorders across race and ethnicity. Drug Alcohol 
Depend. 2012;125 Suppl 1:S44-50. 
73. Cantor J, Stoller KB, Saloner B. The response of substance use disorder 
treatment providers to changes in macroeconomic conditions. J Subst Abuse Treat. 
2017;81:59-65. 
74. Cummings JR, Wen H, Ko M. Decline In Public Substance Use Disorder 
Treatment Centers Most Serious In Counties With High Shares Of Black Residents. 
Health Aff (Millwood). 2016;35(6):1036-44. 
Chapter 10: References 
Justin Christopher Yang- March 2019   177 
75. Arndt S, Acion L, White K. How the states stack up: disparities in substance 
abuse outpatient treatment completion rates for minorities. Drug Alcohol Depend. 
2013;132(3):547-54. 
76. Mennis J, Stahler GJ. Racial and Ethnic Disparities in Outpatient Substance Use 
Disorder Treatment Episode Completion for Different Substances. J Subst Abuse Treat. 
2016;63:25-33. 
77. Brady KT, McCauley JL, Back SE. Prescription Opioid Misuse, Abuse, and 
Treatment in the United States: An Update. Am J Psychiatry. 2016;173(1):18-26. 
78. Ruggles KV, Fang Y, Tate J, Mentor SM, Bryant KJ, Fiellin DA, et al. What are 
the Patterns Between Depression, Smoking, Unhealthy Alcohol Use, and Other 
Substance Use Among Individuals Receiving Medical Care? A Longitudinal Study of 
5479 Participants. AIDS Behav. 2017;21(7):2014-22. 
79. Clark TT. Perceived discrimination, depressive symptoms, and substance use in 
young adulthood. Addict Behav. 2014;39(6):1021-5. 
80. Fink DS, Hu R, Cerda M, Keyes KM, Marshall BD, Galea S, et al. Patterns of 
major depression and nonmedical use of prescription opioids in the United States. Drug 
Alcohol Depend. 2015;153:258-64. 
81. Golub A, Vazan P, Bennett AS, Liberty HJ. Unmet need for treatment of 
substance use disorders and serious psychological distress among veterans: a 
nationwide analysis using the NSDUH. Mil Med. 2013;178(1):107-14. 
82. Keuroghlian AS, Reisner SL, White JM, Weiss RD. Substance use and treatment 
of substance use disorders in a community sample of transgender adults. Drug Alcohol 
Depend. 2015;152:139-46. 
83. Kissinger P, Althoff M, Burton N, Schmidt N, Hembling J, Salinas O, et al. 
Prevalence, patterns and predictors of substance use among Latino migrant men in a 
new receiving community. Drug Alcohol Depend. 2013;133(3):814-24. 
84. Krill PR, Johnson R, Albert L. The Prevalence of Substance Use and Other 
Mental Health Concerns Among American Attorneys. J Addict Med. 2016;10(1):46-52. 
85. Oreskovich MR, Shanafelt T, Dyrbye LN, Tan L, Sotile W, Satele D, et al. The 
prevalence of substance use disorders in American physicians. Am J Addict. 
2015;24(1):30-8. 
86. Spinelli MA, Ponath C, Tieu L, Hurstak EE, Guzman D, Kushel M. Factors 
associated with substance use in older homeless adults: Results from the HOPE HOME 
study. Subst Abus. 2017;38(1):88-94. 
87. Wu LT, Blazer DG, Swartz MS, Burchett B, Brady KT, Workgroup NA. Illicit 
and nonmedical drug use among Asian Americans, Native Hawaiians/Pacific Islanders, 
and mixed-race individuals. Drug Alcohol Depend. 2013;133(2):360-7. 
88. Calhoun PS, Schry AR, Wagner HR, Kimbrel NA, Dennis P, McDonald SD, et 
al. The prevalence of binge drinking and receipt of provider drinking advice among US 
veterans with military service in Iraq or Afghanistan. Am J Drug Alcohol Abuse. 
2016;42(3):269-78. 
89. Hawkins EJ, Malte CA, Grossbard JR, Saxon AJ. Prevalence and Trends of 
Concurrent Opioid Analgesic and Benzodiazepine Use Among Veterans Affairs 
Patients with Post-traumatic Stress Disorder, 2003-2011. Pain Med. 2015;16(10):1943-
54. 
90. Evans E, Grella CE, Murphy DA, Hser Y-I. Using Administrative Data for 
Longitudinal Substance Abuse Research. The Journal of Behavioral Health Services & 
Research. 2010;37(2):252-71. 
91. . !!! INVALID CITATION !!! (91-93). 
92. Fazel S, Långström N, Hjern A, Grann M, Lichtenstein P. Schizophrenia, 
substance abuse, and violent crime. JAMA. 2009;301(19):2016-23. 
Social disparities in the epidemiology and treatment of substance-related use disorders in the United States, 
2002-16 
178  Justin Christopher Yang – March 2019 
93. Virnig BA, McBean M. Administrative data for public health surveillance and 
planning. Annual review of public health. 2001;22:213-30. 
94. Batts K, Pemberton M, Bose J, Weimer B, Henderson L, Penne M, et al. 
Comparing and Evaluating Substance Use Treatment Utilization Estimates from the 
National Survey on Drug Use and Health and Other Data Sources.  CBHSQ Data 
Review. Rockville (MD): Substance Abuse and Mental Health Services Administration 
(US); 2012. p. 1-120. 
95. United States Department of H, Human Services. Substance A, Mental Health 
Services Administration. Center for Behavioral Health S, Quality. National Survey on 
Drug Use and Health, 2016. RTI International; 2018. 
96. United States Department of Health and Human Services. Substance Abuse and 
Mental Health Services Administration. Office of Applied Studies. National Survey of 
Substance Abuse Treatment Services (NSSATS), 2016. Ann Arbor, MI: Inter-university 
Consortium for Political and Social Research; 2016. 
97. Substance Abuse Mental Health Services Administration CfBHSQ. Treatment 
Episode Data Set (TEDS): 2004–2014. National Admissions to Substance Abuse 
Treatment Services. No BHSIS Series S-84, HHS Publication No SMA 16–4986. 2016. 
98. Department of Health and Human Services. Common rule, 45 CFR 46. Federal 
policy for the protection of human subjects; notices and rules. Fed Regist. 
1991;56:28003-32. 
99. Howe N, Strauss W. The Next 20 Years: How Customer and Workforce 
Attitudes Will Evolve. Harvard Business Review. 2007;85(7/8):41-52. 
100. International Monetary Fund. World Economic Outlook: Rebalancing Growth. 
Washington, D.C.: International Monetary Fund; 2010. 
101. Verick S, Islam I. The Great Recession of 2008-2009: Causes, Consequences 
and Policy Responses. Institute for the Study of Labor (IZA); 2010. 
102. Zezza G. The impact of fiscal austerity in the Eurozone. Review of Keynesian 
Economics. 2012(1):37-54. 
103. Darvas Z, Huettl P, De Sousa C, Terzi A, Tschekassin O. Austerity and poverty 
in the European Union. Brussels: Brussels : European Parliament; 2014. 
104. Mladovsky P, Srivastava D, Cylus J, Karanikolos M, Evetovits T, Thomson S, et 
al. Health policy responses to the financial crisis in Europe. Policy Summary 5: World 
Health Organization. 
105. Tapia Granados JA, Rodriguez JM. Health, economic crisis, and austerity: A 
comparison of Greece, Finland and Iceland. Health policy (Amsterdam, Netherlands). 
2015;119(7):941-53. 
106. Matsaganis M, Leventi C. The distributional impact of austerity and the 
recession in Southern Europe. South European Society and Politics. 2014;19(3):393-
412. 
107. Danziger S. Evaluating the Effects of the Great Recession. The Annals of the 
American Academy of Political and Social Science.650:6. 
108. Meyer BD, Sullivan JX. Consumption and Income Inequality and the Great 
Recession. The American Economic Review. 2013;103(3):178-83. 
109. Jenkins SP, Oxford University P. The great recession and the distribution of 
household income [electronic resource] / edited by Stephen P. Jenkins ... [et al.]. 1st ed. 
ed. Oxford: Oxford : Oxford University Press, 2013.; 2013. 
110. Chung JJ. Wealth Inequality as Explained by Quantitative Easing and Law's 
Inertia. 2016. 
111. Verick S. The impact of the global financial crisis on labour markets in OECD 
countries: Why youth and other vulnerable groups have been hit hard.  From the Great 
Recession to Labour Market Recovery: Springer; 2011. p. 119-45. 
Chapter 10: References 
Justin Christopher Yang- March 2019   179 
112. Levenson A. Millennials and the World of Work: An Economist’s Perspective. 
Journal of Business & Psychology. 2010;25(2):257-64. 
113. Mechler H. Off Our Lawns and Out of Our Basements: How We 
(Mis)Understand the Millennial Generation. Journal of College and Character. 
2013;14(4):357-64. 
114. Bannon. Understanding millennials in the workplace. The CPA journal (1975). 
2011;81(11):61. 
115. National Center for Education Statistics. Degree-granting postsecondary 
institutions, by control and level of institution. In: U.S. Department of Education, editor. 
2014. 
116. Elliott W, Lewis M. STUDENT DEBT EFFECTS ON FINANCIAL WELL-
BEING: RESEARCH AND POLICY IMPLICATIONS. Journal of Economic Surveys. 
2015;29(4):614-36. 
117. Board of Governors of the Federal Reserve System (US). Student Loans Owned 
and Securitized, Outstanding [SLOAS]. Federal Reserve Bank of St. Louis; 2017. 
118. Frasquilho D, Matos MG, Salonna F, Guerreiro D, Storti CC, Gaspar T, et al. 
Mental health outcomes in times of economic recession: a systematic literature review. 
BMC public health. 2016;16:115. 
119. Richman JA, Rospenda KM, Johnson TP, Cho YI, Vijayasira G, Cloninger L, et 
al. Drinking in the age of the Great Recession. J Addict Dis. 2012;31(2):158-72. 
120. Vijayasiri G, Richman JA, Rospenda KM. The Great Recession, somatic 
symptomatology and alcohol use and abuse. Addict Behav. 2012;37(9):1019-24. 
121. Rhodes W, Johnston P, Han S, McMullen Q, Hozik L. Illicit Drugs: Price 
Elasticity of Demand and Supply. U.S. Department of Justice; 2002.  Contract No.: 
191856. 
122. Bor J, Basu S, Coutts A, McKee M, Stuckler D. Alcohol use during the great 
recession of 2008-2009. Alcohol Alcohol. 2013;48(3):343-8. 
123. Center for Behavioral Health Statistics and Quality. 2014 National Survey on 
Drug Use and Health: Methodological summary and definitions. Rockville, MD: 
Substance Abuse and Mental Health Services Administration; 2015. 
124. Eyerman R, Turner BS. Outline of a theory of generations. European Journal of 
Social Theory. 1998;1(1):91-106. 
125. Chau PH, Gusmano MK, Cheng JO, Cheung SH, Woo J. Social vulnerability 
index for the older people-Hong Kong and New York City as examples. J Urban Health. 
2014;91(6):1048-64. 
126. Manrique-Espinoza B, Salinas-Rodriguez A, Salgado de Snyder N, Moreno-
Tamayo K, Gutierrez-Robledo LM, Avila-Funes JA. Frailty and Social Vulnerability in 
Mexican Deprived and Rural Settings. J Aging Health. 2016;28(4):740-52. 
127. Peek L, Stough LM. Children with disabilities in the context of disaster: a social 
vulnerability perspective. Child Dev. 2010;81(4):1260-70. 
128. Zahran S, Peek L, Snodgrass JG, Weiler S, Hempel L. Economics of disaster 
risk, social vulnerability, and mental health resilience. Risk analysis : an official 
publication of the Society for Risk Analysis. 2011;31(7):1107-19. 
129. Stuckler D, Reeves A, Karanikolos M, McKee M. The health effects of the 
global financial crisis: can we reconcile the differing views? A network analysis of 
literature across disciplines. Health Economics, Policy and Law. 2015;10(1):83-99. 
130. Kolodny A, Courtwright DT, Hwang CS, Kreiner P, Eadie JL, Clark TW, et al. 
The prescription opioid and heroin crisis: a public health approach to an epidemic of 
addiction. Annual review of public health. 2015;36:559-74. 
131. Nadelmann E, LaSalle L. Two steps forward, one step back: current harm 
reduction policy and politics in the United States. Harm Reduct J. 2017;14(1):37. 
Social disparities in the epidemiology and treatment of substance-related use disorders in the United States, 
2002-16 
180  Justin Christopher Yang – March 2019 
132. Suffoletto B, Kristan J, Chung T, Jeong K, Fabio A, Monti P, et al. An 
Interactive Text Message Intervention to Reduce Binge Drinking in Young Adults: A 
Randomized Controlled Trial with 9-Month Outcomes. PloS one. 
2015;10(11):e0142877. 
133. Kuerbis AN, Yuan SE, Borok J, LeFevre PM, Kim GS, Lum D, et al. Testing 
the Initial Efficacy of a Mailed Screening and Brief Feedback Intervention to Reduce 
At‐Risk Drinking in Middle‐Aged and Older Adults: The Comorbidity Alcohol Risk 
Evaluation Study. Journal of the American Geriatrics Society. 2015;63(2):321-6. 
134. Institute for Health Metrics and Evaluation. GBD Compare Seattle, WA2018 
[Available from: https://vizhub.healthdata.org/gbd-compare/. 
135. Walker ER, Druss BG. Cumulative burden of comorbid mental disorders, 
substance use disorders, chronic medical conditions, and poverty on health among 
adults in the U.S.A. Psychology, Health & Medicine. 2017;22(6):727-35. 
136. Beronio K, Glied S, Frank R. How the Affordable Care Act and Mental Health 
Parity and Addiction Equity Act greatly expand coverage of behavioral health care. The 
journal of behavioral health services & research. 2014;41(4):410-28. 
137. Creedon TB, Cook BL. Access To Mental Health Care Increased But Not For 
Substance Use, While Disparities Remain. Health affairs (Project Hope). 
2016;35(6):1017-21. 
138. Alang SM. Sociodemographic disparities associated with perceived causes of 
unmet need for mental health care. Psychiatr Rehabil J. 2015;38(4):293-9. 
139. Edlund MJ, Booth BM, Feldman ZL. Perceived need for treatment for alcohol 
use disorders: results from two national surveys. Psychiatr Serv. 2009;60(12):1618-28. 
140. Walker ER, Cummings JR, Hockenberry JM, Druss BG. Insurance status, use of 
mental health services, and unmet need for mental health care in the United States. 
Psychiatr Serv. 2015;66(6):578-84. 
141. Han B, Compton WM, Blanco C, Colpe LJ. Prevalence, Treatment, And Unmet 
Treatment Needs Of US Adults With Mental Health And Substance Use Disorders. 
Health affairs (Project Hope). 2017;36(10):1739-47. 
142. United States Department of H, Human Services. Substance A, Mental Health 
Services Administration. Office of Applied S. National Survey on Drug Use and Health, 
2002. Inter-university Consortium for Political and Social Research [distributor]; 2015. 
143. United States Department of H, Human Services. Substance A, Mental Health 
Services Administration. Office of Applied S. National Survey on Drug Use and Health, 
2003. Inter-university Consortium for Political and Social Research [distributor]; 2015. 
144. United States Department of H, Human Services. Substance A, Mental Health 
Services Administration. Office of Applied S. National Survey on Drug Use and Health, 
2004. Inter-university Consortium for Political and Social Research [distributor]; 2015. 
145. United States Department of H, Human Services. Substance A, Mental Health 
Services Administration. Office of Applied S. National Survey on Drug Use and Health, 
2005. Inter-university Consortium for Political and Social Research [distributor]; 2015. 
146. United States Department of H, Human Services. Substance A, Mental Health 
Services Administration. Office of Applied S. National Survey on Drug Use and Health, 
2006. Inter-university Consortium for Political and Social Research [distributor]; 2013. 
147. United States Department of H, Human Services. Substance A, Mental Health 
Services Administration. Office of Applied S. National Survey on Drug Use and Health, 
2007. Inter-university Consortium for Political and Social Research [distributor]; 2015. 
148. United States Department of H, Human Services. Substance A, Mental Health 
Services Administration. Office of Applied S. National Survey on Drug Use and Health, 
2008. Inter-university Consortium for Political and Social Research [distributor]; 2015. 
Chapter 10: References 
Justin Christopher Yang- March 2019   181 
149. United States Department of H, Human Services. Substance A, Mental Health 
Services Administration. Office of Applied S. National Survey on Drug Use and Health, 
2009. Inter-university Consortium for Political and Social Research [distributor]; 2015. 
150. United States Department of H, Human Services. Substance A, Mental Health 
Services Administration. Center for Behavioral Health S, Quality. National Survey on 
Drug Use and Health, 2010. Inter-university Consortium for Political and Social 
Research [distributor]; 2015. 
151. United States Department of H, Human Services. Substance A, Mental Health 
Services Administration. Center for Behavioral Health S, Quality. National Survey on 
Drug Use and Health, 2011. Inter-university Consortium for Political and Social 
Research [distributor]; 2015. 
152. United States Department of H, Human Services. Substance A, Mental Health 
Services Administration. Center for Behavioral Health S, Quality. National Survey on 
Drug Use and Health, 2012. Inter-university Consortium for Political and Social 
Research [distributor]; 2015. 
153. United States Department of H, Human Services. Substance A, Mental Health 
Services Administration. Center for Behavioral Health S, Quality. National Survey on 
Drug Use and Health, 2013. Inter-university Consortium for Political and Social 
Research [distributor]; 2015. 
154. United States Department of H, Human Services. Substance A, Mental Health 
Services Administration. Center for Behavioral Health S, Quality. National Survey on 
Drug Use and Health, 2014. Inter-university Consortium for Political and Social 
Research [distributor]; 2016. 
155. United States Department of H, Human Services. Substance A, Mental Health 
Services Administration. Center for Behavioral Health S, Quality. National Survey on 
Drug Use and Health, 2015. RTI International; 2018. 
156. Allin S, Masseria C. Unmet need as an indicator of health care access. 
Eurohealth. 2009;15(3):7. 
157. Choi NG, DiNitto DM, Marti CN. Alcohol and other substance use, mental 
health treatment use, and perceived unmet treatment need: Comparison between baby 
boomers and older adults. Am J Addict. 2015;24(4):299-307. 
158. Manuel JI, Stebbins MB, Wu E. Gender Differences in Perceived Unmet 
Treatment Needs Among Persons With and Without Co-occurring Disorders. J Behav 
Health Serv Res. 2018;45(1):1-12. 
159. Oh S, DiNitto DM, Kim Y. Substance use and use disorders and treatment 
receipt among adults in families receiving Temporary Assistance for Needy Families 
(TANF), 2003-2014. Addict Behav. 2018;85:173-9. 
160. Chavez LJ, Kelleher KJ, Matson SC, Wickizer TM, Chisolm DJ. Mental Health 
and Substance Use Care Among Young Adults Before and After Affordable Care Act 
(ACA) Implementation: A Rural and Urban Comparison. J Rural Health. 
2018;34(1):42-7. 
161. Wang N, Xie X. The impact of race, income, drug abuse and dependence on 
health insurance coverage among US adults. The European journal of health economics 
: HEPAC : health economics in prevention and care. 2017;18(5):537-46. 
162. Smith LL, Yan F, Charles M, Mohiuddin K, Tyus D, Adekeye O, et al. 
Exploring the Link Between Substance Use and Mental Health Status: What Can We 
Learn from the Self-medication Theory? J Health Care Poor Underserved. 
2017;28(2s):113-31. 
163. Monaghan M. The Affordable Care Act and implications for young adult health. 
Translational Behavioral Medicine. 2014;4(2):170-4. 
Social disparities in the epidemiology and treatment of substance-related use disorders in the United States, 
2002-16 
182  Justin Christopher Yang – March 2019 
164. Judd F, Jackson H, Komiti A, Murray G, Fraser C, Grieve A, et al. Help-seeking 
by rural residents for mental health problems: the importance of agrarian values. 
2006;40(9):769-76. 
165. Fuller J, Edwards J, Procter N, Moss JJAJoRH. How definition of mental health 
problems can influence help seeking in rural and remote communities. 2000;8(3):148-
53. 
166. Smalley KB, Yancey CT, Warren JC, Naufel K, Ryan R, Pugh JLJJocp. Rural 
mental health and psychological treatment: A review for practitioners. 2010;66(5):479-
89. 
167. Wrigley S, Jackson H, Judd F, Komiti AJA, Psychiatry NZJo. Role of stigma 
and attitudes toward help-seeking from a general practitioner for mental health 
problems in a rural town. 2005;39(6):514-21. 
168. Cherry S, Robinson A, Jashinsky J, Bagwell-Adams G, Elliott M, Davis MJJoS, 
Behavioral,, et al. Rural Community Health Needs Assessment Findings: Access to 
Care and Mental Health. 2017;11(1):18. 
169. Smalley KB, Yancey CT, Warren JC, Naufel K, Ryan R, Pugh JL. Rural mental 
health and psychological treatment: a review for practitioners. Journal of Clinical 
Psychology. 2010;66(5):479-89. 
170. Wynn SD, Sherrod RA. Providing mental health care to veterans in rural areas: 
using telehealth in mobile clinics. J Psychosoc Nurs Ment Health Serv. 2012;50(6):22-
8. 
171. Barnwell SV, Juretic MA, Hoerster KD, Van de Plasch R, Felker BL. VA Puget 
Sound Telemental Health Service to rural veterans: a growing program. Psychol Serv. 
2012;9(2):209-11. 
172. Vivolo-Kantor AM, Seth P, Gladden RM, Mattson CL, Baldwin GT, Kite-
Powell A, et al. Vital signs: trends in emergency department visits for suspected opioid 
overdoses—United States, July 2016–September 2017. Morbidity and Mortality 
Weekly Report. 2018;67(9):279. 
173. Rudd RA. Increases in drug and opioid-involved overdose deaths—United 
States, 2010–2015. MMWR Morbidity and mortality weekly report. 2016;65. 
174. Meyer R, Patel AM, Rattana SK, Quock TP, Mody SH. Prescription opioid 
abuse: a literature review of the clinical and economic burden in the United States. 
Popul Health Manag. 2014;17(6):372-87. 
175. Paulozzi LJ, Ryan GWJAjopm. Opioid analgesics and rates of fatal drug 
poisoning in the United States. 2006;31(6):506-11. 
176. Cicero TJ, Inciardi JA, Muñoz AJTJoP. Trends in abuse of OxyContin® and 
other opioid analgesics in the United States: 2002-2004. 2005;6(10):662-72. 
177. Choi NG, DiNitto DM, Marti CN. Treatment use, perceived need, and barriers to 
seeking treatment for substance abuse and mental health problems among older adults 
compared to younger adults. Drug Alcohol Depend. 2014;145:113-20. 
178. Quinn PD, Hur K, Chang Z, Krebs EE, Bair MJ, Scott EL, et al. Incident and 
long-term opioid therapy among patients with psychiatric conditions and medications: a 
national study of commercial health care claims. Pain. 2017;158(1):140-8. 
179. Short VL, Hand DJ, MacAfee L, Abatemarco DJ, Terplan M. Trends and 
disparities in receipt of pharmacotherapy among pregnant women in publically funded 
treatment programs for opioid use disorder in the United States. J Subst Abuse Treat. 
2018;89:67-74. 
180. Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and State 
Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment. Am J 
Public Health. 2015;105(8):e55-63. 
Chapter 10: References 
Justin Christopher Yang- March 2019   183 
181. Thomas CP, Fullerton CA, Kim M, Montejano L, Lyman DR, Dougherty RH, et 
al. Medication-Assisted Treatment With Buprenorphine: Assessing the Evidence. 
Psychiatric Services. 2014;65(2):158-70. 
182. Fullerton CA, Kim M, Thomas CP, Lyman DR, Montejano LB, Dougherty RH, 
et al. Medication-Assisted Treatment With Methadone: Assessing the Evidence. 
Psychiatric Services. 2014;65(2):146-57. 
183. Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) 
National Practice Guideline for the Use of Medications in the Treatment of Addiction 
Involving Opioid Use. Journal of Addiction Medicine. 2015;9(5):358-67. 
184. Lofwall MR, Havens JR. Inability to access buprenorphine treatment as a risk 
factor for using diverted buprenorphine. Drug Alcohol Depend. 2012;126(3):379-83. 
185. United States Department of Health and Human Services. Substance Abuse and 
Mental Health Services Administration. Office of Applied Studies. National Survey of 
Substance Abuse Treatment Services (NSSATS), 2007. Ann Arbor, MI: Inter-university 
Consortium for Political and Social Research; 2007. 
186. United States Department of Health and Human Services. Substance Abuse and 
Mental Health Services Administration. Office of Applied Studies. National Survey of 
Substance Abuse Treatment Services (NSSATS), 2008. Ann Arbor, MI: Inter-university 
Consortium for Political and Social Research; 2008. 
187. United States Department of Health and Human Services. Substance Abuse and 
Mental Health Services Administration. Office of Applied Studies. National Survey of 
Substance Abuse Treatment Services (NSSATS), 2009. Ann Arbor, MI: Inter-university 
Consortium for Political and Social Research; 2009. 
188. United States Department of Health and Human Services. Substance Abuse and 
Mental Health Services Administration. Office of Applied Studies. National Survey of 
Substance Abuse Treatment Services (NSSATS), 2010. Ann Arbor, MI: Inter-university 
Consortium for Political and Social Research; 2010. 
189. United States Department of Health and Human Services. Substance Abuse and 
Mental Health Services Administration. Office of Applied Studies. National Survey of 
Substance Abuse Treatment Services (NSSATS), 2011. Ann Arbor, MI: Inter-university 
Consortium for Political and Social Research; 2011. 
190. United States Department of Health and Human Services. Substance Abuse and 
Mental Health Services Administration. Office of Applied Studies. National Survey of 
Substance Abuse Treatment Services (NSSATS), 2012. Ann Arbor, MI: Inter-university 
Consortium for Political and Social Research; 2012. 
191. United States Department of Health and Human Services. Substance Abuse and 
Mental Health Services Administration. Office of Applied Studies. National Survey of 
Substance Abuse Treatment Services (NSSATS), 2013. Ann Arbor, MI: Inter-university 
Consortium for Political and Social Research; 2013. 
192. United States Department of Health and Human Services. Substance Abuse and 
Mental Health Services Administration. Office of Applied Studies. National Survey of 
Substance Abuse Treatment Services (NSSATS), 2014. Ann Arbor, MI: Inter-university 
Consortium for Political and Social Research; 2014. 
193. United States Department of Health and Human Services. Substance Abuse and 
Mental Health Services Administration. Office of Applied Studies. National Survey of 
Substance Abuse Treatment Services (NSSATS), 2015. Ann Arbor, MI: Inter-university 
Consortium for Political and Social Research; 2015. 
194. U.S. Department of Commerce Economics and Statistics Administration U.S. 
Census Bureau. Census Regions and Divisions of the United States. 
195. Kresina TF, Litwin A, Marion I, Lubran R, Clark HWJJoDPA. United States 
government oversight and regulation of medication assisted treatment for the treatment 
of opioid dependence. 2009;2(1). 
Social disparities in the epidemiology and treatment of substance-related use disorders in the United States, 
2002-16 
184  Justin Christopher Yang – March 2019 
196. Stata Statistical Software. Release 14 [computer program]. 2013. 
197. Vadivelu N, Kai AM, Kodumudi G, Haddad D, Kodumudi V, Kuruvilla N, et al. 
Recommendations for Substance Abuse and Pain Control in Patients with Chronic Pain. 
Current pain and headache reports. 2018;22(4):25. 
198. Pergolizzi JV, Jr., Taylor R, Jr., LeQuang JA, Raffa RB. Managing severe pain 
and abuse potential: the potential impact of a new abuse-deterrent formulation 
oxycodone/naltrexone extended-release product. J Pain Res. 2018;11:301-11. 
199. Clark RE, Samnaliev M, Baxter JD, Leung GY. The evidence doesn’t justify 
steps by state Medicaid programs to restrict opioid addiction treatment with 
buprenorphine. Health Affairs. 2011;30(8):1425-33. 
200. Blum K, Gold M, Clark HW, Dushaj K, Badgaiyan RD. Should the United 
States Government Repeal Restrictions on Buprenorphine/Naloxone Treatment? 
Substance Use & Misuse. 2016;51(12):1674-9. 
201. Knudsen HK. The Supply of Physicians Waivered to Prescribe Buprenorphine 
for Opioid Use Disorders in the United States: A State-Level Analysis. Journal of 
Studies on Alcohol and Drugs. 2015;76(4):644-54. 
202. Knudsen HK, Lofwall MR, Havens JR, Walsh SL. States’ implementation of the 
Affordable Care Act and the supply of physicians waivered to prescribe buprenorphine 
for opioid dependence. Drug and Alcohol Dependence. 2015;157:36-43. 
203. Knudsen HK, Havens JR, Lofwall MR, Studts JL, Walsh SL. Buprenorphine 
physician supply: Relationship with state-level prescription opioid mortality. Drug and 
Alcohol Dependence. 2017;173:S55-S64. 
204. Rieckmann T, Moore L, Croy C, Aarons GA, Novins DK. National Overview of 
Medication-Assisted Treatment for American Indians and Alaska Natives With 
Substance Use Disorders. Psychiatric Services. 2017;68(11):1136-43. 
205. Momper S, Dennis MK, Mueller-Williams A. Service Provider Views of 
Oxycontin Use on an Indian Reservation: Traumatic Effects on the Tribal Community. 
Families in Society: The Journal of Contemporary Social Services. 2012;93(4):312-8. 
206. Rieckmann T, Moore LA, Croy CD, Novins DK, Aarons G. A National Study of 
American Indian and Alaska Native Substance Abuse Treatment: Provider and Program 
Characteristics. Journal of Substance Abuse Treatment. 2016;68:46-56. 
207. Rosenblatt RA, Andrilla CHA, Catlin M, Larson EH. Geographic and Specialty 
Distribution of US Physicians Trained to Treat Opioid Use Disorder. 2015;13(1):23-6. 
208. Stein BD, Pacula RL, Gordon AJ, Burns RM, Leslie DL, Sorbero MJ, et al. 
Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private 
Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in 
Urban and Rural Counties. The Milbank Quarterly. 2015;93(3):561-83. 
209. Degenhardt L, Charlson F, Mathers B, Hall WD, Flaxman AD, Johns N, et al. 
The global epidemiology and burden of opioid dependence: results from the global 
burden of disease 2010 study. Addiction. 2014;109(8):1320-33. 
210. Yang JC, Roman-Urrestarazu A, Brayne C. Binge alcohol and substance use 
across birth cohorts and the global financial crisis in the United States. PloS one. 
2018;13(6):e0199741. 
211. Armenian P, Vo KT, Barr-Walker J, Lynch KL. Fentanyl, fentanyl analogs and 
novel synthetic opioids: A comprehensive review. Neuropharmacology. 2018;134(Pt 
A):121-32. 
212. Blanco C, Iza M, Schwartz RP, Rafful C, Wang S, Olfson M. Probability and 
predictors of treatment-seeking for prescription opioid use disorders: a national study. 
Drug Alcohol Depend. 2013;131(1-2):143-8. 
Chapter 10: References 
Justin Christopher Yang- March 2019   185 
213. Peles E, Schreiber S, Adelson M. Opiate-Dependent Patients on a Waiting List 
for Methadone Maintenance Treatment Are at High Risk for Mortality Until Treatment 
Entry. 2013;7(3):177-82. 
214. Jaffe JH, O'Keeffe C. From morphine clinics to buprenorphine: regulating 
opioid agonist treatment of addiction in the United States. Drug Alcohol Depend. 
2003;70(2 Suppl):S3-11. 
215. Dick AW, Pacula RL, Gordon AJ, Sorbero M, Burns RM, Leslie DL, et al. 
Increasing Potential Access to Opioid Agonist Treatment in U.S. Treatment Shortage 
Areas. Health affairs (Project Hope). 2015;34(6):1028-34. 
216. Gryczynski J, Schwartz RP, Salkever DS, Mitchell SG, Jaffe JH. Patterns in 
admission delays to outpatient methadone treatment in the United States. Journal of 
Substance Abuse Treatment. 2011;41(4):431-9. 
217. Krawczyk N, Picher CE, Feder KA, Saloner B. Only One In Twenty Justice-
Referred Adults In Specialty Treatment For Opioid Use Receive Methadone Or 
Buprenorphine. Health Affairs. 2017;36(12):2046-53. 
218. Uchtenhagen A, Ladjevic T, Rehm JJWGPAPOD. WHO guidelines for 
psychosocially assisted pharmacological treatment of persons dependent on opioids. 
2007. 
219. Carise D, McLellan AT, Gifford LS, Kleber HD. Developing a National 
Addiction Treatment Information System: An Introduction to the Drug Evaluation 
Network System. Journal of Substance Abuse Treatment. 1999;17(1):67-77. 
220. King NB, Fraser V, Boikos C, Richardson R, Harper S. Determinants of 
increased opioid-related mortality in the United States and Canada, 1990–2013: a 
systematic review. American journal of public health. 2014;104(8):e32-e42. 
221. Perlman DC, Jordan AE. The Syndemic of Opioid Misuse, Overdose, HCV, and 
HIV: Structural-Level Causes and Interventions. Curr HIV/AIDS Rep. 2018;15(2):96-
112. 
222. Saloner B, Stoller KB, Barry CL. Medicaid Coverage for Methadone 
Maintenance and Use of Opioid Agonist Therapy in Specialty Addiction Treatment. 
Psychiatr Serv. 2016;67(6):676-9. 
223. Burns RM, Pacula RL, Bauhoff S, Gordon AJ, Hendrikson H, Leslie DL, et al. 
Policies related to opioid agonist therapy for opioid use disorders: The evolution of state 
policies from 2004 to 2013. Subst Abus. 2016;37(1):63-9. 
224. Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies--
tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063-6. 
225. Lynch FL, McCarty D, Mertens J, Perrin NA, Green CA, Parthasarathy S, et al. 
Costs of care for persons with opioid dependence in commercial integrated health 
systems. Addict Sci Clin Pract. 2014;9(1):16. 
226. Dick AW, Pacula RL, Gordon AJ, Sorbero M, Burns RM, Leslie D, et al. 
Growth In Buprenorphine Waivers For Physicians Increased Potential Access To 
Opioid Agonist Treatment, 2002-11. Health Aff (Millwood). 2015;34(6):1028-34. 
227. BBC. Conservative conference: Middle-class drug users to be targeted - Sajid 
Javid: BBC.co.uk; 2018 [updated 2/10/2018. Available from: 
https://www.bbc.co.uk/news/uk-politics-45707227. 
228. Office for National Statistics. Deaths related to drug poisoning in England and 
Wales: 2017 registrations. Office for National Statistics,; 2018. 
229. Robinson JJLc. A crisis hidden in plain sight? Prescription opioid misuse in the 
UK. 2018;15:05. 
230. BBC. Home Office has 'no plans for fix rooms': BBC; 2018 [updated 4/6/2018. 
Available from: https://www.bbc.co.uk/news/uk-scotland-glasgow-west-44357774. 
231. Martin J, Cunliffe J, Décary-Hétu D, Aldridge JJOcriA. The international 
darknet drugs trade—a regional analysis of cryptomarkets. 2018:95. 
Social disparities in the epidemiology and treatment of substance-related use disorders in the United States, 
2002-16 
186  Justin Christopher Yang – March 2019 
232. Sidorchuk A, Goodman A, Koupil IJPo. Social class, social mobility and 
alcohol-related disorders in Swedish men and women: A study of four generations. 
2018;13(2):e0191855. 
233. The Office for National Statistics. User Guide to Crime Statistics for England 
and Wales. In: The Government Statistical Service, editor. London, UK: The Office for 
National Statistics; 2017. 
234. Ristuccia A, LoSchiavo C, Halkitis PN, Kapadia FJIJoDP. Sexualised drug use 
among sexual minority young adults in the United States: The P18 cohort study. 
2018;55:207-14. 
235. Park SH, Al-Ajlouni Y, Palamar JJ, Goedel WC, Estreet A, Elbel B, et al. 
Financial hardship and drug use among men who have sex with men. 2018;13(1):19. 
236. Degenhardt L, Whiteford HA, Ferrari AJ, Baxter AJ, Charlson FJ, Hall WD, et 
al. Global burden of disease attributable to illicit drug use and dependence: findings 
from the Global Burden of Disease Study 2010. Lancet (London, England). 
2013;382(9904):1564-74. 
237. Ayalew M, Tafere M, Asmare Y. Prevalence, Trends, and Consequences of 
Substance Use Among University Students: Implication for Intervention. Int Q 
Community Health Educ. 2018;38(3):169-73. 
238. Mumola CJ, Karberg JC. Drug use and dependence, state and federal prisoners, 
2004: US Department of Justice, Office of Justice Programs, Bureau of Justice …; 
2006. 
239. Newman L, Baum F, Javanparast S, O'Rourke K, Carlon L. Addressing social 
determinants of health inequities through settings: a rapid review. Health Promot Int. 
2015;30 Suppl 2:ii126-43. 
240. Ndumbe-Eyoh S, Moffatt H. Intersectoral action for health equity: a rapid 
systematic review. BMC public health. 2013;13:1056. 
241. Lucyk K, McLaren L. Taking stock of the social determinants of health: A 
scoping review. PloS one. 2017;12(5):e0177306. 
242. Braveman P, Gottlieb L. The social determinants of health: it's time to consider 
the causes of the causes. Public Health Rep. 2014;129 Suppl 2:19-31. 
243. Taylor LA, Tan AX, Coyle CE, Ndumele C, Rogan E, Canavan M, et al. 
Leveraging the Social Determinants of Health: What Works? PloS one. 
2016;11(8):e0160217. 
244. Yu C, McClellan J. Genetics of Substance Use Disorders. Child Adolesc 
Psychiatr Clin N Am. 2016;25(3):377-85. 
245. Prom-Wormley EC, Ebejer J, Dick DM, Bowers MS. The genetic epidemiology 
of substance use disorder: A review. Drug Alcohol Depend. 2017;180:241-59. 
246. Jewell JD, Rose P, Bush R, Bartz K. The Long Term Effectiveness of Drug 
Treatment Court on Reducing Recidivism and Predictors of Voluntary Withdrawal. 
International Journal of Mental Health and Addiction. 2017;15(1):28-39. 
247. Brown RT. Systematic review of the impact of adult drug-treatment courts. 
Transl Res. 2010;155(6):263-74. 
248. Belenko S, Hiller M, Hamilton L. Treating Substance Use Disorders in the 
Criminal Justice System. Current Psychiatry Reports. 2013;15(11):414. 
 
